                                      ABSTRACT
        The invention provides nucleic acids encoding mutants of the acetohydroxyacid
synthase (AHAS) large subunit comprising at least two mutations, for example double
and triple mutants, which are useful for producing transgenic or non-transgenic plants
with improved levels of tolerance to AHAS-inhibiting herbicides.     The invention also
provides expression vectors, cells, plants comprising the polynucleotides encoding the
AHAS large subunit double and triple mutants, plants comprising two or more AHAS
large subunit single mutant polypeptides, and methods for making and using the same.

                                    AHAS MUTANTS
FIELD OF THE INVENTION
         This invention relates generally to compositions and methods for increasing
tolerance of plants to acetohydroxyacid synthase-inhibiting herbicides.
BACKGROUND OF THE INVENTION
         Acetohydroxyacid synthase (AHAS; EC 4.1.3.18, also known as acetolactate
synthase or ALS), is the first enzyme that catalyzes the biochemical synthesis of the
branched     chain  amino    acids   valine,    leucine    and isoleucine    (Singh   (1999)
"Biosynthesis of valine, leucine and isoleucine," in Plant Amino Acids, Singh, B.K.,
ed., Marcel Dekker Inc. New York, New York, pp. 227-247).              AHAS is the site of
action of four structurally diverse herbicide families including the sulfonylureas (Tan
et al. (2005) Pest Manag. Sci. 61:246-57; Mallory-Smith and Retzinger (2003) Weed
Technology 17:620-626; LaRossa and Falco (1984) Trends Biotechnol. 2:158-161),
the   imidazolinones     (Shaner   et al. (1984)        Plant Physiol. 76:545-546),       the
triazolopyrimidines (Subramanian and Gerwick (1989) "Inhibition of acetolactate
synthase by triazolopyrimidines," in Biocatalysis in Agricultural Biotechnology,
Whitaker, J.R. and Sonnet, P.E.. eds., ACS Symposium Series, American Chemical
Society,   Washington,     D.C.,   pp.   277-288),      and the    pyrimidinyloxybenzoates
(Subramanian     et al. (1990)     Plant Physiol. 94: 239-244). Imidazolinone             and
sulfonylurea    herbicides  are widely used in modern agriculture due to their
effectiveness at very low application rates and relative non-toxicity in animals. By
inhibiting AHAS activity, these families of herbicides prevent further growth and
development of susceptible plants including many weed species. Several examples of
commercially available imidazolinone herbicides are PURSUIT® (imazethapyr),
SCEPTER® (imazaquin) and ARSENAL® (imazapyr).                     Examples of sulfonylurea
herbicides are chlorsulfuron, metsulfuron methyl, sulfometuron methyl, chlorimuron
ethyl, thifensulfuron methyl, tribenuron methyl, bensulfuron methyl, nicosulfuron,
ethametsulfuron      methyl,     rimsulfuron,      triflusulfuron    methyl,    triasulfuron,
primisulfuron methyl, cinosulfuron, amidosulfiuon, fluzasulfuron, imazosulfuron,
pyrazosulfuron ethyl and halosulfuron.
                                             - 1-

         Due to their high effectiveness and low-toxicity, imidazolinone herbicides are
favored for application by spraying over the top of a wide area of vegetation. The
ability to spray a herbicide over the top of a wide range of vegetation decreases the
costs associated with plant establishment and maintenance, and decreases the need for
site preparation prior to use of such chemicals. Spraying over the top of a desired
tolerant species also results in the ability to achieve maximum yield potential of the
desired species due to the absence of competitive species. However, the ability to use
such spray-over techniques is dependent upon the presence of imidazolinone-resistant
species of the desired vegetation in the spray over area.
         Among the major agricultural crops, some leguminous species such as
soybean are naturally resistant to imidazolinone herbicides due to their ability to
rapidly metabolize the herbicide compounds (Shaner and Robinson (1985) Weed Sci.
33:469-471). Other crops such as corn (Newhouse et al. (1992) Plant Physiol.
100:882-886) and rice (Barrett et al. (1989) Crop Safeners for Herbicides, Academic
Press, New York, pp. 195-220) are somewhat susceptible to imidazolinone herbicides.
The differential sensitivity to the imidazolinone herbicides is dependent on the
chemical nature of the particular herbicide and differential metabolism of the
compound from a toxic to a non-toxic form in each plant (Shaner et al. (1984) Plant
Physiol. 76:545-546; Brown et al. (1987) Pestic. Biochem. Physiol. 27:24-29). Other
plant physiological differences such as absorption and translocation also play an
important role in sensitivity (Shaner and Robinson (1985) Weed Sci. 33:469-471).
         Plants resistant to imidazolinones, sulfonylureas, triazolopyrimidines, and
pyrimidinyloxybenzoates have been successfully produced using seed, microspore,
pollen, and callus mutagenesis in Zea mays, Arabidopsis thaliana, Brassica napus
(i.e., canola) Glycine max, Nicotiana tabacum, sugarbeet (Beta vulgaris) and Oryza
sativa (Sebastian et al. (1989) Crop Sci. 29:1403-1408; Swanson et al. 1989 Theor.
Apple. Genet. 78:525-530; Newhouse et al. (1991) Theor. Apple. Genet. 83:65-70;
Sathasivan et al. (1991) Plant Physiol. 97:1044-1050; Mourand et al. (1993) J.
Heredity 84:91-96; Wright and Penner (1998) Theor. Apple. Genet. 96:612-620; U.S.
Patent No. 5,545,822).       In all cases, a single, partially dominant nuclear gene
conferred resistance. Four imidazolinone resistant wheat plants were also previously
isolated following seed mutagenesis of Triticum aestivum L. cv. Fidel (Newhouse et
                                            -2-

al. (1992) Plant Physiol. 100:882-886). Inheritance studies confirmed that a single,
partially dominant gene conferred resistance.        Based on allelic studies, the authors
concluded that the mutations in the four identified lines were located at the same
locus. One of the Fidel cultivar resistance genes was designated FS-4 (Newhouse et
al. (1992) PlantPhysiol. 100:882-886).
        Computer-based modeling of the three dimensional conformation of the
AHAS-inhibitor complex predicts several amino acids in the proposed inhibitor
binding pocket as sites where induced mutations would likely confer selective
resistance to imidazolinones (Ott et al. (1996) J Mol. Biol. 263:359-368). Tobacco
plants produced with some of these rationally designed mutations in the proposed
binding sites of the AHAS enzyme have in fact exhibited specific resistance to a
single class of herbicides (Ott et al. (1996) J Mol. Biol. 263:359-368).
        Plant resistance to imidazolinone herbicides has also been reported in a
number of patents. U.S. Patent Nos. 4,761,373, 5,331,107, 5,304,732, 6,211,438,
6,211,439 and 6,222,100 generally describe the use of an altered AHAS gene to elicit
herbicide resistance in plants, and specifically discloses certain imidazolinone
resistant corn lines. U.S. Patent No. 5,013,659 discloses plants exhibiting herbicide
resistance due to mutations in at least one amino acid in one or more conserved
regions.   The mutations       described   therein encode     either  cross-resistance for
imidazolinones      and    sulfonylureas    or    sulfonylurea-specific   resistance,  but
imidazolinone-specific resistance is not described.       U.S. Patent No. 5,731,180 and
U.S. Patent No. 5,767,361 discuss an isolated gene having a single amino acid
substitution in a wild-type monocot AHAS amino acid sequence that results in
imidazolinone-specific     resistance.   In addition, rice plants that are resistant to
herbicides that interfere with AHAS have been developed by mutation breeding and
tissue culture selection.     See, U.S. Patent Nos. 5,545,822, 5,736,629, 5,773,703,
5,773,704, 5,952,553 and 6,274,796.
        In plants, as in all other organisms examined, the AHAS enzyme is comprised
of two subunits: a large subunit (catalytic role) and a small subunit (regulatory role)
(Duggleby and Pang (2000) J Biochem. Mol. Biol. 33:1-36).                The AHAS large
subunit (also referred to herein as AHASL) may be encoded by a single gene as in the
case of Arabidopsis, and sugar beet or by multiple gene family members as in maize,
                                             -3 -

canola, and cotton.     Specific, single-nucleotide substitutions in the large subunit
confer upon the enzyme a degree of insensitivity to one or more classes of herbicides
(Chang and Duggleby (1998) Biochem J 333:765-777).
         For example, bread wheat, Triticum aestivum L., contains three homoeologous
acetohydroxyacid synthase large subunit genes. Each of the genes exhibit significant
expression based on herbicide response and biochemical data from mutants in each of
the three genes (Ascenzi et al. (2003) International Society of Plant Molecular
Biologists Congress, Barcelona, Spain, Ref. No. S10-17). The coding sequences of
all three genes share extensive homology at the nucleotide level (WO 03/014357).
Through sequencing the AHASL genes from several varieties of Triticum aestivum,
the molecular basis of herbicide tolerance in most IMI-tolerant (imidazolinone
tolerant) lines was found to be the mutation S653(At)N, indicating a serine to
asparagine substitution at a position equivalent to the serine at amino acid 653 in
Arabidopsis thaliana (WO 03/014357).       This mutation is due to a single nucleotide
polymorphism (SNP) in the DNA sequence encoding the AHASL protein.
         Multiple AHASL genes are also known to occur in dicotyledonous plants
species.   Recently, Kolkman et al. ((2004) Theor. Apple. Genet. 109: 1147-1159)
reported the identification, cloning, and sequencing for three AHASL genes
(AHASLI,      AHASL2,     and AHASL3)       from herbicide-resistant and wild type
genotypes of sunflower (Helianthus annuus L.).       Kolkman et al. reported that the
herbicide-resistance was due either to the Pro l97Leu (using the Arabidopsis AHASL
amino acid position nomenclature) substitution or the Ala205Val substitution in the
AHASLI protein and that each of these substitutions provided resistance to both
imidazolinone and sulfonylurea herbicides.
         A number of single mutations in the AHAS large subunit are known that result
in tolerance or resistance to herbicides (Duggleby et al. (2000) Journal of Biochem
and Mol. Bio. 33:1-36; Jander et al. (2003) Plant Physiology 131:139-146). For
example, an alanine to valine substitution at position 122 of Arabidopsis AHASL (or
an alanine to threonine substitution at corresponding position 100 of Cocklebur
AHASL) confers resistance to imidazolinone and sulfonylureas. A methionine to
glutamic acid or isoleucine substitution at position 124 of Arabidopsis AHASL
confers resistance to imidazolinones and sulfonylureas. A proline to serine
                                          -4-

substitution at position 197 of Arabidopsis AHASL (or a proline to alanine, glutamic
acid, leucine, glutamine, arginine, valine, tryptophan, or tyrosine substitution at
corresponding position 192 of yeast AHASL) confers resistance to imidazolinones,
sulfonylureas, and triazolopyrimidine. An arginine to alanine or glutamic acid
substitution at position 199 of Arabidopsis AHASL confers imidazolinone resistance.
An alanine to valine substitution at position 205 of Arabidopsis AHASL (or an
alanine to cysteine, aspartic acid, glutamic acid, arginine, threonine, tryptophan or
tyrosine substitution at corresponding position 200 of yeast AHASL) confers
imidazolinones and sulfonylureas resistance. A substitution of almost any amino acid
for the tryptophan at position 574 of Arabidopsis AHASL, corresponding to position
586    of yeast    AHASL,      confers  resistance  to imidazolinones,     sulfonylureas,
triazolopyrimidine,    and   pyrimidyl   oxybenzoates.  A    serine to    phenylalanine,
asparagine, or threonine substitution at position 653 of Arabidopsis AHASL confers
resistance to imidazolinones and pyrimidyl oxybenzoates.
        U.S. Patent Nos. 5,853,973; 5,928,937; and 6,576,455 disclose structure-based
modeling methods for making AHAS variants which include amino acid substitutions
at specific positions that differ from the positions described above. In Mourad et al.
(1992) Planta 188;491-497, it has shown that mutant lines resistant to sulfonylureas
are cross-resistant to triazolopyrimidine, and mutant lines resistant to imidazolinones
are cross-resistant to pyrimidyl oxybenzoates.
        U.S. Patent No. 5,859,348 discloses a double mutant sugar beet AHAS large
subunit having an alanine to threonine substitution at amino acid 113 and a proline to
serine substitution at amino acid 188. Sugar beet plants containing the double mutant
AHAS protein are described as being both imidazolinone and sulfonylurea resistant.
        Mourad et al. (1994) Mol. Gen. Genet. 242:178-184, discloses an Arabidopsis
AHAS double mutant designated csrl-4. The csrl-4 mutant AHAS contained a C to
T nucleotide substitution at position 589 (corresponding to a proline to serine
substitution at amino acid 197 of Arabidopsis AHASL) and a G to A nucleotide
substitution at position 1958 (corresponding to a serine to threonine substitution at
amino acid 653 of Arabidopsis AHASL).
                                           -5 -

         Lee et al. (1988) EMBO Journal 7:1241-1248, discloses a tobacco AHAS
double mutant designated S4-Hra, which includes a Pro-Ala substitution at amino acid
196 (corresponding to the amino acid 197 of Arabidopsis AHASL) and a Trp-Leu
substitution at amino acid 573 (corresponding to amino acid 574 of Arabidopsis
AHASL). Transgenic lines carrying the double mutant gene show resistance to
sulfonylurea herbicide.
         U.S. Patent No. 7,119,256 discloses a double mutant rice AHAS large subunit
having a tryptophan to leucine substitution at amino acid 548 and a serine to
isoleucine substitution at amino acid 627.       Transgenic rice plants expressing a
polynucleotide encoding this double mutant AHAS protein were reported to have
increased resistance to the pyrimidinyl carboxy herbicide, bispyribac-sodium.
         Given their high effectiveness and low-toxicity, imidazolinone herbicides are
favored for agricultural use. However, the ability to use imidazolinone herbicides in a
particular crop production system depends upon the availability of imidazolinone
resistant varieties of the crop plant of interest.   To produce such imidazolinone
resistant varieties, there remains a need for crop plants comprising mutant AHAS
polypeptides which confer demonstrated improved tolerance to imidazolinones and/or
other AHAS-inhibiting herbicides when compared to crop plants with existing AHAS
mutants.
         Although some AHAS mutants have been characterized, there remains a need
for mutant AHAS polypeptides which confer, when expressed in a crop plant of
interest, demonstrated improved herbicide tolerance to one or more classes of AHAS
inhibiting herbicides when compared to existing AHAS mutants in crop plants.
SUMMARY OF THE INVENTION
         This invention relates to new mutant AHAS polypeptides that demonstrate
tolerance to a herbicide, in particular, an imidazolinone herbicide, or sulfonylurea
herbicide, or a mixture thereof. In preferred embodiments, the herbicide tolerance
conferred by the mutants of the invention is improved and/or enhanced relative to that
obtained using known AHAS mutants. The mutants of the invention comprise at least
two amino acid substitutions in the AHAS large subunit polypeptide.
                                          -6-

        In one embodiment, the invention provides an isolated polynucleotide
encoding an AHAS large subunit double mutant polypeptide selected from the group
consisting of a polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine, glycine, valine, or
tryptophan at a position corresponding to position 653 of SEQ ID NO:1 or position
621 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine, cysteine,
or methionine at a position corresponding to position 122 of SEQ ID NO:1 or position
90 of SEQ ID NO:2 and an alanine, glutamic acid, serine, phenylalanine, threonine,
aspartic acid, cysteine, or asparagine at a position corresponding to position 199 of
SEQ ID NO:1 or position 167 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2 and a serine, alanine, glutamic
acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a
position corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID
NO:2; a polypeptide having a valine, threonine, glutamine, cysteine, or methionine at
a position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a glutamic acid, isoleucine, leucine, or asparagine at a position
corresponding to position 124 of SEQ ID NO:1 or position 92 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine at a position corresponding to position 139 of SEQ ID NO:1
or position 107 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and a histidine at a position corresponding to position
269 of SEQ ID NO: 1 or position 237 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a methionine at a position
corresponding to position 416 of SEQ ID NO:1 or position 384 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine at a position corresponding to position 426 of SEQ ID NO: 1
                                          -7-

or position 394 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and a valine at a position corresponding to position
430 of SEQ ID NO: 1 or position 398 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and an isoleucine at a position
corresponding to position 442 of SEQ ID NO:1 or position 410 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine or aspartic acid at a position corresponding to position 445 of
SEQ ID NO:1 or position 413 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a glutamic acid at a position
corresponding to position 580 of SEQ ID NO:1 or position 548 of SEQ ID NO:2; a
polypeptide having a glutamic acid, isoleucine, leucine, or asparagine at a position
corresponding to position 124 of SEQ ID NO: 1 or position 92 of SEQ ID NO:2 and a
phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; a polypeptide having a serine,
alanine, glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or
isoleucine at a position corresponding to position 197 of SEQ ID NO:1 or position
165 of SEQ ID NO:2 and an asparagine at a position corresponding to position 375 of
SEQ ID NO:1 or position 343 of SEQ ID NO:2; a polypeptide having an alanine,
glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine
at a position corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ
ID NO:2 and an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO: 1 or
position 167 of SEQ ID NO:2; a polypeptide having an alanine, glutamic acid, serine,
                                           -8-

phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2 and
a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; and
a polypeptide having a valine, cysteine, aspartic acid, glutamic acid, arginine,
threonine, tryptophan, or tyrosine at a position corresponding to position 205 of SEQ
ID NO:1 or position 173 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine,
glycine, valine, or tryptophan at a position corresponding to position 653 of SEQ ID
NO: 1 or position 621 of SEQ ID NO:2.
        In another embodiment, the invention provides an isolated polynucleotide
encoding an AHAS large subunit triple mutant polypeptide selected from the group
consisting of a polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2, an alanine, glutamic acid, serine, phenylalanine, threonine,
aspartic acid, cysteine, or asparagine at a position corresponding to position 199 of
SEQ ID NO:1 or position 167 of SEQ ID NO:2 and a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2, a serine, alanine, glutamic acid,
leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2, a serine, alanine, glutamic         acid, leucine,   glutamine, arginine, valine,
tryptophan, tyrosine, or isoleucine at a position corresponding to position 197 of SEQ
ID NO:1 or position 165 of SEQ ID NO:2 and an alanine, glutamic acid, serine,
phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
                                           -9-

position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2, an arginine at a position corresponding to position 57 of SEQ ID NO:1 and a
leucine at a position corresponding to position 398 of SEQ ID NO:1 or position 366
of SEQ ID NO:2; a polypeptide having a glutamic acid, isoleucine, leucine, or
asparagine at a position corresponding to position 124 of SEQ ID NO:1 or position 92
of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine, glutamine, arginine, valine,
tryptophan, tyrosine, or isoleucine at a position corresponding to position 197 of SEQ
ID NO:1 or position 165 of SEQ ID NO:2 and an alanine, glutamic acid, serine,
phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2; a
polypeptide having a leucine at a position corresponding to position 95 of SEQ ID
NO: 1 or position 63 of SEQ ID NO:2, a glutamic acid at a position corresponding to
position 416 of SEQ ID NO:1 or position 384 of SEQ ID NO:2 and a phenylalanine,
asparagine, threonine, glycine, valine, or tryptophan at a position corresponding to
position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; and a polypeptide
having a serine, alanine, glutamic acid, leucine, glutamine, arginine, valine,
tryptophan, tyrosine, or isoleucine at a position corresponding to position 197 of SEQ
ID NO:1 or position 165 of SEQ ID NO:2, an alanine, glutamic acid, serine,
phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2 and
any amino acid at a position corresponding to position 574 of SEQ ID NO:1 or
position 542 of SEQ ID NO:2.
        The invention also relates to AHASL polypeptides comprising the double and
triple mutants described above, expression vectors comprising the polynucleotides
encoding the AHASL double and triple mutants described above, cells comprising the
polynucleotides encoding the AHASL double and triple mutants described above,
transgenic plants comprising the polynucleotides and polypeptides described above
and methods of making and using transgenic plants comprising the polynucleotides
encoding the AHASL double and triple mutants described above.
        The invention further relates to transgenic and non-transgenic           plants
comprising one or more polynucleotides comprising two or more mutations. In one
embodiment, the plants of the invention comprise a first polynucleotide encoding a
                                          - 10 -

first AHASL single mutant polypeptide and a second polynucleotide encoding a
second AHASL single mutant polypeptide, or an AHASL encoding polynucleotide
comprising two mutations that result in the amino acid mutations of said first and
second AHASL single mutant polypeptides, wherein said first and second AHASL
single mutant polypeptides are selected from the group consisting of: a first
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a phenylalanine, asparagine, threonine,
glycine, valine, or tryptophan at a position corresponding to position 653 of SEQ ID
NO:1 or position 621 of SEQ ID NO:2; a first polypeptide having a valine, threonine,
glutamine, cysteine, or methionine at a position corresponding to position 122 of SEQ
ID NO: 1 or position 90 of SEQ ID NO:2 and a second polypeptide having an alanine,
glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine
at a position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ
ID NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2 and a second polypeptide having a serine, alanine, glutamic acid,
leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a glutamic acid, isoleucine, leucine, or
asparagine at a position corresponding to position 124 of SEQ ID NO: 1 or position 92
of SEQ ID NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine,
or methionine at a position corresponding to position 122 of SEQ ID NO:1 or position
90 of SEQ ID NO:2 and a second polypeptide having an isoleucine at a position
corresponding to position 139 of SEQ ID NO:1 or position 107 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a histidine at a position corresponding to
position 269 of SEQ ID NO:1 or position 237 of SEQ ID NO:2; a first polypeptide
having a valine, threonine,     glutamine, cysteine, or methionine at a position
                                          -11-

corresponding to position 122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2 and a
second polypeptide having a methionine at a position corresponding to position 416 of
SEQ ID NO:1 or position 384 of SEQ ID NO:2; a first polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a second polypeptide
having an isoleucine at a position corresponding to position 426 of SEQ ID NO: 1 or
position 394 of SEQ ID NO:2; a first polypeptide having a valine, threonine,
glutamine, cysteine, or methionine at a position corresponding to position 122 of SEQ
ID NO: 1 or position 90 of SEQ ID NO:2 and a second polypeptide having a valine at
a position corresponding to position 430 of SEQ ID NO: 1 or position 398 of SEQ ID
NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2 and a second polypeptide having an isoleucine at a position
corresponding to position 442 of SEQ ID NO:1 or position 410 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having an isoleucine or aspartic acid at a position
corresponding to position 445 of SEQ ID NO:1 or position 413 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a glutamic acid at a position corresponding to
position 580 of SEQ ID NO: 1 or position 548 of SEQ ID NO:2; a first glutamic acid,
isoleucine, leucine, or asparagine at a position corresponding to position 124 of SEQ
ID NO:1 or position 92 of SEQ ID NO:2 and a second polypeptide having a
phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
first polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO: 1 or position 165 of SEQ ID NO:2 and a second polypeptide having a
phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
first polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
                                          - 12 -

valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and a second polypeptide having an
asparagine at a position corresponding to position 375 of SEQ ID NO:1 or position
343 of SEQ ID NO:2; a first polypeptide having an alanine, glutamic acid, leucine,
glutamine, arginine,    valine, tryptophan, tyrosine, or isoleucine       at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
a second polypeptide having an alanine, glutamic acid, serine, phenylalanine,
threonine, aspartic acid, cysteine, or asparagine at a position corresponding to position
199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2; a first polypeptide having an
alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or
asparagine at a position corresponding to position 199 of SEQ ID NO:1 or position
167 of SEQ ID NO:2 and a second polypeptide having a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; and a first polypeptide having a
valine, cysteine, aspartic acid, glutamic acid, arginine, threonine, tryptophan, or
tyrosine at a position corresponding to position 205 of SEQ ID NO:1 or position 173
of SEQ ID NO:2 and a second polypeptide having a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2.
        In another embodiment, the invention provides transgenic and non-transgenic
plants comprising a first polynucleotide encoding a first AHASL single mutant
polypeptide, a second polynucleotide encoding a second AHASL single mutant
polypeptide, and a third polynucleotide encoding a third AHASL single mutant
polypeptide; or an AHASL encoding polynucleotide comprising three mutations,
wherein the three nucleotide        mutations result    in the amino acid mutations
corresponding to the mutations of said first, second and third AHASL single mutant
polypeptides; or an AHASL encoding polynucleotide comprising a single mutation
and an AHASL encoding polynucleotide comprising a double mutations, wherein the
nucleotide mutations result in the amino acid mutations corresponding to the amino
acid mutations of said first, second and third AHASL single mutant polypeptides,
wherein said first, second, and third AHASL single mutant polypeptides are selected
from the group consisting of: a first polypeptide having a valine, threonine, glutamine,
                                          - 13 -

cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2, a second polypeptide having an alanine, glutamic
acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a
position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID
NO:2 and a third polypeptide having a phenylalanine, asparagine, threonine, glycine,
valine, or tryptophan at a position corresponding to position 653 of SEQ ID NO: 1 or
position 621 of SEQ ID NO:2; a first polypeptide having a valine, threonine,
glutamine, cysteine, or methionine at a position corresponding to position 122 of SEQ
ID NO:1 or position 90 of SEQ ID NO:2, a second polypeptide having a serine,
alanine, glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or
isoleucine at a position corresponding to position 197 of SEQ ID NO:1 or position
165 of SEQ ID NO:2 and a third polypeptide having a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; a first polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2, a second polypeptide having a
serine, alanine, glutamic acid, leucine, glutamine, arginine, valine, tryptophan,
tyrosine, or isoleucine at a position corresponding to position 197 of SEQ ID NO:1 or
position 165 of SEQ ID NO:2 and a third polypeptide having an alanine, glutamic
acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a
position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID
NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2, a second polypeptide having an arginine at a position
corresponding to position 57 of SEQ ID NO:1 and a third polypeptide having a
leucine at a position corresponding to position 398 of SEQ ID NO:1 or position 366
of SEQ ID NO:2; a first polypeptide having a glutamic acid, isoleucine, leucine, or
asparagine at a position corresponding to position 124 of SEQ ID NO: 1 or position 92
of SEQ ID NO:2, a second polypeptide having a serine, alanine, glutamic acid,
leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
a third polypeptide having an alanine, glutamic acid, serine, phenylalanine, threonine,
                                           - 14 -

aspartic acid, cysteine, or asparagine at a position corresponding to position 199 of
SEQ ID NO:1 or position 167 of SEQ ID NO:2; a first polypeptide having a leucine at
a position corresponding to position 95 of SEQ ID NO:1 or position 63 of SEQ ID
NO:2, a second polypeptide having a glutamic acid at a position corresponding to
position 416 of SEQ ID NO:1 or position 384 of SEQ ID NO:2 and a third
polypeptide having a phenylalanine, asparagine, threonine, glycine, valine, or
tryptophan at a position corresponding to position 653 of SEQ ID NO:1 or position
621 of SEQ ID NO:2; and a first polypeptide having a serine, alanine, glutamic acid,
leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2, a
second polypeptide having an alanine, glutamic acid, serine, phenylalanine, threonine,
aspartic acid, cysteine, or asparagine at a position corresponding to position 199 of
SEQ ID NO:1 or position 167 of SEQ ID NO:2 and a third polypeptide having any
amino acid at a position corresponding to position 574 of SEQ ID NO:1 or position
542 of SEQ ID NO:2.
        The present invention provides a method for controlling weeds in the vicinity
of the transgenic and non-transgenic plants of the invention. Such plants comprise
increased herbicide resistance relative to a wild-type plant. The method comprises
applying an effective amount of an AHAS-inhibiting herbicide to the weeds and to the
plant of the invention.
        BRIEF DESCRIPTION OF THE DRAWINGS
        Figure 1 sets forth the full length sequence of the Arabidopsis AHAS large
subunit protein (amino acid sequence SEQ ID NO: 1; nucleic acid sequence SEQ ID
NO: 31) with putative translation showing positions of mutations indicated in bold
and underlined.    DNA numbering is on the left and amino acid numbering on the
right.
        Figure 2 sets forth the sequence of the maize AHAS large subunit protein
(amino acid sequence SEQ ID NO: 2; nucleic acid sequence SEQ ID NO: 32) with
amino acids at positions of claimed mutations indicated in bold and underlined. DNA
numbering is on the left and amino acid numbering on the right.
                                         - 15 -

        Figure 3 is an alignment of the positions of correspondence of the Arabidopsis
AHAS large subunit protein (AtAHASL, SEQ ID NO: 1) with the AHAS large
subunit protein of a number of species where the double and triple mutations of the
invention may be made showing the position of substitutions which correspond to the
positions of substitution in SEQ ID NO: 1: Amaranthus sp. (AsAHASL SEQ ID
NO:9), Brassicanapus (BnAHASL1A SEQ ID NO:3, BnAHASL1C SEQ ID NO:10,
BnAHASL2A SEQ ID NO: 11), Camelina microcarpa(CmAHASL1 SEQ ID NO: 12,
CmAHASL2 SEQ ID NO:13), Solanum tuberosum (StAHASLI SEQ ID NO:16,
StAHASL2 SEQ ID NO:17), Oryza sativa (OsAHASL SEQ ID NO:4), Lolium
multiflorum (LmAHASL SEQ ID NO:20), Solanum ptychanthum (SpAHASL SEQ ID
NO:14), Sorghum bicolor (SbAHASL SEQ ID NO:15), Glycine max (GmAHASL
SEQ ID NO:18), Helianthus annuus (HaAHASL1 SEQ ID NO:5, HaAHASL2 SEQ
ID NO:6, HaAHASL3 SEQ ID NO:7), Triticum aestivum (TaAHASL1A SEQ ID
NO:21, TaAHASL1B SEQ ID NO:22, TaAHASL1D SEQ ID NO:23), Xanthium sp.
(XsAHASL SEQ ID NO:19), Zea mays (ZmAHASL1 SEQ ID NO:8, ZmAHASL2
SEQ ID NO:2), Gossypium hirsutum (GhAHASA5 SEQ ID NO:24, GhAHASA19
SEQ ID NO:25), and E.co/i (ilvB SEQ ID NO:26, ilvG SEQ ID NO:27, ilvI SEQ ID
NO:28).
        Figure 4 is a map of the AE base vector used for construction of Arabidopsis
AHASL mutants AE2-AE8 in E. coli, with relative positions of mutations in
ArabidopsisAHASL indicated.
        Figure 5 is a vector map of plant transformation base vector AP used for
construction of vectors AP2-AP5, which differ only by the mutations indicated in
Table 1.
        Figure 6 is a map of base vector ZE used to study maize AHASL mutants
ZE2, ZE5, ZE6, and ZE7 in E. coli, with relative positions of mutations indicated.
        Figure 7 is a map of plant transformation vector ZP used as a base vector for
construction of vectors ZP2-ZP 10.
        Figure 8 is a table showing the concordant amino acid positions of AHASL
genes derived from different species.
                                         - 16  -

        Figure 9 is a table showing the protein identity percentage of the AHASL
genes derived from different species. The analysis was performed in Vector NTI
software suite (gap opening penalty       =   10, gap extension penalty    =  0.05, gap
separation penalty  = 8, blosum 62MT2 matrix).
        Figure 10 sets forth the results of a vertical plate growth assay of seeds from
several lines of Arabidopsis plated on media with 37.5 micromolar of imazethapyr.
The seeds used were: 1) wild type ecotype Columbia 2; 2) the csrl-2 mutant
(homozygous for the AtAHASL S653N mutation in the genomic copy of the AHAS
large subunit gene); 3) Columbia 2 transformed with AP 1; 4) Columbia 2 transformed
with AP7; and 5) Columbia 2 transformed with AP2.
        Figure 11 is a vector map of plant transformation base vector AUP used for
construction of vectors AUP2 and AUP, which differ only by the mutations indicated
in Table 3.
        Figure 12 is a vector map of plant transformation vector BAP1, which
comprises the coding sequence for an AtAHASL with the S653N mutation.
DETAILED DESCRIPTION OF THE INVENTION
        The invention provides polynucleotides encoding AHASL with at least two
mutations, for example double and triple mutants, that demonstrate tolerance to
herbicides, in particular, to imidazolinone herbicides and optionally, to sulfonylurea,
triazolopyrimidine sulfoanilide, and/or pyrimidyl oxybenzoate herbicides.           The
AHASL mutants of the invention may be used to create transgenic plants that
demonstrate levels of herbicide resistance sufficient to confer commercial levels of
herbicide tolerance when present on only one parent of a hybrid cross or on one
genome of a polyploid plant. The polynucleotides of the invention may also be used
as selectable markers for transformation of linked genes encoding other traits, as set
forth in U.S. Patent No. 6,025,541.
        Although the AHASL proteins of various species differ in length by a few
amino acids, the relative positions of residues subject to modification in accordance
with the present invention are conserved (Figure 8).         Accordingly, the mutations
described herein are expressed in terms of positions corresponding to the amino acid
residue numbers of the Arabidopsis AHASL polypeptide (SEQ ID NO: 1, Figure 1,
                                          - 17 -

Figure 8) unless noted otherwise or apparent from the context. For example, residue
122 of the Arabidopsis AHASL corresponds to residue 90 of maize AHASL, residue
104 of Brassica napus AHASL 1A, residue 107 of B. napus AHASL IC, residue 96
of 0. sativa AHASL, residue 113 of Amaranthus AHASL, residue 26 of Escherichia
coli ilvG, residue 117 of Saccharomyces cerevisiae AHASL, residue 113 of sugar
beet, residue 111 of cotton, residue 120 of Camelina microcarpa AHASL1, residue
117 of Camelina microcarpaAHASL2, residue 109 of Solanum tuberosum AHASLI,
residue 111 of Solanum tuberosum AHASL2, residue 92 of Lolium multiflorum,
residue 27 of Solanum ptychanthum, residue 93 of Sorghum bicolor, residue 103 of
Glycine max, residue 107 of Helianthus annuus AHASLI, residue 101 of Helianthus
annuus AHASL2, residue 97 of Helianthus annuus AHASL3, residue 59 of Triticum
aestivum, and residue 100 of Xanthium sp. These correspondences are well known to
those of skill in the art. Based on such correspondence, the corresponding positions in
AHAS large subunit sequences not specifically disclosed herein could be readily
determined by the skilled artisan.      Specific exemplary regions of correspondence
relevant to the present invention are set forth in Figure 3.
        In a preferred embodiment, the invention provides an isolated polynucleotide
encoding an Arabidopsis AHASL double mutant selected from the group consisting
of a polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a
position corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID
NO:2; a polypeptide having a valine, threonine, glutamine, cysteine, or methionine at
a position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO: 1 or
position 167 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and a serine, alanine, glutamic acid, leucine,
glutamine,    arginine,   valine, tryptophan, tyrosine, or isoleucine    at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
                                           -18  -

position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a glutamic acid, isoleucine, leucine, or asparagine at a position
corresponding to position 124 of SEQ ID NO:1 or position 92 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine at a position corresponding to position 139 of SEQ ID NO:1
or position 107 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and a histidine at a position corresponding to position
269 of SEQ ID NO: 1 or position 237 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a methionine at a position
corresponding to position 416 of SEQ ID NO:1 or position 384 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine at a position corresponding to position 426 of SEQ ID NO: 1
or position 394 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and a valine at a position corresponding to position
430 of SEQ ID NO: 1 or position 398 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and an isoleucine at a position
corresponding to position 442 of SEQ ID NO:1 or position 410 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine or aspartic acid at a position corresponding to position 445 of
SEQ ID NO:1 or position 413 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a glutamic acid at a position
corresponding to position 580 of SEQ ID NO:1 or position 548 of SEQ ID NO:2; a
polypeptide having a glutamic acid, isoleucine, leucine, or asparagine at a position
corresponding to position 124 of SEQ ID NO: 1 or position 92 of SEQ ID NO:2 and a
                                         - 19 -

phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; a polypeptide having a serine,
alanine, glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or
isoleucine at a position corresponding to position 197 of SEQ ID NO:1 or position
165 of SEQ ID NO:2 and an asparagine at a position corresponding to position 375 of
SEQ ID NO:1 or position 343 of SEQ ID NO:2; a polypeptide having an alanine,
glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine
at a position corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ
ID NO:2 and an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO: 1 or
position 167 of SEQ ID NO:2; a polypeptide having an alanine, glutamic acid, serine,
phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2 and
a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; and
a polypeptide having a valine, cysteine, aspartic acid, glutamic acid, arginine,
threonine, tryptophan, or tyrosine at a position corresponding to position 205 of SEQ
ID NO:1 or position 173 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine,
glycine, valine, or tryptophan at a position corresponding to position 653 of SEQ ID
NO: 1 or position 621 of SEQ ID NO:2.
        In another preferred      embodiment,    the invention provides     an isolated
polynucleotide    encoding    an Arabidopsis AHAS         large  subunit triple mutant
polypeptide selected from the group consisting of:       a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2, an alanine, glutamic acid,
serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2 and
                                          - 20 -

a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2, a serine, alanine, glutamic         acid, leucine,  glutamine, arginine, valine,
tryptophan, tyrosine, or isoleucine at a position corresponding to position 197 of SEQ
ID NO:1 or position 165 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine,
glycine, valine, or tryptophan at a position corresponding to position 653 of SEQ ID
NO:1 or position 621 of SEQ ID NO:2; a polypeptide having a valine, threonine,
glutamine, cysteine, or methionine at a position corresponding to position 122 of SEQ
ID NO:1 or position 90 of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine,
glutamine,   arginine,  valine, tryptophan, tyrosine, or isoleucine      at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or
asparagine at a position corresponding to position 199 of SEQ ID NO:1 or position
167 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine, cysteine,
or methionine at a position corresponding to position 122 of SEQ ID NO:1 or position
90 of SEQ ID NO:2, an arginine at a position corresponding to position 57 of SEQ ID
NO:1 and a leucine at a position corresponding to position 398 of SEQ ID NO:1 or
position 366 of SEQ ID NO:2; a polypeptide having a glutamic acid, isoleucine,
leucine, or asparagine at a position corresponding to position 124 of SEQ ID NO: 1 or
position 92 of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine, glutamine,
arginine, valine, tryptophan, tyrosine, or isoleucine at a position corresponding to
position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and an alanine,
glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine
at a position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ
ID NO:2; a polypeptide having a leucine at a position corresponding to position 95 of
SEQ ID NO:1 or position 63 of SEQ ID NO:2, a glutamic acid at a position
corresponding to position 416 of SEQ ID NO:1 or position 384 of SEQ ID NO:2 and
a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; and
a polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
                                          -21  -

valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO:1 or position 165 of SEQ ID NO:2, an alanine, glutamic acid, serine,
phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2 and
any amino acid at a position corresponding to position 574 of SEQ ID NO:1 or
position 542 of SEQ ID NO:2.
        Other preferred embodiments include AHASL double and triple mutants from
other   species, wherein    the   double and triple mutations        occur at positions
corresponding to those of the specific Arabidopsis and maize mutants described above
and in table shown in Figure 8. For example, corresponding double and triple mutants
of AHASL from microorganisms such as E. coli, S. cerevisiae, Salmonella,
Synichocystis; and from plants such as wheat, rye, oat, triticale, rice, barley, sorghum,
millet, sugar beet, sugarcane, soybean, peanut, cotton, rapeseed, canola, Brassica
species, manihot, melon, squash, pepper, sunflower, tagetes, solanaceous plants,
potato, sweet potato, tobacco, eggplant, tomato, Vicia species, pea, alfalfa, coffee,
cacao are also within the scope of the present invention.        Such double and triple
mutants can be made using known methods, for example, in vitro using site-directed
mutagenesis, or in vivo using targeted mutagenesis or similar techniques, as described
in U.S. Patent Nos. 5,565,350; 5,731,181; 5756,325; 5,760,012; 5,795,972 and
5,871,984.
        The polynucleotides of the invention are provided in expression cassettes for
expression in the plant of interest. The cassette will include regulatory sequences
operably linked to an AHASL polynucleotide sequence of the invention. The term
"regulatory element" as used herein refers to a polynucleotide that is capable of
regulating the transcription of an operably linked polynucleotide. It includes, but not
limited to, promoters, enhancers, introns, 5' UTRs, and 3' UTRs.            By "operably
linked" is intended a functional linkage between a promoter and a second sequence,
wherein the promoter sequence initiates and mediates transcription of the DNA
sequence corresponding to the second sequence. Generally, operably linked means
that the nucleic acid sequences being linked are contiguous and, where necessary to
join two protein coding regions, contiguous and in the same reading frame. The
                                          - 22 -

cassette may additionally contain at least one additional gene to be cotransformed into
the organism.     Alternatively, the additional gene(s) can be provided on multiple
expression cassettes.
        Such an expression cassette is provided with a plurality of restriction sites for
insertion of the AHASL polynucleotide sequence to be under the transcriptional
regulation of the regulatory regions. The expression cassette may additionally contain
selectable marker genes.
        The expression cassette will include in the 5'-3' direction of transcription, a
transcriptional and translational initiation region (i.e., a promoter), an AHASL
polynucleotide sequence of the invention, and a transcriptional and translational
termination region (i.e., termination region) functional in plants. The promoter may
be native or analogous, or foreign or heterologous, to the plant host and/or to the
AHASL polynucleotide sequence of the invention. Additionally, the promoter may
be the natural sequence or alternatively a synthetic sequence. Where the promoter is
"foreign" or "heterologous" to the plant host, it is intended that the promoter is not
found in the native plant into which the promoter is introduced. Where the promoter
is "foreign" or "heterologous" to the AHASL polynucleotide sequence of the
invention, it is intended that the promoter is not the native or naturally occurring
promoter for the operably linked AHASL polynucleotide sequence of the invention.
As used herein, a chimeric gene comprises a coding sequence operably linked to a
transcription initiation region that is heterologous to the coding sequence.
        While it may be preferable to express the AHASL polynucleotides of the
invention using heterologous promoters, the native promoter sequences may be used.
Such constructs would change expression levels of the AHASL protein in the plant or
plant cell. Thus, the phenotype of the plant or plant cell is altered.
        The termination region may be native with the transcriptional initiation region,
may be native with the operably linked AHASL sequence of interest, may be native
with the plant host, or may be derived from another source (i.e., foreign or
heterologous to the promoter, the AHASL polynucleotide sequence of interest, the
plant host, or any combination thereof). Convenient termination regions are available
from the Ti-plasmid of A. tumefaciens, such as the octopine synthase and nopaline
synthase termination regions.      See also Guerineau et al. (1991) Mol. Gen. Genet.
                                            -23 -

262:141-144; Proudfoot (1991) Cell 64:671-674; Sanfacon et al. (1991) Genes Dev.
5:141-149; Mogen et al. (1990) Plant Cell 2:1261-1272; Munroe et al. (1990) Gene
91:151-158; Ballas et al. (1989) Nucleic Acids Res. 17:7891-7903; and Joshi et al.
(1987) Nucleic Acid Res. 15:9627-9639.
         Where appropriate, the gene(s) may be optimized for increased expression in
the transformed plant.    That is, the genes can be synthesized using plant-preferred
codons for improved expression. See, for example, Campbell and Gowri (1990) Plant
Physiol. 92:1-11 for a discussion of host-preferred codon usage.          Methods are
available in the art for synthesizing plant-preferred genes.   See, for example, U.S.
Patent Nos. 5,380,831, and 5,436,391, and Murray et al. (1989) Nucleic Acids Res.
17:477-498, herein incorporated by reference.
         Additional sequence modifications are known to enhance gene expression in a
cellular   host.    These   include   elimination  of sequences    encoding   spurious
polyadenylation signals, exon-intron splice site signals, transposon-like repeats, and
other such well-characterized sequences that may be deleterious to gene expression.
The G-C content of the sequence may be adjusted to levels average for a given
cellular host, as calculated by reference to known genes expressed in the host cell.
When possible, the sequence is modified to avoid predicted hairpin secondary mRNA
structures.
         Nucleotide sequences for enhancing gene expression can also be used in the
plant expression vectors. These include the introns of the maize AdhI, intronl gene
(Callis et al. Genes and Development 1:1183-1200, 1987), and leader sequences, (W
sequence) from the Tobacco Mosaic virus (TMV), Maize Chlorotic Mottle Virus and
Alfalfa Mosaic Virus (Gallie et al. Nucleic Acid Res. 15:8693-8711, 1987 and
Skuzeski et al.Plant Mol. Biol. 15:65-79, 1990). The first intron from the shrunken-I
locus of maize, has been shown to increase expression of genes in chimeric gene
constructs.    U.S. Pat. Nos. 5,424,412 and 5,593,874 disclose the use of specific
introns in gene expression constructs, and Gallie et al. (Plant Physiol. 106:929-939,
1994) also have shown that introns are useful for regulating gene expression on a
tissue specific basis. To further enhance or to optimize AHAS large subunit gene
expression, the plant expression vectors of the invention may also contain DNA
                                          - 24 -

sequences containing matrix attachment regions (MARs).         Plant cells transformed
with such modified expression systems, then, may exhibit overexpression or
constitutive expression of a nucleotide sequence of the invention.
         The expression cassettes may additionally contain 5' leader sequences in the
expression cassette construct. Such leader sequences can act to enhance translation.
Translation leaders are known in the art and include: picornavirus leaders, for
example, EMCV leader (Encephalomyocarditis 5' noncoding region) (Elroy-Stein et
al. (1989) Proc. Natl. Acad. Sci. USA 86:6126-6130); potyvirus leaders, for example,
TEV leader (Tobacco Etch Virus) (Gallie et al. (1995) Gene 165(2):233-238),
MDMV leader (Maize Dwarf Mosaic Virus) (Virology 154:9-20), and human
immunoglobulin heavy-chain binding protein (BiP) (Macejak et al. (1991) Nature
353:90-94); untranslated leader from the coat protein mRNA of alfalfa mosaic virus
(AMV RNA 4) (Jobling et al. (1987) Nature 325:622-625); tobacco mosaic virus
leader (TMV) (Gallie et al. (1989) in Molecular Biology of RNA, ed. Cech (Liss,
New York), pp. 237-256); and maize chlorotic mottle virus leader (MCMV) (Lommel
et al. (1991)    Virology 81:382-385).     See also, Della-Cioppa et al. (1987) Plant
Physiol. 84:965-968.      Other methods known to enhance translation can also be
utilized, for example, introns, and the like.
         In preparing the expression cassette, the various DNA fragments may be
manipulated, so as to provide for the DNA sequences in the proper orientation and, as
appropriate, in the proper reading frame. Toward this end, adapters or linkers may be
employed to join the DNA fragments or other manipulations may be involved to
provide for convenient restriction sites, removal of superfluous DNA, removal of
restriction sites, or the like.  For this purpose, in vitro mutagenesis, primer repair,
restriction, annealing, resubstitutions, e.g., transitions and transversions, may be
involved.
         A number of promoters can be used in the practice of the invention. The
promoters can be selected based on the desired outcome. The nucleic acids can be
combined with constitutive, tissue-preferred, or other promoters for expression in
plants.
                                           -25 -

        Such constitutive promoters include, for example, the core promoter of the
Rsyn7 promoter and other constitutive promoters disclosed in WO 99/43838 and U.S.
Patent No. 6,072,050; the core CaMV 35S promoter (Odell et al. (1985) Nature
313:810-812); rice actin (McElroy et al. (1990) Plant Cell 2:163-171); ubiquitin
(Christensen et al. (1989) Plant Mol. Biol. 12:619-632 and Christensen et al. (1992)
Plant Mol. Biol. 18:675-689); pEMU (Last et al. (1991) Theor. Apple. Genet. 81:581
588); MAS (Velten et al. (1984) EMBO J 3:2723-2730); ALS promoter (U.S. Patent
No. 5,659,026), and the like. Other constitutive promoters include, for example, U.S.
Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597;          5,466,785; 5,399,680;
5,268,463; 5,608,142; and 6,177,611.
        Tissue-preferred promoters can be utilized to target enhanced AHASL
expression within a particular plant tissue. Such tissue-preferred promoters include,
but are not limited to, leaf-preferred promoters, root-preferred promoters, seed
preferred promoters, and stem-preferred promoters.          Tissue-preferred promoters
include Yamamoto et al. (1997) PlantJ 12(2):255-265; Kawamata et al. (1997) Plant
Cell Physiol. 38(7):792-803; Hansen et al. (1997) Mol. Gen Genet. 254(3):337-343;
Russell et al. (1997) Transgenic Res. 6(2):157-168; Rinehart et al. (1996) Plant
Physiol. 112(3):1331-1341; Van Camp et al. (1996) Plant Physiol. 112(2):525-535;
Canevascini et al. (1996) Plant Physiol. 112(2):513-524; Yamamoto et al. (1994)
Plant Cell Physiol. 35(5):773-778; Lam (1994) Results Probl. Cell Differ. 20:181
196; Orozco et al. (1993) Plant Mol Biol. 23(6):1129-1138; Matsuoka et al. (1993)
Proc Natl. Acad. Sci. USA 90(20):9586-9590; and Guevara-Garcia et al. (1993) Plant
J 4(3):495-505. Such promoters can be modified, if necessary, for weak expression.
        In one embodiment, the nucleic acids of interest are targeted to the chloroplast
for expression.    In this manner, where the nucleic acid of interest is not directly
inserted into the chloroplast, the expression cassette will additionally contain a
chloroplast-targeting sequence comprising a nucleotide sequence that encodes a
chloroplast transit peptide to direct the gene product of interest to the chloroplasts.
Such transit peptides are known in the art.        With respect to chloroplast-targeting
sequences, "operably linked" means that the nucleic acid sequence encoding a transit
peptide   (i.e., the   chloroplast-targeting    sequence) is linked   to the    AHASL
polynucleotide of the invention such that the two sequences are contiguous and in the
                                           - 26  -

same reading frame. See, for example, Von Heijne et al. (1991) PlantMol. Biol. Rep.
9:104-126; Clark et al. (1989) J Biol. Chem. 264:17544-17550; Della-Cioppa et al.
(1987) Plant Physiol. 84:965-968; Romer et al. (1993) Biochem. Biophys. Res.
Commun. 196:1414-1421; and Shah et al. (1986) Science 233:478-481.             While the
AHASL proteins of the invention include a native chloroplast transit peptide, any
chloroplast transit peptide known in the art can be fused to the amino acid sequence of
a mature AHASL protein of the invention by operably linking a choloroplast-targeting
sequence to the 5'-end of a nucleotide sequence encoding a mature AHASL protein of
the invention.
        Chloroplast targeting sequences are known in the art and include the
chloroplast small subunit of ribulose-1,5-bisphosphate carboxylase (Rubisco) (de
Castro Silva Filho et al. (1996) Plant Mol. Biol. 30:769-780; Schnell et al. (1991) J
Biol. Chem. 266(5):3335-3342);        5 -(enolpyruvyl)shikimate-3 -phosphate    synthase
(EPSPS) (Archer et al. (1990) J Bioenerg. Biomemb. 22(6):789-810); tryptophan
synthase (Zhao et al. (1995) J Biol. Chem. 270(11):6081-6087);              plastocyanin
(Lawrence et al. (1997) J Biol. Chem. 272(33):20357-20363); chorismate synthase
(Schmidt et al. (1993) J Biol. Chem. 268(36):27447-27457); and the light harvesting
chlorophyll a/b binding protein (LHBP) (Lamppa et al. (1988) J Biol. Chem.
263:14996-14999).     See also Von Heijne et al. (1991) Plant Mol. Biol. Rep. 9:104
126; Clark et al. (1989) J Biol. Chem. 264:17544-17550; Della-Cioppa et al. (1987)
Plant Physiol. 84:965-968; Romer et al. (1993) Biochem. Biophys. Res. Commun.
196:1414-1421; and Shah et al. (1986) Science 233:478-481.
        Methods for transformation of chloroplasts are known in the art.         See, for
example, Svab et al. (1990) Proc. Natl. Acad. Sci. USA 87:8526-8530; Svab and
Maliga (1993) Proc. Natl. Acad. Sci. USA 90:913-917; Svab and Maliga (1993)
EMBO J 12:601-606. The method relies on particle gun delivery of DNA containing
a selectable marker and targeting of the DNA to the plastid genome through
homologous      recombination.      Additionally,    plastid   transformation   can    be
accomplished by transactivation of a silent plastid-borne transgene by tissue-preferred
expression of a nuclear-encoded and plastid-directed RNA polymerase.              Such a
system has been reported in McBride et al. (1994) Proc. Natl. Acad. Sci. USA
91:7301-7305.
                                          -27  -

        The nucleic acids of interest to be targeted to the chloroplast may be optimized
for expression in the chloroplast to account for differences in codon usage between
the plant nucleus and this organelle. In this manner, the nucleic acids of interest may
be synthesized using chloroplast-preferred codons. See, for example, U.S. Patent No.
5,380,831, herein incorporated by reference.
        In particular, the present invention describes using polynucleotides encoding
AHASL mutant polypeptides comprising at least two mutations to engineer plants
which are herbicide tolerant.      This strategy has herein been demonstrated using
ArabidopsisAHASL mutants in Arabidopsis thalianaand maize AHASL2 mutants in
com, but its application is not restricted to these genes or to these plants. In preferred
embodiments, the herbicide is imidazolinone and/or sulfonylurea. In other preferred
embodiments, the herbicide tolerance is improved and/or enhanced compared to wild
type plants and to known AHAS mutants.
        The invention also provides a method of producing a transgenic crop plant
containing AHASL mutant coding nucleic acid comprising at least two mutations,
wherein expression of the nucleic acid(s) in the plant results in herbicide tolerance as
compared to wild-type plants or to known AHAS mutant type plants comprising: (a)
introducing into a plant cell an expression vector comprising nucleic acid encoding an
AHASL mutant with at least two mutations, and (b) generating from the plant cell a
transgenic plant which is herbicide tolerant. The plant cell includes, but is not limited
to, a protoplast, gamete producing cell, and a cell that regenerates into a whole plant.
As used herein, the term "transgenic" refers to any plant, plant cell, callus, plant
tissue, or plant part that contains all or part of at least one recombinant
polynucleotide. In many cases, all or part of the recombinant polynucleotide is stably
integrated into a chromosome or stable extra-chromosomal element, so that it is
passed on to successive generations.
        In another embodiment, the invention relates to using the mutant AHASL
polypeptides of the invention as selectable markers. The invention provides a method
of identifying or selecting a transformed plant cell, plant tissue, plant or part thereof
comprising a) providing a transformed plant cell, plant tissue, plant or part thereof,
wherein said transformed plant cell, plant tissue, plant or part thereof comprises an
isolated nucleic acid encoding an AHAS large subunit double mutant polypeptide of
                                           -28-

the invention as described above, wherein the polypeptide is used as a selection
marker, and wherein said transformed plant cell, plant tissue, plant or part thereof may
optionally comprise a further isolated nucleic acid of interest; b) contacting the
transformed plant cell, plant tissue, plant or part thereof with at least one AHAS
inhibitor or AHAS inhibiting compound; c) determining whether the plant cell, plant
tissue, plant or part thereof is affected by the inhibitor or inhibiting compound; and d)
identifying or selecting the transformed plant cell, plant tissue, plant or part thereof.
         The invention is also embodied in purified AHASL proteins that contain the
double and triple mutations described herein, which are useful in molecular modeling
studies to design further improvements to herbicide tolerance. Methods of protein
purification are well known, and can be readily accomplished using commercially
available products or specially designed methods, as set forth for example, in Protein
Biotechnology, Walsh and Headon (Wiley, 1994).
         The invention further provides non-transgenic and transgenic herbicide
tolerant plants comprising one polynucleotide encoding an AHASL double mutant
polypeptide, or two polynucleotides encoding AHASL single mutant polypeptides.
Non-transgenic plants generated therefrom can be produced by cross-pollinating a
first plant with a second plant and allowing the pollen acceptor plant (can be either the
first or second plant) to produce seed from this cross pollination. Seeds and progeny
plants generated thereof can have the double mutations crossed onto one single allele
or two alleles. The pollen-acceptor plant can be either the first or second plant. The
first plant comprises a first polynucleotide encoding a first AHASL single mutant
polypeptide. The second plant comprises a second polynucleotide encoding a second
AHASL single mutant polypeptide.           The first and second AHASL single mutant
polypeptides comprise a different single amino acid substitution relative to a wild
type AHASL polypeptide. Seeds or progeny plants arising therefrom which comprise
one polynucleotide encoding the AHASL double mutant polypeptide or two
polynucleotides encoding the two AHASL single mutant polypeptides can be
selected.    The selected progeny plants display an unexpectedly higher level of
tolerance to an AHAS-inhibiting herbicide, for example an imidazolinone herbicide or
sulfonylurea herbicide, than is predicted from the combination of the two AHASL
single mutant polypeptides in a single plant. The progeny plants display a synergy
                                            - 29 -

with respect to herbicide tolerance, whereby the level of herbicide tolerance in the
progeny plants comprising the first and second mutations from the parent plants is
greater than the herbicide tolerance of a plant comprising two copies of the first
polynucleotide or two copies of the second polynucleotide.
        When the first and second plants are homozygous for the first and second
polynucleotides, respectively, each of the resulting progeny plants comprises one
copy of each of the first and second polynucleotides and the selection step can be
omitted. When at least one of the first and second plants is heterozygous, progeny
plants comprising both polynucleotides can be selected, for example, by analyzing the
DNA of progeny plants to identify progeny plants comprising both the first and
second polynucleotides or by testing the progeny plants for increased herbicide
tolerance. The progeny plants that comprise both the first and second polynucleotides
display a level of herbicide tolerance that is greater than the herbicide tolerance of a
plant comprising two copies of the first polypeptide or two copies of the second
polypeptide.
        In one embodiment, the plants of the invention comprise a first polynucleotide
encoding a first AHASL single mutant polypeptide and a second polynucleotide
encoding a second AHASL single mutant polypeptide, or an AHASL encoding
polynucleotide comprising two nucleotide mutations that result in the amino acid
mutations corresponding to the amino acid mutations of said first and said second
AHASL single mutant polypeptides, wherein said first and said second AHASL single
mutant polypeptides are selected from the group consisting of: a first polypeptide
having a valine, threonine, glutamine, cysteine, or methionine at a position
corresponding to position 122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2 and a
second polypeptide having a phenylalanine, asparagine, threonine, glycine, valine, or
tryptophan at a position corresponding to position 653 of SEQ ID NO:1 or position
621 of SEQ ID NO:2; a first polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and a second polypeptide having an alanine, glutamic
acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a
position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID
NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine, or
                                         -30-

methionine at a position corresponding to position 122 of SEQ ID NO:1 or position
90 of SEQ ID NO:2 and a second polypeptide having a serine, alanine, glutamic acid,
leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a glutamic acid, isoleucine, leucine, or
asparagine at a position corresponding to position 124 of SEQ ID NO: 1 or position 92
of SEQ ID NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine,
or methionine at a position corresponding to position 122 of SEQ ID NO:1 or position
90 of SEQ ID NO:2 and a second polypeptide having an isoleucine at a position
corresponding to position 139 of SEQ ID NO:1 or position 107 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a histidine at a position corresponding to
position 269 of SEQ ID NO:1 or position 237 of SEQ ID NO:2; a first polypeptide
having a valine, threonine,     glutamine, cysteine, or methionine at a position
corresponding to position 122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2 and a
second polypeptide having a methionine at a position corresponding to position 416 of
SEQ ID NO:1 or position 384 of SEQ ID NO:2; a first polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a second polypeptide
having an isoleucine at a position corresponding to position 426 of SEQ ID NO: 1 or
position 394 of SEQ ID NO:2; a first polypeptide having a valine, threonine,
glutamine, cysteine, or methionine at a position corresponding to position 122 of SEQ
ID NO: 1 or position 90 of SEQ ID NO:2 and a second polypeptide having a valine at
a position corresponding to position 430 of SEQ ID NO: 1 or position 398 of SEQ ID
NO:2; a first polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2 and a second polypeptide having an isoleucine at a position
corresponding to position 442 of SEQ ID NO:1 or position 410 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
                                         -31  -

position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having an isoleucine or aspartic acid at a position
corresponding to position 445 of SEQ ID NO:1 or position 413 of SEQ ID NO:2; a
first polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a second polypeptide having a glutamic acid at a position corresponding to
position 580 of SEQ ID NO: 1 or position 548 of SEQ ID NO:2; a first glutamic acid,
isoleucine, leucine, or asparagine at a position corresponding to position 124 of SEQ
ID NO:1 or position 92 of SEQ ID NO:2 and a second polypeptide having a
phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
first polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO: 1 or position 165 of SEQ ID NO:2 and a second polypeptide having a
phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a position
corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a
first polypeptide having a serine, alanine, glutamic acid, leucine, glutamine, arginine,
valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and a second polypeptide having an
asparagine at a position corresponding to position 375 of SEQ ID NO:1 or position
343 of SEQ ID NO:2; a first polypeptide having an alanine, glutamic acid, leucine,
glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
a second polypeptide having an alanine, glutamic acid, serine, phenylalanine,
threonine, aspartic acid, cysteine, or asparagine at a position corresponding to position
199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2; a first polypeptide having an
alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or
asparagine at a position corresponding to position 199 of SEQ ID NO:1 or position
167 of SEQ ID NO:2 and a second polypeptide having a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; and a first polypeptide having a
valine, cysteine, aspartic acid, glutamic acid, arginine, threonine, tryptophan, or
                                          -32-

tyrosine at a position corresponding to position 205 of SEQ ID NO:1 or position 173
of SEQ ID NO:2 and a second polypeptide having a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2. Non-transgenic plants comprising
the double mutations of AHASL polynucleotides can be produced by methods other
than the cross pollination described above, such as, for example but not limited to,
targeted in vivo mutagenesis as described in Kochevenko et al. (Plant Phys. 132:174
184, 2003). The double mutations can be localized on a single allele, or two alleles of
a plant genome.
        Another embodiment of the invention relates to a transgenic plant transformed
with an expression vector comprising an isolated polynucleotide, wherein the isolated
polynucleotide encodes an acetohydroxyacid synthase large subunit (AHASL) double
mutant polypeptide selected from the group consisting of: a polypeptide having a
valine, threonine, glutamine, cysteine, or methionine at a position corresponding to
position 122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a phenylalanine,
asparagine, threonine, glycine, valine, or tryptophan at a position corresponding to
position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a polypeptide having
a valine, threonine, glutamine, cysteine, or methionine at a position corresponding to
position 122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and an alanine,
glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine
at a position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ
ID NO:2; a polypeptide having a valine, threonine, glutamine, cysteine, or methionine
at a position corresponding to position 122 of SEQ ID NO: 1 or position 90 of SEQ ID
NO:2 and a serine, alanine, glutamic acid, leucine, glutamine, arginine, valine,
tryptophan, tyrosine, or isoleucine at a position corresponding to position 197 of SEQ
ID NO:1 or position 165 of SEQ ID NO:2; a polypeptide having a valine, threonine,
glutamine, cysteine, or methionine at a position corresponding to position 122 of SEQ
ID NO: 1 or position 90 of SEQ ID NO:2 and a glutamic acid, isoleucine, leucine, or
asparagine at a position corresponding to position 124 of SEQ ID NO: 1 or position 92
of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine, cysteine, or
methionine at a position corresponding to position 122 of SEQ ID NO: 1 or position
90 of SEQ ID NO:2 and an isoleucine at a position corresponding to position 139 of
                                          - 33 -

SEQ ID NO:1 or position 107 of SEQ ID NO:2; a polypeptide having a valine,
threonine, glutamine, cysteine, or methionine at a position corresponding to position
122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a histidine at a position
corresponding to position 269 of SEQ ID NO:1 or position 237 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a methionine at a position corresponding to position 416 of SEQ ID NO:1
or position 384 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and an isoleucine at a position corresponding to
position 426 of SEQ ID NO: 1 or position 394 of SEQ ID NO:2; a polypeptide having
a valine, threonine, glutamine, cysteine, or methionine at a position corresponding to
position 122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2 and a valine at a
position corresponding to position 430 of SEQ ID NO:1 or position 398 of SEQ ID
NO:2; a polypeptide having a valine, threonine, glutamine, cysteine, or methionine at
a position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and an isoleucine at a position corresponding to position 442 of SEQ ID NO: 1
or position 410 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2 and an isoleucine or aspartic acid at a position
corresponding to position 445 of SEQ ID NO:1 or position 413 of SEQ ID NO:2; a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2 and a glutamic acid at a position corresponding to position 580 of SEQ ID
NO:1 or position 548 of SEQ ID NO:2; a polypeptide having a glutamic acid,
isoleucine, leucine, or asparagine at a position corresponding to position 124 of SEQ
ID NO: 1 or position 92 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine,
glycine, valine, or tryptophan at a position corresponding to position 653 of SEQ ID
NO:1 or position 621 of SEQ ID NO:2; a polypeptide having a serine, alanine,
glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine
at a position corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ
ID NO:2 and a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at
                                          - 34 -

a position corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID
NO:2; a polypeptide having a serine, alanine, glutamic acid, leucine, glutamine,
arginine, valine, tryptophan, tyrosine, or isoleucine at a position corresponding to
position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and an asparagine at a
position corresponding to position 375 of SEQ ID NO:1 or position 343 of SEQ ID
NO:2; a polypeptide having an alanine, glutamic acid, leucine, glutamine, arginine,
valine, tryptophan, tyrosine, or isoleucine at a position corresponding to position 197
of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and an alanine, glutamic acid,
serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a position
corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID NO:2; a
polypeptide having an alanine, glutamic acid, serine, phenylalanine, threonine,
aspartic acid, cysteine, or asparagine at a position corresponding to position 199 of
SEQ ID NO:1 or position 167 of SEQ ID NO:2 and a phenylalanine, asparagine,
threonine, glycine, valine, or tryptophan at a position corresponding to position 653 of
SEQ ID NO:1 or position 621 of SEQ ID NO:2; and a polypeptide having a valine,
cysteine, aspartic acid, glutamic acid, arginine, threonine, tryptophan, or tyrosine at a
position corresponding to position 205 of SEQ ID NO:1 or position 173 of SEQ ID
NO:2 and a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a
position corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID
NO:2.
        The invention further provides non-transgenic and transgenic herbicide
tolerant plants comprising one polynucleotide encoding an AHASL triple mutant
polypeptide, or one or more AHASL encoding polynucleotides comprising three
mutations.     For the production of a non-transgenic plant with one or more
polynucleotides comprising three mutations, a progeny plant comprising one or two
polynucleotides comprising said first and said second mutations described above is
cross pollinated with third plant that comprises a third polynucleotide encoding a third
AHASL single mutant polypeptide.         The third AHASL single mutant polypeptide
comprises a different single amino acid substitution relative to a wild-type AHASL
polypeptide than either the first or second AHASL single mutant polypeptides. Seeds
or progeny plants that comprise one or more polynucleotides comprising the three
mutations are selected as described above. The selected progeny plants comprise a
                                          - 35 -

level of herbicide tolerance that is greater than the additive effect of combining the
three AHASL single mutant polypeptides in a single plant. Non-transgenic plants
comprising the triple or multiple mutations of AHASL polynucleotides can be
produced by methods other than the cross pollination described above, such as, for
example but not limited to, targeted in vivo mutagenesis as described above. The
multiple mutations can be localized on a single allele, or multiple alleles of a plant
genome.
        In one embodiment, plants of the invention comprise a first polynucleotide
encoding a first AHASL single mutant polypeptide, a second polynucleotide encoding
a second AHASL single mutant polypeptide, and a third polynucleotide encoding a
third AHASL single mutant polypeptide. In another embodiment, plants of the
invention comprise an AHASL encoding polynucleotide comprising three mutations,
wherein the three nucleotide mutations result in the amino acid mutations
corresponding to the mutations of said first, said second and said third AHASL single
mutant polypeptides. In yet another embodiment, plants of the invention comprise an
AHASL encoding polynucleotide comprising a single mutation and a polynucleotide
comprising a double mutations, wherein the nucleotide mutations result in the amino
acid mutations corresponding to the mutations of aforementioned first, second and
third AHASL single mutant polypeptides, wherein said first, second, and third
AHASL single mutant polypeptides are selected from the group consisting of: a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2, an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO: 1 or
position 167 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine, glycine,
valine, or tryptophan at a position corresponding to position 653 of SEQ ID NO: 1 or
position 621 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine, glutamine,
arginine, valine, tryptophan, tyrosine, or isoleucine at a position corresponding to
position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and a phenylalanine,
asparagine, threonine, glycine, valine, or tryptophan at a position corresponding to
                                          - 36 -

position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a polypeptide having
a valine, threonine, glutamine, cysteine, or methionine at a position corresponding to
position 122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2, a serine, alanine,
glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine
at a position corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ
ID NO:2 and an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO: 1 or
position 167 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2, an arginine at a position corresponding to position 57
of SEQ ID NO: 1 and a leucine at a position corresponding to position 398 of SEQ ID
NO:1 or position 366 of SEQ ID NO:2; a polypeptide having a glutamic acid,
isoleucine, leucine, or asparagine at a position corresponding to position 124 of SEQ
ID NO:1 or position 92 of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine,
glutamine,   arginine,  valine, tryptophan, tyrosine, or isoleucine      at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or
asparagine at a position corresponding to position 199 of SEQ ID NO:1 or position
167 of SEQ ID NO:2; a polypeptide having a leucine at a position corresponding to
position 95 of SEQ ID NO:1 or position 63 of SEQ ID NO:2, a glutamic acid at a
position corresponding to position 416 of SEQ ID NO:1 or position 384 of SEQ ID
NO:2 and a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a
position corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID
NO:2; and a polypeptide having a serine, alanine, glutamic acid, leucine, glutamine,
arginine, valine, tryptophan, tyrosine, or isoleucine at a position corresponding to
position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2, an alanine, glutamic
acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a
position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID
NO:2 and any amino acid at a position corresponding to position 574 of SEQ ID
NO: 1 or position 542 of SEQ ID NO:2.
                                          - 37 -

        Alternatively, plants comprising one or more polynucleotides encoding
AHASL single mutant polypeptides are produced by transforming a plant with two or
more of such polynucleotides or transforming a first plant with a first polynucleotide
encoding a first AHASL single mutant polypeptide and cross pollinating the first plant
with a second plant comprising a second polynucleotide encoding a second AHASL
single mutant polypeptide.     The second plant comprises a second polynucleotide
comprising second AHASL single mutant polypeptide that is endogenous or was
introduced via transformation.        The first and second AHASL         single mutant
polypeptides comprise a different single amino acid substitution relative to a wild
type AHASL polypeptide. As necessary, seeds or progeny plants comprising both the
first and second polynucleotides are selected as described above.
        Yet another embodiment of the invention relates to a transgenic plant
transformed with an expression vector comprising an isolated polynucleotide, wherein
the isolated polynucleotide encodes an acetohydroxyacid synthase large subunit
(AHASL) triple mutant polypeptide selected from the group consisting of: a
polypeptide having a valine, threonine, glutamine, cysteine, or methionine at a
position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2, an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO: 1 or
position 167 of SEQ ID NO:2 and a phenylalanine, asparagine, threonine, glycine,
valine, or tryptophan at a position corresponding to position 653 of SEQ ID NO: 1 or
position 621 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine, glutamine,
arginine, valine, tryptophan, tyrosine, or isoleucine at a position corresponding to
position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and a phenylalanine,
asparagine, threonine, glycine, valine, or tryptophan at a position corresponding to
position 653 of SEQ ID NO:1 or position 621 of SEQ ID NO:2; a polypeptide having
a valine, threonine, glutamine, cysteine, or methionine at a position corresponding to
position 122 of SEQ ID NO:1 or position 90 of SEQ ID NO:2, a serine, alanine,
glutamic acid, leucine, glutamine, arginine, valine, tryptophan, tyrosine, or isoleucine
at a position corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ
                                          - 38 -

ID NO:2 and an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid,
cysteine, or asparagine at a position corresponding to position 199 of SEQ ID NO:1 or
position 167 of SEQ ID NO:2; a polypeptide having a valine, threonine, glutamine,
cysteine, or methionine at a position corresponding to position 122 of SEQ ID NO: 1
or position 90 of SEQ ID NO:2, an arginine at a position corresponding to position 57
of SEQ ID NO: 1 and a leucine at a position corresponding to position 398 of SEQ ID
NO:1 or position 366 of SEQ ID NO:2; a polypeptide having a glutamic acid,
isoleucine, leucine, or asparagine at a position corresponding to position 124 of SEQ
ID NO:1 or position 92 of SEQ ID NO:2, a serine, alanine, glutamic acid, leucine,
glutamine,   arginine,    valine, tryptophan, tyrosine, or isoleucine      at a position
corresponding to position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2 and
an alanine, glutamic acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or
asparagine at a position corresponding to position 199 of SEQ ID NO:1 or position
167 of SEQ ID NO:2; a polypeptide having a leucine at a position corresponding to
position 95 of SEQ ID NO:1 or position 63 of SEQ ID NO:2, a glutamic acid at a
position corresponding to position 416 of SEQ ID NO:1 or position 384 of SEQ ID
NO:2 and a phenylalanine, asparagine, threonine, glycine, valine, or tryptophan at a
position corresponding to position 653 of SEQ ID NO:1 or position 621 of SEQ ID
NO:2; and a polypeptide having a serine, alanine, glutamic acid, leucine, glutamine,
arginine, valine, tryptophan, tyrosine, or isoleucine at a position corresponding to
position 197 of SEQ ID NO:1 or position 165 of SEQ ID NO:2, an alanine, glutamic
acid, serine, phenylalanine, threonine, aspartic acid, cysteine, or asparagine at a
position corresponding to position 199 of SEQ ID NO:1 or position 167 of SEQ ID
NO:2 and any amino acid at a position corresponding to position 574 of SEQ ID
NO: 1 or position 542 of SEQ ID NO:2.
        The present invention provides herbicide-tolerant or herbicide-resistant plants
comprising a herbicide-tolerant or herbicide-resistant AHASL protein including, but
not limited to, AHASL single mutant polypeptides and AHASL double and triple
mutant polypeptides that are encoded by the polynucleotides of the present invention.
By a "herbicide-tolerant" or "herbicide-resistant" plant, it is intended that a plant that
is tolerant or resistant to at least one herbicide at a level that would normally kill, or
inhibit the growth of, a normal or wild-type plant. By "herbicide-tolerant AHASL
                                           - 39 -

protein" or "herbicide-resistant AHASL protein", it is intended that such an AHASL
protein displays higher AHAS activity, relative to the AHAS activity of a wild-type
AHASL protein, when in the presence of at least one herbicide that is known to
interfere with AHAS activity and at a concentration or level of the herbicide that is
known to inhibit the AHAS activity of the wild-type AHASL protein. Furthermore,
the AHAS activity of such a herbicide-tolerant or herbicide-resistant AHASL protein
may be referred to herein as "herbicide-tolerant" or "herbicide-resistant" AHAS
activity.
        For the present invention, the terms "herbicide-tolerant" and "herbicide
resistant" are used interchangeable and are intended to have an equivalent meaning
and an equivalent scope.    Similarly, the terms "herbicide-tolerance" and "herbicide
resistance" are used interchangeable and are intended to have an equivalent meaning
and an equivalent scope.         Likewise, the terms "imidazolinone-resistant"      and
"imidazolinone-resistance" are used interchangeable and are intended to be of an
equivalent meaning and an equivalent scope as the terms "imidazolinone-tolerant" and
"imidazolinone-tolerance", respectively.
        The invention encompasses herbicide-resistant AHASL polynucleotides and
herbicide-resistant AHASL proteins. By "herbicide-resistant AHASL polynucleotide"
is intended a polynucleotide that encodes a protein comprising herbicide-resistant
AHAS activity.     By "herbicide-resistant AHASL protein" is intended a protein or
polypeptide that comprises herbicide-resistant AHAS activity.
        Further, it is recognized that a herbicide-tolerant or herbicide-resistant
AHASL protein can be introduced into a plant by transforming a plant or ancestor
thereof with a nucleotide sequence encoding a herbicide-tolerant or herbicide-resistant
AHASL protein. Such herbicide-tolerant or herbicide-resistant AHASL proteins are
encoded by the herbicide-tolerant or herbicide-resistant AHASL polynucleotides.
Alternatively, a herbicide-tolerant or herbicide-resistant AHASL protein such as, for
example, an AHASL single mutation polypeptide as disclosed herein, may occur in a
plant as a result of a naturally occurring or induced mutation in an endogenous
AHASL gene in the genome of a plant or progenitor thereof.
                                          - 40 -

         The present invention provides plants, plant tissues, plant cells, and host cells
with increased resistance or tolerance to at least one herbicide, particularly an
imidazolinone or sulfonylurea herbicide. The preferred amount or concentration of
the herbicide is an "effective amount" or "effective concentration."            By "effective
amount" and "effective concentration" is intended an amount and concentration,
respectively, that is sufficient to kill or inhibit the growth of a similar, wild-type,
plant, plant tissue, plant cell, or host cell, but that said amount does not kill or inhibit
as severely the growth of the herbicide-resistant plants, plant tissues, plant cells, and
host cells of the present invention. Typically, the effective amount of a herbicide is
an amount that is routinely used in agricultural production systems to kill weeds of
interest. Such an amount is known to those of ordinary skill in the art.
         By "similar, wild-type, plant, plant tissue, plant cell or host cell" is intended a
plant, plant tissue, plant cell, or host cell, respectively, that lacks the herbicide
resistance characteristics and/or particular polynucleotide of the invention that are
disclosed herein. The use of the term "wild-type" is not, therefore, intended to imply
that a plant, plant tissue, plant cell, or other host cell lacks recombinant DNA in its
genome, and/or does not possess herbicide-resistant characteristics that are different
from those disclosed herein.
         As used herein unless clearly indicated otherwise, the term "plant" intended to
mean a plant at any developmental stage, as well as any part or parts of a plant that
may be attached to or separate from a whole intact plant.              Such parts of a plant
include, but are not limited to, organs, tissues, and cells of a plant. Examples of
particular plant parts include a stem, a leaf, a root, an inflorescence, a flower, a floret,
a fruit, a pedicle, a peduncle, a stamen, an anther, a stigma, a style, an ovary, a petal, a
sepal, a carpel, a root tip, a root cap, a root hair, a leaf hair, a seed hair, a pollen grain,
a microspore, a cotyledon, a hypocotyl, an epicotyl, xylem, phloem, parenchyma,
endosperm, a companion cell, a guard cell, and any other known organs, tissues, and
cells of a plant. Furthermore, it is recognized that a seed is a plant.
         The plants of the present invention include both non-transgenic plants and
transgenic plants.     By "non-transgenic plant" is intended to mean a plant lacking
recombinant DNA in its genome. By "transgenic plant" is intended to mean a plant
comprising recombinant DNA in its genome.                 Such a transgenic plant can be
                                             -41 -

produced by introducing recombinant DNA into the genome of the plant. When such
recombinant DNA is incorporated into the genome of the transgenic plant, progeny of
the plant can also comprise the recombinant DNA. A progeny plant that comprises at
least a portion of the recombinant DNA of at least one progenitor transgenic plant is
also a transgenic plant.
        In certain embodiments, the present invention involves herbidicide-resistant
plants that are produced by mutation breeding. Such plants comprise a polynucleotide
encoding an AHAS large subunit single mutant polypeptide and are tolerant to one or
more AHAS-inhibiting herbicides. Such methods can involve, for example, exposing
the plants or seeds to a mutagen, particularly a chemical mutagen such as, for
example, ethyl methanesulfonate (EMS) and selecting for plants that have enhanced
tolerance to at least one AHAS-inhibiting herbicide, particularly an imidazolinone
herbicide or sulfonylurea herbicide. However, the present invention is not limited to
herbicide-tolerant plants that are produced by a mutagenesis method involving the
chemical mutagen EMS. Any mutagenesis method known in the art may be used to
produce the herbicide-resistant plants of the present invention.      Such mutagenesis
methods can involve, for example, the use of any one or more of the following
mutagens: radiation, such as X-rays, Gamma rays (e.g., cobalt 60 or cesium 137),
neutrons, (e.g., product of nuclear fission by uranium 235 in an atomic reactor), Beta
radiation (e.g., emitted from radioisotopes such as phosphorus 32 or carbon 14), and
ultraviolet radiation (preferably from 2500 to 2900 nm), and chemical mutagens such
as base analogues (e.g., 5-bromo-uracil), related compounds (e.g., 8-ethoxy caffeine),
antibiotics (e.g., streptonigrin), alkylating agents (e.g., sulfur mustards, nitrogen
mustards, epoxides, ethylenamines, sulfates, sulfonates, sulfones, lactones), azide,
hydroxylamine, nitrous acid, or acridines.       Herbicide-resistant plants can also be
produced by using tissue culture methods to select for plant cells comprising
herbicide-resistance    mutations and then regenerating       herbicide-resistant plants
therefrom.    See, for example, U.S. Patent Nos. 5,773,702 and 5,859,348, both of
which are herein incorporated in their entirety by reference.         Further details of
mutation breeding can be found in "Principals of Cultivar Development" Fehr, 1993
Macmillan Publishing Company the disclosure of which is incorporated herein by
reference.
                                          - 42 -

        The present invention provides methods for enhancing the tolerance or
resistance of a plant, plant tissue, plant cell, or other host cell to at least one herbicide
that interferes with the activity of the AHAS enzyme. Preferably, such a herbicide is
an imidazolinone herbicide, a sulfonylurea herbicide, a triazolopyrimidine herbicide, a
pyrimidinyloxybenzoate herbicide, a sulfonylamino-carbonyltriazolinone herbicide,
or mixture thereof. More preferably, such a herbicide is an imidazolinone herbicide, a
sulfonylurea    herbicide, or mixture thereof             For the present invention, the
imidazolinone herbicides include, but are not limited to, PURSUIT® (imazethapyr),
CADRE® (imazapic), RAPTOR® (imazamox), SCEPTER® (imazaquin), ASSERT®
(imazethabenz), ARSENAL® (imazapyr), a derivative of any of the aforementioned
herbicides, and a mixture of two or more of the aforementioned herbicides, for
example, imazapyr/imazamox (ODYSSEY®). More specifically, the imidazolinone
herbicide can be selected from, but is not limited to, 2- (4-isopropyl-4-methyl-5-oxo
2-imidiazolin-2-yl) -nicotinic acid, [2- (4-isopropyl)-4-] [methyl-5-oxo-2-imidazolin
2-yl)-3-quinolinecarboxylic]      acid,  [5-ethyl-2-     (4-isopropyl-]   4-methyl-5-oxo-2
imidazolin-2-yl) -nicotinic acid, 2- (4-isopropyl-4-methyl-5-oxo-2- imidazolin-2-yl)
5- (methoxymethyl)-nicotinic acid, [2- (4-isopropyl-4-methyl-5-oxo-2-] imidazolin-2
yl)-5-methylnicotinic acid, and a mixture of methyl [6- (4-isopropyl-4-] methyl-5
oxo-2-imidazolin-2-yl) -m-toluate and methyl [2- (4-isopropyl-4-methyl-5-] oxo-2
imidazolin-2-yl) -p-toluate.    The use of 5-ethyl-2- (4-isopropyl-4-methyl-5-oxo- 2
imidazolin-2-yl) -nicotinic acid and [2- (4-isopropyl-4-methyl-5-oxo-2-imidazolin-2-]
yl)-5- (methoxymethyl)-nicotinic acid is preferred.         The use of [2- (4-isopropyl-4-]
methyl-5-oxo-2-imidazolin-2-yl)-5-      (methoxymethyl)-nicotinic acid is particularly
preferred.
        For the present invention, the sulfonylurea herbicides include, but are not
limited to, chlorsulfuron, metsulfuron methyl, sulfometuron methyl, chlorimuron
ethyl, thifensulfuron methyl, tribenuron methyl, bensulfuron methyl, nicosulfuron,
ethametsulfuron      methyl,     rimsulfuron,      triflusulfuron    methyl,     triasulfuron,
primisulfuron methyl, cinosulfuron, amidosulfiuon, fluzasulfuron, imazosulfuron,
pyrazosulfuron ethyl, halosulfuron, azimsulfuron, cyclosulfuron, ethoxysulfuron,
flazasulfuron,   flupyrsulfuron    methyl, foramsulfuron,       iodosulfuron, oxasulfuron,
mesosulfuron, prosulfuron, sulfosulfuron, trifloxysulfuron, tritosulfuron, a derivative
                                            - 43 -

of any of the aforementioned herbicides, and a mixture of two or more of the
aforementioned herbicides.        The triazolopyrimidine herbicides of the invention
include, but are not limited to, cloransulam, diclosulam, florasulam, flumetsulam,
metosulam, and penoxsulam. The pyrimidinyloxybenzoate (or pyrimidinyl carboxy)
herbicides of the invention include, but are not limited to, bispyribac, pyrithiobac,
pyriminobac, pyribenzoxim and pyriftalid. The sulfonylamino-carbonyltriazolinone
herbicides include, but are not limited to, flucarbazone and propoxycarbazone.
        It is recognized that pyrimidinyloxybenzoate herbicides are closely related to
the pyrimidinylthiobenzoate herbicides and are generalized under the heading of the
latter name by the Weed Science Society of America. Accordingly, the herbicides of
the present invention further include pyrimidinylthiobenzoate herbicides, including,
but not limited to, the pyrimidinyloxybenzoate herbicides described above.
        The present invention provides methods for enhancing AHAS activity in a
plant comprising transforming a plant with a polynucleotide construct comprising a
promoter operably linked to an AHASL nucleotide sequence of the invention. The
methods involve introducing a polynucleotide construct of the invention into at least
one plant cell and regenerating a transformed plant therefrom. The methods involve
the use of a promoter that is capable of driving gene expression in a plant cell.
Preferably, such a promoter is a constitutive promoter or a tissue-preferred promoter.
The methods find use in enhancing or increasing the resistance of a plant to at least
one herbicide that interferes with the catalytic activity of the AHAS enzyme,
particularly an imidazolinone herbicide.
        The present invention provides expression cassettes for expressing the
polynucleotides of the invention in plants, plant tissues, plant cells, and other host
cells. The expression cassettes comprise a promoter expressible in the plant, plant
tissue, plant cell, or other host cells of interest operably linked to a polynucleotide of
the invention that comprises a nucleotide sequence encoding either a full-length (i.e.
including the chloroplast transit peptide) or mature AHASL protein (i.e. without the
chloroplast transit peptide). If expression is desired in the plastids or chloroplasts of
plants or plant cells, the expression cassette may also comprise an operably linked
chloroplast-targeting sequence that encodes a chloroplast transit peptide.
                                            - 44 -

         The expression cassettes of the invention find use in a method for enhancing
the herbicide tolerance of a plant or a host cell. The method involves transforming the
plant or host cell with an expression cassette of the invention, wherein the expression
cassette comprises a promoter that is expressible in the plant or host cell of interest
and the promoter is operably linked to a polynucleotide of the invention that
comprises a nucleotide sequence encoding an imidazolinone-resistant AHASL protein
of the invention.
         The use of the term "polynucleotide constructs" herein is not intended to limit
the present invention to polynucleotide constructs comprising DNA.               Those of
ordinary skill in the art will recognize that polynucleotide constructs, particularly
polynucleotides and oligonucleotides, comprised of ribonucleotides and combinations
of ribonucleotides and deoxyribonucleotides may also be employed in the methods
disclosed herein.     Thus, the polynucleotide constructs of the present invention
encompass all polynucleotide constructs that can be employed in the methods of the
present invention for transforming plants including, but not limited to, those
comprised of deoxyribonucleotides, ribonucleotides, and combinations thereof Such
deoxyribonucleotides and ribonucleotides include both naturally occurring molecules
and synthetic analogues.       The polynucleotide constructs of the invention also
encompass all forms of polynucleotide constructs including, but not limited to, single
stranded forms, double-stranded forms, hairpins, stem-and-loop structures, and the
like.  Furthermore, it is understood by those of ordinary skill in the art that each
nucleotide sequences disclosed herein also encompasses the complement of that
exemplified nucleotide sequence.
         Further, it is recognized that, for expression of a polynucleotide of the
invention in a host cell of interest, the polynucleotide is typically operably linked to a
promoter that is capable of driving gene expression in the host cell of interest. The
methods of the invention for expressing the polynucleotides in host cells do not
depend on particular promoter. The methods encompass the use of any promoter that
is known in the art and that is capable of driving gene expression in the host cell of
interest.
                                           - 45 -

        The present invention encompasses AHASL polynucleotide molecules and
fragments and variants thereof. Polynucleotide molecules that are fragments of these
nucleotide sequences are also encompassed by the present invention. By "fragment"
is intended a portion of the nucleotide sequence encoding an AHASL protein of the
invention. Preferably, a fragment of an AHASL nucleotide sequence of the invention
encodes a biologically active portion of an AHASL protein. A biologically active
portion of an AHASL protein can be prepared by isolating a portion of one of the
AHASL nucleotide sequences of the invention, expressing the encoded portion of the
AHASL protein (e.g., by recombinant expression in vitro), and assessing the activity
of the encoded portion of the AHASL protein. Polynucleotide molecules that are
fragments of an AHASL nucleotide sequence and encode biologically active portions
of AHASL proteins comprise at least about 500, 750, 1000, 1250, 1500, 1600, 1700,
1800, 1900, or 2000 nucleotides, or up to the number of nucleotides present in a full
length nucleotide sequence disclosed herein (for example, 2013 nucleotides for SEQ
ID NO: 30) depending upon the intended use.
        A fragment of an AHASL nucleotide sequence that encodes a biologically
active portion of an AHASL protein of the invention will encode at least about 200,
300, 400, 500, 550, 650, or 650 contiguous amino acids, or up to the total number of
amino acids present in a full-length AHASL protein of the invention (for example,
670 amino acids for SEQ ID NO: 1).
        Polynucleotide molecules comprising nucleotide sequences that are variants of
the nucleotide sequences disclosed herein are also encompassed by the present
invention. "Variants" of the AHASL nucleotide sequences of the invention include
those sequences that encode the mutant AHASL polypeptides disclosed herein but
that differ conservatively because of the degeneracy of the genetic code.      These
naturally occurring allelic variants can be identified with the use of well-known
molecular biology techniques, such as polymerase         chain reaction (PCR) and
hybridization techniques as outlined below.      Variant nucleotide sequences also
include synthetically derived nucleotide sequences that have been generated, for
example, by using site-directed mutagenesis but which still encode the AHASL
protein disclosed in the present       invention as discussed below.        Generally,
polynucleotide sequence variants of the invention will have at least about 80%, 85%,
                                         - 46 -

90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity to a particular
nucleotide sequence disclosed herein.       A variant AHASL polynucleotide sequence
will encode an AHASL mutant polypeptide, respectively, that has an amino acid
sequence having at least about 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,
97%, 98%, or 99% identity to the amino acid sequence of an AHASL polypeptide
disclosed herein.
        In addition, the skilled artisan will further appreciate that changes can be
introduced by mutation into the polynucleotides sequences of the invention thereby
leading to changes in the amino acid sequence of the encoded AHASL double and
triple mutant polypeptides without altering the biological activity of the double and
triple mutant polypeptides.     Thus, an isolated polynucleotide molecule encoding an
AHASL double and triple mutant polypeptide having a sequence that differs from the
double and triple mutant sequences set forth in Figures 1 and 2 can be created by
introducing one or more nucleotide substitutions, additions, or deletions into the
corresponding nucleotide sequence disclosed herein, such that one or more amino acid
substitutions, additions or deletions are introduced into the encoded protein.
Mutations    can be     introduced    by standard techniques,      such   as  site-directed
mutagenesis and PCR-mediated mutagenesis. Such variant nucleotide sequences are
also encompassed by the present invention.
        For example, preferably, conservative amino acid substitutions may be made
at one or more predicted, preferably nonessential             amino acid residues.        A
"nonessential" amino acid residue is a residue that can be altered from the wild-type
sequence of an AHASL protein (e.g., the sequence of SEQ ID NO: 1) without altering
the biological activity, whereas an "essential" amino acid residue is required for
biological activity.   A "conservative amino acid substitution" is one in which the
amino acid residue is replaced with an amino acid residue having a similar side chain.
Families of amino acid residues having similar side chains have been defined in the
art. These families include amino acids with basic side chains (e.g., lysine, arginine,
histidine), acidic side chains (e.g., aspartic acid, glutamic acid), uncharged polar side
chains (e.g., glycine, asparagine, glutamine, serine, threonine, tyrosine, cysteine),
nonpolar side chains (e.g., alanine, valine, leucine, isoleucine, proline, phenylalanine,
methionine,    tryptophan),    beta-branched    side   chains  (e.g.,  threonine,   valine,
                                           -47-

isoleucine) and aromatic side chains (e.g., tyrosine, phenylalanine, tryptophan,
histidine). Such substitutions would not be made for conserved amino acid residues,
or for amino acid residues residing within a conserved motif.
        The proteins of the invention may be altered in various ways including amino
acid   substitutions, deletions, truncations,   and insertions.      Methods    for such
manipulations are generally known in the art.      For example, amino acid sequence
variants of the AHASL proteins can be prepared by mutations in the DNA. Methods
for mutagenesis and nucleotide sequence alterations are well known in the art. See,
for example, Kunkel (1985) Proc. Natl. Acad. Sci. USA 82:488-492; Kunkel et al.
(1987) Methods in Enzymol. 154:367-382; U.S. Patent No. 4,873,192; Walker and
Gaastra, eds. (1983)     Techniques in Molecular Biology (MacMillan Publishing
Company, New York) and the references cited therein. Guidance as to appropriate
amino acid substitutions that do not affect biological activity of the protein of interest
may be found in the model of Dayhoff et al. (1978) Atlas of Protein Sequence and
Structure (Natl. Biomed. Res. Found., Washington, D.C.), herein incorporated by
reference.    Conservative substitutions, such as exchanging one amino acid with
another having similar properties, may be preferable.
        It is recognized that the polynucleotide molecules and polypeptides of the
invention encompass polynucleotide molecules and polypeptides comprising a
nucleotide or an amino acid sequence that is sufficiently identical to the double or
triple nucleotide sequences set forth in Figures 1 and 2, or to the amino acid
sequences set forth in Figures 1 and 2. The term "sufficiently identical" is used herein
to refer to a first amino acid or nucleotide sequence that contains a sufficient or
minimum number of identical or equivalent (e.g., with a similar side chain) amino
acid residues or nucleotides to a second amino acid or nucleotide sequence such that
the first and second amino acid or nucleotide sequences have a common structural
domain and/or common functional activity. For example, amino acid or nucleotide
sequences that contain a common structural domain having at least about 80%
identity, preferably 85% identity, more preferably 90%, 95%, or 98% identity are
defined herein as sufficiently identical.
                                          - 48-

        To determine the percent identity of two amino acid sequences or of two
nucleic acids, the sequences are aligned for optimal comparison purposes.            The
percent identity between the two sequences is a function of the number of identical
positions shared by the sequences (i.e., percent identity      =  number of identical
positions/total number of positions (e.g., overlapping positions) x 100).        In one
embodiment, the two sequences are the same length. The percent identity between
two sequences can be determined using techniques similar to those described below,
with or without allowing gaps. In calculating percent identity, typically exact matches
are counted.
        The determination of percent identity between two sequences can be
accomplished using a mathematical algorithm. A preferred, nonlimiting example of a
mathematical algorithm utilized for the comparison of two sequences is the algorithm
of Karlin and Altschul (1990) Proc. Natl. Acad. Sci. USA 87:2264, modified as in
Karlin and Altschul (1993) Proc. Natl. Acad. Sci. USA 90:5873-5877.             Such an
algorithm is incorporated into the NBLAST and XBLAST programs of Altschul et al.
(1990) J Mol. Biol. 215:403. BLAST nucleotide searches can be performed with the
NBLAST program, score       = 100, wordlength   =  12, to obtain nucleotide sequences
homologous to the polynucleotide molecules of the invention.            BLAST protein
searches can be performed with the XBLAST program, score       = 50, wordlength   = 3, to
obtain amino acid sequences homologous to protein molecules of the invention. To
obtain gapped alignments for comparison purposes, Gapped BLAST can be utilized as
described in Altschul et al. (1997) Nucleic Acids Res. 25:3389. Alternatively, PSI
Blast can be used to perform an iterated search that detects distant relationships
between molecules.     See, Altschul et al. (1997) supra. When utilizing BLAST,
Gapped BLAST, and PSI-Blast programs, the default parameters of the respective
programs      (e.g.,  XBLAST        and    NBLAST)        can    be     used.        See
http://www.ncbi.nlm.nih.gov.      Another   preferred,   non-limiting   example of a
mathematical algorithm utilized for the comparison of sequences is the algorithm of
Myers and Miller (1988) CABIOS 4:11-17. Such an algorithm is incorporated into the
ALIGN program (version 2.0), which is part of the GCG sequence alignment software
                                        - 49 -

package. When utilizing the ALIGN program for comparing amino acid sequences, a
PAM120 weight residue table, a gap length penalty of 12, and a gap penalty of 4 can
be used. Alignment may also be performed manually by inspection.
        Unless otherwise stated, sequence identity/similarity values provided herein
refer to the value obtained using the full-length sequences of the invention and using
multiple alignment by mean of the algorithm Clustal W (Nucleic Acid Research,
22(22):4673-4680, 1994) using the program AlignX included in the software package
Vector NTI Suite Version 9 (Invitrogen, 1600 Faraday Ave., Carlsbad, CA 92008)
using the default parameters; or any equivalent program thereof.        By "equivalent
program" is intended any sequence comparison program that, for any two sequences
in question, generates an alignment having identical nucleotide or amino acid residue
matches    and an identical percent sequence        identity when compared to the
corresponding alignment generated by AlignX in the software package Vector NTI
Suite Version 9.
        The   deletions,  insertions,   and substitutions   of the protein sequences
encompassed herein are not expected to produce radical changes in the characteristics
of the protein.    However, when it is difficult to predict the exact effect of the
substitution, deletion, or insertion in advance of doing so, one skilled in the art will
appreciate that the effect will be evaluated by routine screening assays. That is, the
activity can be evaluated by AHAS activity assays.       See, for example, Singh et al.
(1988) Anal. Biochem. 171:173-179, herein incorporated by reference.
        As disclosed herein, the polynucleotides of the invention find use in enhancing
the herbicide tolerance of plants that comprise in their genomes a gene encoding a
herbicide-tolerant AHASL protein. Such a gene may be an endogenous gene or a
transgene. Additionally, in certain embodiments, the polynucleotides of the present
invention can be stacked with any combination of polynucleotide sequences of
interest in order to create plants with a desired phenotype.         For example, the
polynucleotides    of the    present   invention  may be     stacked  with   any other
polynucleotides encoding polypeptides having pesticidal and/or insecticidal activity,
such as, for example, the Bacillus thuringiensistoxin proteins (described in U.S.
                                           - 50 -

Patent Nos. 5,366,892; 5,747,450; 5,737,514; 5,723,756; 5,593,881; and Geiser et al.
(1986) Gene 48:109). The combinations generated can also include multiple copies
of any one of the polynucleotides of interest.
         While the polynucleotides of the invention find use as selectable marker genes
for plant transformation, the expression cassettes of the invention can include another
selectable marker gene for the selection of transformed cells.        Selectable marker
genes, including those of the present invention, are utilized for the selection of
transformed cells or tissues.    Marker genes include, but are not limited to, genes
encoding antibiotic resistance, such as those encoding neomycin phosphotransferase
II (NEO) and hygromycin phosphotransferase (HPT), as well as genes conferring
resistance to herbicidal compounds, such as glufosinate ammonium, bromoxynil,
imidazolinones, and 2,4-dichlorophenoxyacetate (2,4-D).       See generally, Yarranton
(1992) Curr. Opin. Biotech. 3:506-511; Christopherson et al. (1992) Proc. Natl. Acad.
Sci. USA 89:6314-6318; Yao et al. (1992) Cell 71:63-72; Reznikoff (1992) Mol.
Microbiol. 6:2419-2422; Barkley et al. (1980) in The Operon, pp. 177-220; Hu et al.
(1987) Cell 48:555-566; Brown et al. (1987) Cell 49:603-612; Figge et al. (1988) Cell
52:713-722; Deuschle et al. (1989) Proc. Natl. Acad. Aci. USA 86:5400-5404; Fuerst
et al. (1989) Proc. Natl. Acad. Sci. USA 86:2549-2553; Deuschle et al. (1990) Science
248:480-483; Gossen (1993) Ph.D. Thesis, University of Heidelberg; Reines et al.
(1993) Proc. Natl. Acad. Sci. USA 90:1917-1921; Labow et al. (1990) Mol. Cell. Biol.
10:3343-3356; Zambretti et al. (1992) Proc. Natl.Acad. Sci. USA 89:3952-3956; Baim
et al. (1991) Proc. Natl. Acad. Sci. USA 88:5072-5076; Wyborski et al. (1991) Nucleic
Acids Res. 19:4647-4653; Hillenand-Wissman (1989) Topics Mol. Struc. Biol. 10:143
162; Degenkolb      et al. (1991)     Antimicrob. Agents Chemother. 35:1591-1595;
Kleinschnidt et al. (1988) Biochemistry 27:1094-1104; Bonin (1993) Ph.D. Thesis,
University of Heidelberg; Gossen et al. (1992) Proc. Natl. Acad. Sci. USA 89:5547
5551; Oliva et al. (1992) Antimicrob. Agents Chemother. 36:913-919; Hlavka et al.
(1985) Handbook of Experimental Pharmacology,Vol. 78 ( Springer-Verlag, Berlin);
Gill et al. (1988) Nature 334:721-724. Such disclosures are herein incorporated by
reference.
                                          -51  -

        The above list of selectable marker genes is not meant to be limiting. Any
selectable marker gene can be used in the present invention.
        The isolated polynucleotide molecules comprising nucleotide sequence that
encode the AHASL proteins of the invention can be used in vectors to transform
plants so that the plants created have enhanced resistant to herbicides, particularly an
imidazolinone    herbicide    or  sulfonylurea    herbicide.   The   isolated   AHASL
polynucleotide molecules of the invention can be used in vectors alone or in
combination with a nucleotide sequence encoding the small subunit of the AHAS
(AHASS) enzyme in conferring herbicide resistance in plants. See, U.S. Patent No.
6,348,643; which is herein incorporated by reference.
        The invention also relates to a plant expression vector comprising a promoter
that drives expression in a plant operably linked to an isolated polynucleotide
molecule of the invention.       The isolated polynucleotide molecule comprises a
nucleotide sequence encoding an AHASL protein of the invention, or a functional
fragment and variant thereof. The plant expression vector of the invention does not
depend on a particular promoter, only that such a promoter is capable of driving gene
expression in a plant cell. Preferred promoters include constitutive promoters and
tissue-preferred promoters.
        The transformation vectors of the invention can be used to produce plants
transformed with a gene of interest.        The transformation vector will comprise a
selectable marker gene of the invention and a gene of interest to be introduced and
typically expressed in the transformed plant.          Such a selectable marker gene
comprises a polynucleotide of the invention that encodes an AHASL double or triple
mutant polypeptide, wherein the polynucleotide is operably linked to a promoter that
drives expression in a host cell. For use in plants and plant cells, the transformation
vector comprises a selectable marker gene comprising a polynucleotide of the
invention that encodes an AHASL double or triple mutant polypeptide operably
linked to a promoter that drives expression in a plant cell.
        The genes of interest of the invention vary depending on the desired outcome.
For example, various changes in phenotype can be of interest including modifying the
fatty acid composition in a plant, altering the amino acid content of a plant, altering a
plant's insect and/or pathogen defense mechanisms, and the like. These results can be
                                          -  52 -

achieved by providing expression of heterologous products or increased expression of
endogenous products in plants.       Alternatively, the results can be achieved by
providing for a reduction of expression of one or more endogenous products,
particularly enzymes or cofactors in the plant. These changes result in a change in
phenotype of the transformed plant.
        In one embodiment of the invention, the genes of interest include insect
resistance genes such as, for example, Bacillus thuringiensistoxin protein genes (U.S.
Patent Nos. 5,366,892; 5,747,450; 5,736,514; 5,723,756; 5,593,881; and Geiser et al.
(1986) Gene 48:109).
        The AHASL proteins or polypeptides of the invention can be purified from,
for example, sunflower plants and can be used in compositions. Also, an isolated
polynucleotide molecule encoding an AHASL protein of the invention can be used to
express an AHASL protein of the invention in a microbe such as E. coli or a yeast.
The expressed AHASL protein can be purified from extracts of E. coli or yeast by any
method known to those of ordinary skill in the art.
        The polynucleotides of the invention find use in methods for enhancing the
resistance of herbicide-tolerant plants.     In one embodiment of the invention, the
herbicide-tolerant plants that comprise a polynucleotide of the invention that encodes
an AHASL double or triple mutant polypeptide.           The invention further provides
herbicide-tolerant plants that comprise two or more polynucleotides encoding
AHASL single mutant polypeptides.          Polynucleotides encoding herbicide-tolerant
AHASL proteins and herbicide-tolerant plants comprising an endogenous gene that
encodes a herbicide-tolerant AHASL protein include the polynucleotides and plants of
the present invention and those that are known in the art. See, for example, U.S.
Patent Nos. 5,013,659, 5,731,180, 5,767,361,        5,545,822,  5,736,629, 5,773,703,
5,773,704, 5,952,553 and 6,274,796;         all of which are herein incorporated by
reference.   Such methods for enhancing the resistance of herbicide-tolerant plants
comprise transforming a herbicide-tolerant plant with at least one polynucleotide
construct comprising a promoter that drives expression in a plant cell that is operably
linked to a polynucleotide of the invention.
                                          - 53  -

        Numerous plant transformation vectors and methods for transforming plants
are available. See, for example, An, G. et al. (1986) Plant Physiol., 81:301-305; Fry,
J., et al. (1987) Plant Cell Rep. 6:321-325; Block, M. (1988)               Theor. Apple
Genet.76:767-774; Hinchee, et al. (1990) Stadler. Genet. Symp.203212.203-212;
Cousins, et al. (1991) Aust. J Plant Physiol. 18:481-494; Chee, P. P. and Slightom, J.
L. (1992) Gene. 118:255-260; Christou, et al. (1992) Trends. Biotechnol. 10:239-246;
D'Halluin, et al. (1992) Bio/Technol. 10:309-314; Dhir, et al. (1992) Plant Physiol.
99:81-88; Casas et al. (1993) Proc. Nat. Acad Sci. USA 90:11212-11216; Christou, P.
(1993) In Vitro Cell. Dev. Biol.-Plant; 29P:119-124; Davies, et al. (1993) Plant Cell
Rep. 12:180-183; Dong, J. A. and Mchughen, A. (1993) Plant Sci. 91:139-148;
Franklin, C. I. and Trieu, T. N. (1993) Plant. Physiol. 102:167; Golovkin, et al.
(1993) Plant Sci. 90:41-52; Guo Chin Sci. Bull. 38:2072-2078; Asano, et al. (1994)
Plant Cell Rep. 13; Ayeres N. M. and Park, W. D. (1994) Crit. Rev. Plant. Sci.
13:219-239; Barcelo, et al. (1994) Plant. J. 5:583-592; Becker, et al. (1994) Plant. J
5:299-307; Borkowska et al. (1994) Acta. Physiol Plant. 16:225-230; Christou, P.
(1994) Agro. Food. Ind. Hi Tech. 5: 17-27; Eapen et al. (1994) Plant Cell Rep.
13:582-586; Hartman, et al. (1994) Bio-Technology 12: 919923; Ritala, et al. (1994)
Plant. Mol. Biol. 24:317-325; and Wan, Y. C. and Lemaux, P. G. (1994) Plant
Physiol. 104:3748.
        The methods of the invention involve introducing a polynucleotide construct
into a plant. By "introducing" is intended presenting to the plant the polynucleotide
construct in such a manner that the construct gains access to the interior of a cell of
the plant. The methods of the invention do not depend on a particular method for
introducing a polynucleotide construct to a plant, only that the polynucleotide
construct gains access to the interior of at least one cell of the plant. Methods for
introducing polynucleotide constructs into plants are known in the art including, but
not limited to, stable transformation methods, transient transformation methods, and
virus-mediated methods.
        By "stable transformation" is intended that the polynucleotide construct
introduced into a plant integrates into the genome of the plant and is capable of being
                                           - 54 -

inherited by progeny thereof.        By "transient transformation" is intended that a
polynucleotide construct introduced into a plant does not integrate into the genome of
the plant.
         For the transformation of plants and plant cells, the nucleotide sequences of
the invention are inserted using standard techniques into any vector known in the art
that is suitable for expression of the nucleotide sequences in a plant or plant cell. The
selection of the vector depends on the preferred transformation technique and the
target plant species to be transformed. In an embodiment of the invention, an AHASL
nucleotide sequence is operably linked to a plant promoter that is known for high
level expression in a plant cell, and this construct is then introduced into a plant that is
susceptible to an imidazolinone or sulfonylurea herbicide and a transformed plant is
regenerated.      The transformed plant is tolerant to exposure to a level of an
imidazolinone or sulfonylurea herbicide that would kill or significantly injure an
untransformed plant. This method can be applied to any plant species; however, it is
most beneficial when applied to crop plants.
         Methodologies for constructing plant expression cassettes and introducing
foreign nucleic acids into plants are generally known in the art and have been
previously described. For example, foreign DNA can be introduced into plants, using
tumor-inducing (Ti) plasmid vectors. Agrobacterium based transformation techniques
are well known in the art. The Agrobacterium strain (e.g., Agrobacterium tumefaciens
or Agrobacterium rhizogenes) comprises a plasmid (Ti or Ri plasmid) and a T-DNA
element which is transferred to the plant following infection with Agrobacterium. The
T-DNA (transferred DNA) is integrated into the genome of the plant cell. The T-DNA
may be localized on the Ri- or Ti-plasmid or is separately comprised in a so-called
binary vector. Methods for the Agrobacterium-mediated transformation are described,
for example, in Horsch RB et al. (1985) Science 225:1229f. The Agrobacterium
mediated     transformation    can   be  used     in both    dicotyledonous   plants    and
monocotyledonous plants. The transformation of plants by Agrobacteria is described
in White FF, Vectors for Gene Transfer in Higher Plants; Vol. 1, Engineering and
Utilization, edited by S.D. Kung and R. Wu, Academic Press, 1993, pp. 15 - 38; Jenes
B et al. (1993) Techniques for Gene Transfer, in: Transgenic Plants, Vol. 1,
Engineering and Utilization, edited by S.D. Kung and R. Wu, Academic Press, pp.
                                           - 55 -

128-143; Potrykus (1991) Annu Rev Plant Physiol Plant Molec Biol 42:205- 225.
Other methods utilized for foreign DNA delivery involve the use of PEG mediated
protoplast transformation, electroporation, microinjection whiskers, and biolistics or
microprojectile bombardment for direct DNA uptake. Such methods are known in the
art. (U.S. Pat. No. 5,405,765 to Vasil et al.; Bilang et al. (1991) Gene 100: 247-250;
Scheid et al. (1991) Mol. Gen. Genet., 228: 104-112; Guerche et al. (1987) Plant
Science 52: 111-116; Neuhause et al. (1987) Theor. Apple Genet. 75: 30-36; Klein et
al. (1987) Nature 327: 70-73; Howell et al. (1980) Science 208:1265; Horsch et al.
(1985) Science 227: 1229-123 1; DeBlock et al. (1989) Plant Physiology 91: 694-701;
Methods for Plant Molecular Biology (Weissbach and Weissbach, eds.) Academic
Press, Inc. (1988) and Methods in Plant Molecular Biology (Schuler and Zielinski,
eds.) Academic Press, Inc. (1989).    The method of transformation depends upon the
plant cell to be transformed, stability of vectors used, expression level of gene
products and other parameters.
        Other suitable methods of introducing nucleotide sequences into plant cells
and subsequent insertion into the plant genome include microinjection as Crossway et
al. (1986) Biotechniques 4:320-334, electroporation as described by Riggs et al.
(1986)    Proc. Natl. Acad. Sci.       USA    83:5602-5606, Agrobacterium-mediated
transformation as described by Townsend et al. U.S. Patent No. 5,563,055, Zhao et al.
U.S. Patent No. 5,981,840, direct gene transfer as described by Paszkowski et al.
(1984) EMBO J 3:2717-2722, and ballistic particle acceleration as described in, for
example, Sanford et al. U.S. Patent No. 4,945,050; Tomes et al. U.S. Patent No.
5,879,918; Tomes et al. U.S. Patent No. 5,886,244; Bidney et al. U.S. Patent No.
5,932,782; Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via
Microprojectile   Bombardment,"     in Plant Cell, Tissue, and Organ Culture:
FundamentalMethods, ed. Gamborg and Phillips (Springer-Verlag, Berlin); McCabe
et al. (1988) Biotechnology 6:923-926); and Lec        transformation (WO 00/28058).
Also see, Weissinger et al. (1988) Ann. Rev. Genet. 22:421-477; Sanford et al. (1987)
ParticulateScience and Technology 5:27-37 (onion); Christou et al. (1988) Plant
Physiol. 87:671-674 (soybean); McCabe et al. (1988) Bio/Technology 6:923-926
(soybean); Finer and McMullen (1991)          In Vitro Cell Dev. Biol. 27P:175-182
(soybean); Singh et al. (1998) Theor. Apple. Genet. 96:319-324 (soybean); Datta et al.
                                         - 56  -

(1990) Biotechnology 8:736-740 (rice); Klein et al. (1988) Proc. Natl. Acad. Sci. USA
85:4305-4309 (maize); Klein et al. (1988) Biotechnology 6:559-563 (maize); Tomes,
U.S. Patent No. 5,240,855; Buising et al. U.S. Patent Nos. 5,322,783 and 5,324,646;
Tomes et al. (1995) "Direct DNA Transfer into Intact Plant Cells via Microprojectile
Bombardment," in Plant Cell, Tissue, and Organ Culture: FundamentalMethods, ed.
Gamborg (Springer-Verlag, Berlin) (maize); Klein et al. (1988) Plant Physiol.
91:440-444    (maize);  Fromm et al. (1990)        Biotechnology 8:833-839 (maize);
Hooykaas-Van Slogteren et al. (1984) Nature (London) 311:763-764; Bowen et al.
U.S. Patent No. 5,736,369 (cereals); Bytebier et al. (1987) Proc.Natl. A cad. Sci. USA
84:5345-5349 (Liliaceae); De Wet et al. (1985) in The Experimental Manipulation of
Ovule Tissues, ed. Chapman et al. (Longman, New York), pp. 197-209 (pollen);
Kaeppler et al. (1990) Plant Cell Reports 9:415-418 and Kaeppler et al. (1992) Theor.
Apple. Genet. 84:560-566 (whisker-mediated transformation); D'Halluin et al. (1992)
Plant Cell 4:1495-1505 (electroporation); Li et al. (1993) Plant Cell Reports 12:250
255 and Christou and Ford (1995) Annals of Botany 75:407-413 (rice); Osjoda et al.
(1996) Nature Biotechnology 14:745-750 (maize via Agrobacterium tumefaciens); all
of which are herein incorporated by reference.
        The polynucleotides of the invention may be introduced into plants by
contacting plants with a virus or viral nucleic acids. Generally, such methods involve
incorporating a polynucleotide construct of the invention within a viral DNA or RNA
molecule. It is recognized that the AHASL protein of the invention may be initially
synthesized as part of a viral polyprotein, which later may be processed by proteolysis
in vivo or in vitro to produce the desired recombinant protein.          Further, it is
recognized that promoters of the invention also encompass promoters utilized for
transcription by viral RNA polymerases.        Methods for introducing polynucleotide
constructs into plants and expressing a protein encoded therein, involving viral DNA
or RNA molecules, are known in the art.           See, for example, U.S. Patent Nos.
5,889,191, 5,889,190, 5,866,785, 5,589,367 and 5,316,931; herein incorporated by
reference.
        The cells that have been transformed may be grown into plants in accordance
with conventional ways.      See, for example, McCormick et al. (1986) Plant Cell
Reports 5:81-84.    These plants may then be grown, and either pollinated with the
                                          - 57 -

same transformed strain or different strains, and the resulting hybrid having
constitutive expression of the desired phenotypic characteristic identified. Two or
more generations may be grown to ensure that expression of the desired phenotypic
characteristic is stably maintained and inherited and then seeds harvested to ensure
expression of the desired phenotypic characteristic has been achieved. In this manner,
the present invention provides transformed seed (also referred to as "transgenic seed")
having a polynucleotide construct of the invention, for example, an expression
cassette of the invention, stably incorporated into their genome.
        The present invention may be used for transformation of any plant species,
including, but not limited to, monocots and dicots. Examples of plant species of
interest include, but are not limited to, corn or maize (Zea mays), Brassicasp. (e.g., B.
napus, B. rapa,B. juncea), particularly those Brassicaspecies useful as sources of seed
oil, alfalfa (Medicago sativa), rice (Oryza sativa), rye (Secale cereale), sorghum
(Sorghum bicolor, Sorghum vulgare), millet (e.g., pearl millet (Pennisetum glaucum),
proso millet (Panicum miliaceum), foxtail millet (Setaria italica), finger millet
(Eleusine coracana)), sunflower (Helianthus annuus), safflower (Carthamus
tinctorius), wheat (Triticum aestivum, T. Turgidum ssp. durum), soybean (Glycine
max), tobacco (Nicotiana tabacum), potato (Solanum tuberosum), peanuts (Arachis
hypogaea), cotton (Gossypium barbadense, Gossypium hirsutum), sweet potato
(Ipomoea batatus), cassava (Manihot esculenta), coffee (Coffea spp.), coconut (Cocos
nucifera), pineapple (Ananas comosus), citrus trees (Citrus spp.), cocoa (Theobroma
cacao), tea (Camellia sinensis), banana (Musa spp.), avocado (Persea americana),fig
(Ficus casica), guava (Psidium guajava), mango (Mangifera indica), olive (Olea
europaea), papaya (Carica papaya), cashew (Anacardium occidentale), macadamia
(Macadamia integrifolia), almond (Prunus amygdalus), sugar beets (Beta vulgaris),
sugarcane (Saccharum spp.), oats, barley, vegetables, ornamentals, and conifers.
Preferably, plants of the present invention are crop plants (for example, sunflower,
Brassica sp., cotton, sugar beet, soybean, peanut, alfalfa, safflower, tobacco, corn,
rice, wheat, rye, barley triticale, sorghum, millet, etc.).
        The plants of the invention are herbicide-resistant plants and thus, find use in
methods for controlling weeds that involve the application of a herbicide. Thus, the
present invention further provides a method for controlling weeds in the vicinity of a
                                           - 58 -

herbicide-resistant plant of the invention.      The method comprises applying an
effective amount of a herbicide to the weeds and to the herbicide-resistant plant,
wherein the plant has increased resistance to at least one AHAS-inhibiting herbicide,
particularly an imidazolinone or sulfonylurea herbicide, when compared to a wild
type plant. In such a method for controlling weeds, the herbicide-resistant plants of
the invention are preferably crop plants, including, but not limited to, sunflower,
alfalfa, Brassica sp., soybean, cotton, safflower, peanut, tobacco, tomato, potato,
wheat, rice, maize, sorghum, barley, rye, millet, and sorghum.
        By providing plants having increased resistance to herbicides, particularly
imidazolinone and sulfonylurea herbicides, a wide variety of formulations can be
employed for protecting plants from weeds, so as to enhance plant growth and reduce
competition for nutrients. A herbicide can be used by itself for pre-emergence, post
emergence, pre-planting and at planting control of weeds in areas surrounding the
plants described herein or an imidazolinone herbicide formulation can be used that
contains other additives. The herbicide can also be used as a seed treatment. Additives
found in an imidazolinone or sulfonylurea herbicide formulation include other
herbicides, detergents, adjuvants, spreading agents, sticking agents, stabilizing agents,
or the like.   The herbicide formulation can be a wet or dry preparation and can
include, but is not limited to, flowable powders, emulsifiable concentrates and liquid
concentrates. The herbicide and herbicide formulations can be applied in accordance
with conventional methods, for example, by spraying, irrigation, dusting, or the like.
        The present invention provides non-transgenic and transgenic plants and seeds
with increased tolerance to at least one herbicide, particularly an AHAS-inhibiting
herbicide,   more particularly imidazolinone      and sulfonylurea    herbicides,   most
particularly imidazolinone herbicides. In preferred embodiment of the invention, the
plants and seeds of the invention display a higher level of herbicide tolerance that
similar plants that comprise only one AHASL single mutant polypeptide. Such plants
and seeds of the invention find use in improved methods for controlling weeds that
allow for the application of a herbicide to the weeds and to the herbicide-resistant
plant at an effective amount that comprises a higher herbicidal concentration or rate
than can be used with similar plants that comprise only one AHASL single mutant
                                          - 59 -

polypeptide.     Accordingly, such improved methods provide superior weed control
when compared to existing methods involving plants comprising only one AHASL
single mutant polypeptide and the application of a lower herbicidal concentration or
rate.
        The     present   invention   provides    herbicide-resistant plants   comprising
polynucleotides     encoding AHASL        double or triple mutant polypeptides        and
herbicide-resistant plants comprising two or more polynucleotides encoding AHASL
single mutant polypeptides. These herbicide-resistant plants of the present invention
find use in methods for producing herbicide-resistant plants through conventional
plant breeding involving sexual reproduction. The methods comprise crossing a first
plant that is a herbicide-resistant plant of the invention to a second plant that is not
resistant to the herbicide.     The second plant can be any plant that is capable of
producing viable progeny plants (i.e., seeds) when crossed with the first plant.
Typically, but not necessarily, the first and second plants are of the same species. The
methods can optionally involve selecting for progeny plants that comprise the
polynucleotide encoding the AHASL mutant polypeptide or the two or more
polynucleotides encoding AHASL single mutant polypeptides of the first plant. The
methods of the invention can further involve one or more generations of backcrossing
the progeny plants of the first cross to a plant of the same line or genotype as either
the first or second plant.       Alternatively, the progeny of the first cross or any
subsequent cross can be crossed to a third plant that is of a different line or genotype
than either the first or second plant.
        The herbicide-resistant plants of the invention that comprise polynucleotides
encoding AHASL double or triple mutant polypeptides and herbicide-resistant plants
comprising     two    or   more   polynucleotides    encoding    AHASL     single mutant
polypeptides also find use in methods for increasing the herbicide-resistance of a plant
through conventional plant breeding involving sexual reproduction.           The methods
comprise crossing a first plant that is a herbicide-resistant plant of the invention to a
second plant that may or may not be resistant to the same herbicide or herbicides as
the first plant or may be resistant to different herbicide or herbicides than the first
plant. The second plant can be any plant that is capable of producing viable progeny
plants (i.e., seeds) when crossed with the first plant. Typically, but not necessarily,
                                           - 60 -

the first and second plants are of the same species.           The methods can optionally
involve selecting for progeny plants that comprise the polynucleotide encoding the
AHASL mutant polypeptide or the two or more polynucleotides encoding AHASL
single   mutant polypeptides        of the     first plant and the     herbicide   resistance
characteristics of the second plant. The progeny plants produced by this method of
the present invention have increased resistance to a herbicide when compared to either
the first or second plant or both. When the first and second plants are resistant to
different herbicides, the progeny plants will have the combined herbicide tolerance
characteristics of the first and second plants.         The methods of the invention can
further involve one or more generations of backcrossing the progeny plants of the first
cross to a plant of the same line or genotype as either the first or second plant.
Alternatively, the progeny of the first cross or any subsequent cross can be crossed to
a third plant that is of a different line or genotype than either the first or second plant.
         The present invention also provides plants, plant organs, plant tissues, plant
cells, seeds, and non-human host cells that are transformed with the at least one
polynucleotide molecule, expression cassette,            or transformation vector of the
invention. Such transformed plants, plant organs, plant tissues, plant cells, seeds, and
non-human host cells have enhanced tolerance or resistance to at least one herbicide,
at levels of the herbicide that kill or inhibit the growth of an untransformed plant,
plant tissue, plant cell, or non-human host cell, respectively.              Preferably, the
transformed plants, plant tissues, plant cells, and seeds of the invention are
Arabidopsisthaliana and crop plants.
         The present invention provides methods that involve the use of at least one
AHAS-inhibiting herbicide selected from the group consisting of imidazolinone
herbicides,       sulfonylurea         herbicides,       triazolopyrimidine       herbicides,
pyrimidinyloxybenzoate herbicides, sulfonylamino-carbonyltriazolinone herbicides,
and mixtures thereof.       In these methods, the AHAS-inhibiting herbicide can be
applied by any method known in the art including, but not limited to, seed treatment,
soil treatment, and foliar treatment.
         Prior to application, the AHAS-inhibiting herbicide can be converted into the
customary formulations, for example solutions, emulsions, suspensions, dusts,
                                             -  61  -

powders, pastes and granules. The use form depends on the particular intended
purpose; in each case, it should ensure a fine and even distribution of the compound
according to the invention.
         The formulations are prepared in a known manner (see e.g. for review US
3,060,084, EP-A 707 445 (for liquid concentrates), Browning, "Agglomeration",
Chemical      Engineering,   Dec. 4,   1967,   147-48,   Perry's   Chemical   Engineer's
Handbook, 4th Ed., McGraw-Hill, New York, 1963, pages 8-57 and et seq. WO
91/13546, US 4,172,714, US 4,144,050, US 3,920,442, US 5,180,587, US 5,232,701,
US 5,208,030, GB 2,095,558, US 3,299,566, Klingman, Weed Control as a Science,
John Wiley and Sons, Inc., New York, 1961, Hance et al. Weed Control Handbook,
8th Ed., Blackwell Scientific Publications, Oxford, 1989 and Mollet, H., Grubemann,
A., Formulation technology, Wiley VCH Verlag GmbH, Weinheim (Germany), 2001,
2. D. A. Knowles, Chemistry and Technology of Agrochemical Formulations, Kluwer
Academic Publishers, Dordrecht, 1998 (ISBN 0-7514-0443-8), for example by
extending the active compound with auxiliaries suitable for the formulation of
agrochemicals, such as solvents and/or carriers, if desired emulsifiers, surfactants and
dispersants, preservatives, antifoaming agents, anti-freezing agents, for seed treatment
formulation also optionally colorants and/or binders and/or gelling agents.
         Examples of suitable solvents are water, aromatic solvents (for example
Solvesso products, xylene), paraffins (for example mineral oil fractions), alcohols (for
example      methanol, butanol, pentanol, benzyl alcohol), ketones        (for example
cyclohexanone, gamma-butyrolactone), pyrrolidones (NMP, NOP), acetates (glycol
diacetate), glycols, fatty acid dimethylamides, fatty acids and fatty acid esters. In
principle, solvent mixtures may also be used.
         Examples of suitable carriers are ground natural minerals (for example
kaolins, clays, talc, chalk) and ground synthetic minerals (for example highly disperse
silica, silicates).
         Suitable emulsifiers are nonionic and anionic emulsifiers (for example
polyoxyethylene fatty alcohol ethers, alkylsulfonates and arylsulfonates).
         Examples of dispersants are lignin-sulfite waste liquors and methylcellulose.
                                          - 62 -

         Suitable surfactants used are alkali metal, alkaline earth metal and ammonium
salts   of lignosulfonic      acid,   naphthalenesulfonic     acid,   phenolsulfonic     acid,
dibutylnaphthalenesulfonic acid, alkylarylsulfonates, alkyl sulfates, alkylsulfonates,
fatty alcohol sulfates, fatty acids and sulfated fatty alcohol glycol ethers, furthermore
condensates      of  sulfonated     naphthalene      and   naphthalene     derivatives   with
formaldehyde, condensates of naphthalene or of naphthalenesulfonic acid with phenol
and formaldehyde, polyoxyethylene octylphenol ether, ethoxylated isooctylphenol,
octylphenol, nonylphenol, alkylphenol polyglycol ethers, tributylphenyl polyglycol
ether, tristearylphenyl polyglycol ether, alkylaryl polyether alcohols, alcohol and fatty
alcohol ethylene oxide condensates, ethoxylated castor oil, polyoxyethylene alkyl
ethers, ethoxylated polyoxypropylene, lauryl alcohol polyglycol ether acetal, sorbitol
esters, lignosulfite waste liquors and methylcellulose.
         Substances which are suitable for the preparation of directly sprayable
solutions, emulsions, pastes or oil dispersions are mineral oil fractions of medium to
high boiling point, such as kerosene or diesel oil, furthermore coal tar oils and oils of
vegetable or animal origin, aliphatic, cyclic and aromatic hydrocarbons, for example
toluene, xylene, paraffin, tetrahydronaphthalene, alkylated naphthalenes or their
derivatives, methanol, ethanol, propanol, butanol, cyclohexanol, cyclohexanone,
isophorone,     highly    polar   solvents,     for   example     dimethyl    sulfoxide,   N
methylpyrrolidone or water.
         Also anti-freezing agents such as glycerin, ethylene glycol, propylene glycol
and bactericides such as can be added to the formulation.
         Suitable antifoaming agents are for example antifoaming agents based on
silicon or magnesium stearate.
         Suitable    preservatives      are,     for     example,     dichlorophenol      and
benzylalcoholhemiformaldehyde.
         Seed Treatment formulations may additionally               comprise binders and
optionally colorants.
         Binders can be added to improve the adhesion of the active materials on the
seeds after treatment. Suitable binders are block copolymers EO/PO surfactants but
also polyvinylalcoholsl, polyvinylpyrrolidones, polyacrylates, polymethacrylates,
                                             - 63 -

polybutenes, polyisobutylenes, polystyrene, polyethyleneamines, polyethyleneamides,
polyethyleneimines         (Lupasol@,      Polymin@),        polyethers,    polyurethans,
polyvinylacetate, tylose and copolymers derived from these polymers.
         Optionally, also colorants can be included in the formulation. Suitable
colorants or dyes for seed treatment formulations are Rhodamin B, C.I. Pigment Red
112, C.I. Solvent Red 1, pigment blue 15:4, pigment blue 15:3, pigment blue 15:2,
pigment blue 15:1, pigment blue 80, pigment yellow 1, pigment yellow 13, pigment
red 112, pigment red 48:2, pigment red 48:1, pigment red 57:1, pigment red 53:1,
pigment orange 43, pigment orange 34, pigment orange 5, pigment green 36, pigment
green 7, pigment white 6, pigment brown 25, basic violet 10, basic violet 49, acid red
51, acid red 52, acid red 14, acid blue 9, acid yellow 23, basic red 10, basic red 108.
         An example of a suitable gelling agent is carrageen (Satiagel@).
         Powders, materials for spreading, and dustable products can be prepared by
mixing or concomitantly grinding the active substances with a solid carrier.
         Granules,    for   example    coated   granules,   impregnated    granules   and
homogeneous granules, can be prepared by binding the active compounds to solid
carriers. Examples of solid carriers are mineral earths such as silica gels, silicates,
talc, kaolin, attaclay, limestone, lime, chalk, bole, less, clay, dolomite, diatomaceous
earth, calcium sulfate, magnesium sulfate, magnesium oxide, ground synthetic
materials, fertilizers, such as, for example, ammonium sulfate, ammonium phosphate,
ammonium nitrate, ureas, and products of vegetable origin, such as cereal meal, tree
bark meal, wood meal and nutshell meal, cellulose powders and other solid carriers.
         In general, the formulations comprise from 0.01 to 95% by weight, preferably
from 0.1 to 90% by weight, of the AHAS-inhibiting herbicide. In this case, the
AHAS-inhibiting herbicides are employed in a purity of from 90% to 100% by
weight, preferably 95% to 100% by weight (according to NMR spectrum). For seed
treatment purposes, respective formulations can be diluted 2-10 fold leading to
concentrations in the ready to use preparations of 0.01 to 60% by weight active
compound by weight, preferably 0.1 to 40% by weight.
         The AHAS-inhibiting herbicide can be used as such, in the form of their
formulations or the use forms prepared therefrom, for example in the form of directly
sprayable solutions, powders, suspensions or dispersions, emulsions, oil dispersions,
                                           - 64 -

pastes, dustable products, materials for spreading, or granules, by means of spraying,
atomizing, dusting, spreading or pouring. The use forms depend entirely on the
intended purposes; they are intended to ensure in each case the finest possible
distribution of the AHAS-inhibiting herbicide according to the invention.
        Aqueous use forms can be prepared from emulsion concentrates, pastes or
wettable powders (sprayable powders, oil dispersions) by adding water. To prepare
emulsions, pastes or oil dispersions, the substances, as such or dissolved in an oil or
solvent, can be homogenized in water by means of a wetter, tackifier, dispersant or
emulsifier. However, it is also possible to prepare concentrates composed of active
substance, wetter, tackifier, dispersant or emulsifier and, if appropriate, solvent or oil,
and such concentrates are suitable for dilution with water.
        The active compound concentrations in the ready-to-use preparations can be
varied within relatively wide ranges. In general, they are from 0.0001 to 10%,
preferably from 0.01 to 1% per weight.
        The AHAS-inhibiting herbicide may also be used successfully in the ultra
low-volume process (ULV), it being possible to apply formulations comprising over
95% by weight of active compound, or even to apply the active compound without
additives.
        The following are examples of formulations:
                1.      Products for dilution with water for foliar applications. For seed
                treatment purposes, such products may be applied to the seed diluted or
                undiluted.
                A)      Water-soluble concentrates (SL, LS)
                Ten parts by weight of the AHAS-inhibiting herbicide are dissolved in
                90 parts by weight of water or a water-soluble solvent. As an
                alternative, wetters or other auxiliaries are added. The AHAS
                inhibiting herbicide dissolves upon dilution with water, whereby a
                formulation with 10 % (w/w) of AHAS-inhibiting herbicide                 is
                obtained.
                                           -65-

B)      Dispersible concentrates (DC)
Twenty parts by weight of the AHAS-inhibiting            herbicide are
dissolved in 70 parts by weight of cyclohexanone with addition of 10
parts by weight of a dispersant, for example polyvinylpyrrolidone.
Dilution with water gives a dispersion, whereby a formulation with
20% (w/w) of AHAS-inhibiting herbicide is obtained.
C)      Emulsifiable concentrates (EC)
Fifteen parts by weight of the AHAS-inhibiting herbicide are dissolved
in   7 parts by weight       of   xylene   with  addition of calcium
dodecylbenzenesulfonate and castor oil ethoxylate (in each case 5 parts
by weight). Dilution with water gives an emulsion, whereby a
formulation with 15% (w/w) of AHAS-inhibiting herbicide is obtained.
D)      Emulsions (EW, EO, ES)
Twenty-five parts by weight of the AHAS-inhibiting herbicide are
dissolved in 35 parts by weight of xylene with addition of calcium
dodecylbenzenesulfonate and castor oil ethoxylate (in each case 5 parts
by weight). This mixture is introduced into 30 parts by weight of water
by means of an emulsifier machine (e.g. Ultraturrax) and made into a
homogeneous emulsion. Dilution with water gives an emulsion,
whereby a formulation with 25% (w/w) of AHAS-inhibiting herbicide
is obtained.
E)      Suspensions (SC, OD, FS)
In an agitated ball mill, 20 parts by weight of the AHAS-inhibiting
herbicide are comminuted with addition of 10 parts by weight of
dispersants, wetters and 70 parts by weight of water or of an organic
solvent to give a fine AHAS-inhibiting herbicide suspension. Dilution
with water gives a stable suspension of the AHAS-inhibiting herbicide,
whereby a formulation with 20% (w/w) of AHAS-inhibiting herbicide
is obtained.
                          - 66  -

F)       Water-dispersible granules and water-soluble granules (WG,
SG)
Fifty parts by weight of the AHAS-inhibiting herbicide are ground
finely with addition of 50 parts by weight of dispersants and wetters
and made as water-dispersible or water-soluble granules by means of
technical appliances (for example extrusion, spray tower, fluidized
bed). Dilution with water gives a stable dispersion or solution of the
AHAS-inhibiting herbicide, whereby a formulation with 50% (w/w) of
AHAS-inhibiting herbicide is obtained.
G)       Water-dispersible powders and water-soluble powders (WP,
SP, SS, WS)
Seventy-five parts by weight of the AHAS-inhibiting herbicide are
ground in a rotor-stator mill with addition of 25 parts by weight of
dispersants, wetters and silica gel. Dilution with water gives a stable
dispersion or solution of the AHAS-inhibiting herbicide, whereby a
formulation with 75% (w/w) of AHAS-inhibiting herbicide is obtained.
H)       Gel-Formulation (GF)
In an agitated ball mill, 20 parts by weight of the AHAS-inhibiting
herbicide are comminuted with addition of 10 parts by weight of
dispersants, 1 part by weight of a gelling agent wetters and 70 parts by
weight of water or of an organic solvent to give a fine AHAS
inhibiting herbicide suspension. Dilution with water gives a stable
suspension of the AHAS-inhibiting herbicide, whereby a formulation
with 20% (w/w) of AHAS-inhibiting herbicide is obtained. This gel
formulation is suitable for us as a seed treatment.
2.       Products to be applied undiluted for foliar applications. For
seed treatment purposes, such products may be applied to the seed
diluted.
                           - 67 -

                A)      Dustable powders (DP, DS)
                Five parts by weight of the AHAS-inhibiting herbicide are ground
                finely and mixed intimately with 95 parts by weight of finely divided
                kaolin. This gives a dustable product having 5% (w/w) of AHAS
                inhibiting herbicide.
                B)      Granules (GR, FG, GG, MG)
                One-half part by weight of the AHAS-inhibiting herbicide is ground
                finely and associated with 95.5 parts by weight of carriers, whereby a
                formulation with 0.5%       (w/w) of AHAS-inhibiting         herbicide is
                obtained. Current methods are extrusion, spray-drying or the fluidized
                bed. This gives granules to be applied undiluted for foliar use.
         Conventional seed treatment formulations include for example flowable
concentrates FS, solutions LS, powders for dry treatment DS, water dispersible
powders for slurry treatment WS, water-soluble powders SS and emulsion ES and EC
and gel formulation GF. These formulations can be applied to the seed diluted or
undiluted. Application to the seeds is carried out before sowing, or either directly on
the seeds.
         In a preferred embodiment a FS formulation is used for seed treatment.
Typcially, an FS formulation may comprise 1-800 g/l of active ingredient, 1-200 g/l
Surfactant, 0 to 200 g/l antifreezing agent, 0 to 400 g/l of binder, 0 to 200 g/l of a
pigment and up to 1 liter of a solvent, preferably water.
For seed treatment, seeds of the herbicide resistant plants according of the present
invention are treated with herbicides, preferably herbicides selected from the group
consisting of AHAS-inhibiting herbicides such as amidosulfuron, azimsulfuron,
bensulfuron,      chlorimuron,     chlorsulfuron,     cinosulfuron,     cyclosulfamuron,
ethametsulfuron,     ethoxysulfuron,   flazasulfuron,   flupyrsulfuron,   foramsulfuron,
halosulfuron, imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron, nicosulfuron,
oxasulfuron, primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron,
sulfosulfuron, thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron,
tritosulfuron,   imazamethabenz,      imazamox,     imazapic,    imazapyr,     imazaquin,
imazethapyr, cloransulam, diclosulam, florasulam, flumetsulam, metosulam,
                                          - 68 -

penoxsulam,        bispyribac,      pyriminobac,      propoxycarbazone,      flucarbazone,
pyribenzoxim, pyriftalid, pyrithiobac, and mixtures thereof, or with a formulation
comprising a AHAS-inhibiting herbicide.
         The term seed treatment comprises all suitable seed treatment techniques
known in the art, such as seed dressing, seed coating, seed dusting, seed soaking, and
seed pelleting.
         In accordance with one variant of the present invention, a further subject of the
invention is a method of treating soil by the application, in particular into the seed
drill: either of a granular formulation containing the AHAS-inhibiting herbicide as a
composition/formulation (e.g .a granular formulation, with optionally one or more
solid or liquid, agriculturally acceptable carriers and/or optionally with one or more
agriculturally acceptable surfactants. This method is advantageously employed, for
example, in seedbeds of cereals, maize, cotton, and sunflower.
         The present invention also comprises seeds coated with or containing with a
seed treatment formulation comprising at least one AHAS-inhibiting herbicide
selected from the group consisting of amidosulfuron, azimsulfuron, bensulfuron,
chlorimuron,      chlorsulfuron,     cinosulfuron,    cyclosulfamuron,    ethametsulfuron,
ethoxysulfuron,      flazasulfuron,     flupyrsulfuron,    foramsulfuron,     halosulfuron,
imazosulfuron, iodosulfuron, mesosulfuron, metsulfuron, nicosulfuron, oxasulfuron,
primisulfuron, prosulfuron, pyrazosulfuron, rimsulfuron, sulfometuron, sulfosulfuron,
thifensulfuron, triasulfuron, tribenuron, trifloxysulfuron, triflusulfuron, tritosulfuron,
imazamethabenz,        imazamox,      imazapic,     imazapyr,   imazaquin,    imazethapyr,
cloransulam,     diclosulam,     florasulam,    flumetsulam,    metosulam,    penoxsulam,
bispyribac, pyriminobac, propoxycarbazone, flucarbazone, pyribenzoxim, pyriftalid
and pyrithiobac.
         The term seed embraces seeds and plant propagules of all kinds including but
not limited to true seeds, seed pieces, suckers, corms, bulbs, fruit, tubers, grains,
cuttings, cut shoots and the like and means in a preferred embodiment true seeds.
         The term "coated with and/or containing" generally signifies that the active
ingredient is for the most part on the surface of the propagation product at the time of
                                             - 69 -

application, although a greater or lesser part of the ingredient may penetrate into the
propagation product, depending on the method of application. When the said
propagation product is (re)planted, it may absorb the active ingredient.
        The seed treatment application with the AHAS-inhibiting herbicide or with a
formulation comprising the AHAS-inhibiting herbicide is carried out by spraying or
dusting the seeds before sowing of the plants and before emergence of the plants.
        In the treatment of seeds, the corresponding formulations are applied by
treating the seeds with an effective amount of the AHAS-inhibiting herbicide or a
formulation comprising the AHAS-inhibiting herbicide. Herein, the application rates
are generally from 0.1 g to 10 kg of the a.i. (or of the mixture of a.i. or of the
formulation) per 100 kg of seed, preferably from 1 g to 5 kg per 100 kg of seed, in
particular from 1 g to 2.5 kg per 100 kg of seed. For specific crops such as lettuce the
rate can be higher.
        The present invention provides a method for combating undesired vegetation
or controlling weeds comprising contacting the seeds of the resistant plants according
to the present invention before sowing and/or after pregermination with an AHAS
inhibiting herbicide. The method can further comprise sowing the seeds, for example,
in soil in a field or in a potting medium in greenhouse. The method finds particular
use in combating undesired vegetation or controlling weeds in the immediate vicinity
of the seed.
        The control of undesired vegetation is understood as meaning the killing of
weeds and/or otherwise retarding or inhibiting the normal growth of the weeds.
Weeds, in the broadest sense, are understood as meaning all those plants which grow
in locations where they are undesired.
        The weeds of the present invention include, for example, dicotyledonous and
monocotyledonous weeds.         Dicotyledonous weeds include, but are not limited to,
weeds of the genera: Sinapis, Lepidium, Galium, Stellaria, Matricaria, Anthemis,
Galinsoga,    Chenopodium, Urtica, Senecio,       Amaranthus,    Portulaca, Xanthium,
Convolvulus, Ipomoea, Polygonum, Sesbania, Ambrosia, Cirsium, Carduus, Sonchus,
Solanum, Rorippa, Rotala, Lindernia, Lamium, Veronica, Abutilon, Emex, Datura,
Viola, Galeopsis, Papaver, Centaurea, Trifolium, Ranunculus, and Taraxacum.
Monocotyledonous weeds include, but are not limited to, weeds of of the genera:
                                          -70 -

Echinochloa, Setaria, Panicum, Digitaria, Phleum, Poa, Festuca, Eleusine, Brachiaria,
Lolium, Bromus, Avena, Cyperus, Sorghum, Agropyron, Cynodon, Monochoria,
Fimbristyslis, Sagittaria, Eleocharis, Scirpus, Paspalum, Ischaemum, Sphenoclea,
Dactyloctenium, Agrostis, Alopecurus, and Apera.
         In addition, the weeds of the present invention can include, for example, crop
plants that are growing in an undesired location.       For example, a volunteer maize
plant that is in a field that predominantly comprises soybean plants can be considered
a weed, if the maize plant is undesired in the field of soybean plants.
         The articles "a" and "an" are used herein to refer to one or more than one (i.e.,
to at least one) of the grammatical object of the article. By way of example, "an
element" means one or more elements.
         As used herein, the word "comprising," or variations such as "comprises" or
"comprising," will be understood to imply the inclusion of a stated element, integer or
step, or group of elements, integers or steps, but not the exclusion of any other
element, integer or step, or group of elements, integers or steps.
         The following examples are offered by way of illustration and not by way of
limitation. Any variations in the exemplified methods that occur to the skilled artisan
are intended to fall within the scope of the present invention.
Example 1
Vectors containing Arabidopsis AHASL mutant genes
         The entire XbaI fragment of Arabidopsis thaliana genomic DNA that contains
the entire AHAS large subunit gene with some additional DNA, inclusive of the XbaI
sites at the 5' and 3' ends is set forth in SEQ ID NO: 34 (AtAHASL). Bases 2484 to
4496 of SEQ ID NO: 34 encompass the coding sequence of the Arabidopsis thaliana
AHAS large subunit gene serine 653 to threonine mutant allele, inclusive of the stop
codon shown in SEQ ID NO: 30. A smaller genomic fragment of the Arabidopsis
thaliana AHAS large subunit gene serine 653 to threonine mutant allele shown in
SEQ ID NO: 33, encompassed in bases 2484 to 5717 of SEQ ID NO: 34, includes the
coding sequence and the 3' end, up to and including the 3' end XbaI site, with the first
two bases of the NcoI site found at the start codon of AtAHASL left off for clarity.
                                            - 71 -

        The DNA fragment of SEQ ID NO: 33 encoding the full-length Arabidopsis
AHASL single mutation S653N and 3' untranslated region was cloned into pKK233-2
to yield the vector designated AEl for expression and testing in E. coli. (pKK233-2,
bacterial expression vector, Pharmacia, GenBank Accession No. X70478).          Vectors
AE2 through AE9 were generated from AEl by mutagenesis and standard cloning
procedures.    Figure 4 shows the map of the AEl base vector, with positions of
mutations indicated.
        Vector API (Figure 5) is a plant transformation vector that includes a genomic
fragment of Arabidopsis thaliana DNA that includes the AtAHASL gene with the
single S653N mutation (SEQ ID NO:34). The DNA fragment as shown in SEQ ID
NO: 34 was cloned into API in the reverse-complement orientation. Vectors AP2
AP7 were generated from AP1 and the AE plasmids using standard cloning
procedures and differ only by mutations as indicated in Table 1. For convenience in
cloning, different fragments were used to generate AP6 and AP7, compared to AP2
AP5. Thus, AP6 and AP7 are 47 base pairs shorter than API-AP5 . This difference is
in the plasmid backbone and not the Arabidopsis thalianagenomic fragment.
        Vectors AE10 through AE24 were made as follows.                 The wild type
Arabidopsis thaliana AHAS large subunit gene was amplified under mutagenic
conditions using the Genemorph II random mutagenesis kit (Stratagene, La Jolla,
California), resulting in randomly mutagenized amplified DNA fragments of this
gene. This mutant DNA was then cloned back into AE7, replacing the wild type A.
thaliana large subunit gene (between the unique SaclI and Agel sites on AE7) with
the mutagenized forms.    This DNA was transformed into E. coli strain TOP10 and
selected on LB agar medium in such a fashion as to have a large number of unique
transformants, each with independent, mutagenized AHAS genes.           These colonies
were scraped together and plasmid DNA was prepared from this entire primary
library. This DNA was transformed into AHAS minus E. coli and again selected on
LB agar media with carbenicillin.     Plasmid positive colonies from this step were
replica plated using velveteen onto minimal agar medium without branched chain
amino acids and containing 30-micromolar imazethapyr. Those colonies that grew on
this selective media possessed a functional A. thaliana AHAS mutant gene that was
also imidazolinone tolerant.
                                         - 72 -

        The DNA sequence of the A. thaliana AHAS large subunit gene was
determined for each of the growth positive colonies. No effort was made to determine
the sequence of the A. thalianaAHAS large subunit genes that did not confer growth
on the selective media.    Because the AHAS function and imidazolinone tolerance
screen was on a secondary library, replicates of the same mutations were found, as
determined by DNA sequence analysis.       Only one clone of each was advanced for
testing on increasing imidazolinone concentrations and inclusion in Table 1.
                                        - 73 -

    Table 1
                                                      E.        coli Transgenic           Plant
           Arabidopsis                                Imazethapyr    Tolerance:         X-fold
E.    coli Transformation                             Tolerance      improvement           over
Plasmid* Vector*             Mutations*               Score**       APi @(approximate)
AEl        API               S653N                    +             NA
AE2        AP2               A122T & S653N            ++             16
AE3        AP3               P197S & S653N            +             2
                             A122T,      R199A,     &NA              16
AE4        AP8               S653N
AE5        AP4               R199A, & S653N           +++            1.5
                             A122T,      P197S,     &NA              8
AE6        AP5               S653N
AE7                          Wild type                - (IN)         NA
AE8        AP6               A122T and R199A          +++            2
AE9        AP7               A122T and P197S          NA             8
                             A122T,      S57R     and+++            NA
AE10                         S398L
AElI                         A122T and V1391          ++            NA
AE12                         A122T and Q269H          +              NA
AE13                         A122T and K416M          ++             NA
AE14                         A122T and L4261          +++           NA
AE15                         A122T and A430V          +++            NA
AE16                         A122T and N4421          ++            NA
AE17                         A122T and N4451          ++            NA
AE18                         A122T and N445D          +++            NA
AE19                         A122T and K580E          +++            NA
                             A122T,           V439G,+                NA
AE20                         D595G, and S653N
AE21                         PI97S and D375N          +++           NA
AE22                         D375N                    untestedt      NA
                             D375N, K83R, V2541,
AE23                         M2771, and D315Y         +              NA
                             Q95L, K416E,         and
AE24                         S653N                    +              NA
                    * List of vectors for expression of AtAHASL2 in E. coli (AE plasmids)
            and for plant transformation plasmids (AP plasmids).         Mutations in each
            vector are indicated relative to SEQ ID NO: 1.
                                               - 74 -

                ** A simple single, double or triple plus system, +, ++, or +++ for
        respectively increasing colony size, was used to visually score the tolerance of
        the Arabidopsis AHAS function in AHAS minus E. coli containing the AE
        plasmids in the presence of the AHAS inhibitor imazethapyr. A "-", indicates
        there was no growth, meaning the mutation combination caused an inactive
        protein or there was no tolerance for imazethapyr at the selected rate.      IN
        means inactive protein, while NT means not imidazolinone tolerant.          NA
        means no data available (not tested).
                i Not tested compared to S653N, fact of tolerance determined by
        screening protocol.
                0 For transgenic plants comprising the API vector, 18.75 pM
        imazethapyr was the highest concentration which allowed good growth of the
        plants in the microtiter format plates. This concentration was used as the basis
        for determining X-fold improvement over AP 1.
Example 2
Vectors containing Zea mays AHASL mutant genes
        The Zea mays AHASL2 gene (SEQ ID NO: 29) was cloned into the bacterial
expression vector pTrcHis A (Invitrogen Corporation, Carlsbad, CA), fused to the
vector tag and translational start site, beginning with base 160 of SEQ ID NO: 29.
Mutagenesis and subcloning procedures were utilized to create vectors ZE2, ZE5,
ZE6, and ZE7 using ZEl as a base vector. Subcloning procedures were used to make
ZE3 from ZEl, which is the maize AHASL2 gene fused to the vector tag and
translational start site of pTrcHis A, beginning with base 121 of SEQ ID NO: 29.
Since no functional difference was noted in E. coli between ZEl or ZE3, standard
mutagenesis and subcloning procedures were utilized to create vectors ZE4 and ZE8
through ZE22 using ZE3 as a base vector.
        A plant transformation vector with an expression cassette comprising the
maize ubiquitin promoter in combination with a polynucleotide encoding the maize
AHASL2 S653N mutant was prepared using standard methods and designated ZP1
(Figure 7).    To produce plant transformation vectors for expression of the other
                                           -75  -

AHASL mutants, standard cloning techniques were used to replace polynucleotide
segments of ZP1 with polynucleotide fragments of the ZE vectors encoding the
mutations.
        Vectors ZE23 through ZE38 were made as follows.             Vector ZE3 was
subjected to saturating site directed mutagenesis using the QuikChange@ Multi Site
Directed Mutagenesis Kit (Stratagene, La Jolla, California) following the "General
Guidelines for Creating Engineered Mutant CloneTM Collections" appendix protocol.
Mutagenic oligonucleotides that would generate all possible codons at the critical
sites of the maize AHAS large subunit were used in various combinations to create a
collection of mutants with substitutions at residues A90, M92, P165, R167, S621, and
G622. The mutant collection plasmids were transformed into AHAS deficient E. coli
and plated on LB agar medium supplemented with 100 ug per liter of carbenicillin.
Colonies from this were picked into M9 salts at 1x concentration (for an isotonic
buffer) in microtiter plates and then replica plated on minimal agar medium without
branched chain amino acids and containing 150 micromolar imazethapyr.         Those
colonies that grew on this selective media possessed a functional maize AHAS mutant
gene that was also imidazolinone tolerant.
        The DNA sequence of the maize AHAS large subunit gene was determined for
each of the growth positive colonies. No effort was made to determine the sequence
of the maize AHAS large subunit genes that did not confer growth on the selective
media.
                                         - 76 -

       Table 2
    E.    .UMaize                                 E      oiImidlinn Maize      Whole
           Transformation Mutations*                   race Sioli     plant Tolerance
Plasmid*
           Vector*                                                  Score@
ZEl        -              S621N                   +                 NA
ZE2        -              wild type               - (NT)            NA
ZE3        -              wild type               - (NT)            NA
ZE4        ZP1            S621N                   +
ZE5        -              W542L, S621N            - (IN)            NA
ZE6        ZP4            P165S,S621N             +
ZE7        -              W542L                   - (NT)            NA
ZE8        -              M92E, S621N             - (IN)            NA
ZE9        ZP5            R167S,S621N             +++                ++
ZE1O       ZP2            A90T,S621N              +++                ++
ZEll       ZP3            A90T, R167S, S621N      +++                +++
ZE12       ZP9            M921, S621N             +++                ++
ZE13       -              R167A,S621N             NA                NA
ZE14       -              A173V, S621N            ++                NA
ZE15       ZP8            A90T, M921              +++               +++
ZE16       ZP10           A90T, M92E              NA                NA
ZE17       ZP6            A90T,R167A              +++               +++
ZE18                      P165S                   - (NT)            NA
ZE19       -              P165S, R167A            - (NT)            NA
ZE20       -              T1711, S621N            +                 NA
ZE21       ZP7            A90T                    ++                 ++
ZE22       -              A90T,P165S              +++               NA
ZE23       ZP11           A90Q                    +++                +++
ZE24       ZP12           A90Q, M92L              ++                 ++
ZE25       -              A90Q, M921              +++               NA
ZE26       -              A90C                    ++                NA
ZE27       -              A90M, M921              +                 NA
ZE28       -              P165E, R167F            - (NT)            NA
ZE29       -              P165V, R167A            - (NT)            NA
ZE30       -              P165E, R167T            +
ZE31       -              P1651, R167D            - (IN)            NA
ZE32       -              P1651, R167E            +                 NA
ZE33       -              M921, P165E, R167A      - (NT)            NA
ZE34       -              A90M, P165R, R167C      - (IN)            NA
ZE35       -              M92N, S621G             +++               NA
                          P165S, R167N, S621V,+++                   NA
ZE36       -
                          G622D
ZE37       -              S621W                   +++               NA
ZE38       -              P165S, R167C, W542M     +++               NA
                                           - 77 -

                * List of vectors for expression of ZmAHASL2 in
                                                                           E. coli (ZE
        plasmids) and for plant transformation plasmids (ZP plasmids). Mutations in
        each vector are indicated relative to SEQ ID NO: 2.
                ** A simple single, double or triple plus system, +, ++, or +++ for
        respectively increasing colony size, was used to visually score the tolerance of
        the maize AHAS function in AHAS minus E. coli containing the ZE plasmids
        in the presence of the AHAS inhibitor imazethapyr. A "-", indicates there was
        no growth, meaning the mutation combination caused an inactive protein or
        there was no tolerance for imazethapyr at the selected rate. IN means inactive
        protein, while NT means not imidazolinone tolerant.        NA means no data
        available (not tested).
                0 The maize whole plant tolerance scores are based on combined
        results from tests conducted in the greenhouse and at multiple field sites over
        several growing seasons.      The scoring system for the maize whole plant
        tolerance was the same as described above for the E. coli imidazolinone
        tolerance. Note that all ZP constructs with +++ scores are tolerant to more
        than three thousand grams imazamox per hectare, which represents the highest
        tested spray rate.
Example 3
E. coli Complementation Assay
        E. coli strain JMC1 (genotype [ilvBl201 ilvHI2202 rbs-221 ara thi delta(pro
lac) recA56 srlC300::Tnl0],DE(hsdR)::Cat)is a knockout for all copies of ilvG of
the native E. coli AHASL gene.         This strain can only grow on minimal growth
medium lacking leucine, isoleucine, and valine if AHASL is complemented by an
exogenous AHASL gene (see Singh, et al. (1992) Plant Physiol. 99, 812-816; Smith,
et al. (1989)     Proc. Natl. Acad. Sci. USA         86, 4179-4183).      This E. coli
complementation assay was used to screen for AHASL enzyme activity and herbicide
tolerance encoded by the AE and ZE vectors in the absence and presence of the
imidazolinone herbicide Pursuit* (imazethapyr, BASF Corporation, Florham Park,
NJ).
                                          -78  -

Example 4
Biochemical Characterization
        Based on growth during complementation testing or simple activity tests,
certain of the ZE series of vectors were used for AHAS biochemical assay inhibition
testing in crude E. coli lysates.    A 2-4 ml culture of LB containing 50 [g/ml
carbenicillin (LB-carb) was inoculated with a single colony of JMC1 transformed
with the ZE vector to be tested and incubated overnight at 37 0 C with shaking. The
following morning, 0.5-1 ml of overnight culture was used to inoculate 20 ml of LB
carb, which was incubated at 37 0 C with shaking until the culture optical density (OD)
at 600 nm was approximately 0.6 to 0.8 OD units.             Isopropyl-1 -thio-beta D
galactopyranoside (IPTG) was added to a concentration of 0.1 mM and the cultures
incubated with shaking for 1-1.5 hours. The culture was centrifuged to pellet the cells
and the supernatant discarded. The cell pellet was lysed with AHAS assay buffer (as
in Singh et al. (1988) Anal. Biochem. 171:173-179) supplemented with 10 mg/ml
lysozyme and subjected to brief sonication. The insoluble fraction was pelleted by
centrifugation and the supernatant used in an assay for AHAS activity.          At each
concentration of imazethapyr inhibitor used, the activity was compared to an
uninhibited control of the same ZE mutant. This results in a "percent of control"
measurement.
Example 5
Plant Transformation
        The AP vectors were transformed into A. thaliana ecotype Col-2.         The TI
seeds were selected for transformation on plates with 100 nM Pursuit* as the selective
agent. T2 seeds from approximately twenty independent transformation events (lines)
were plated on MS agar with increasing Pursuit* concentrations, to score increases in
tolerance compared to APl.     The vectors were scored by comparison of the highest
concentrations  of Pursuit* having uninhibited       growth of seedlings by visual
examination. The results of the Arabidopsis transformation experiments are shown in
Table 1.
                                         - 79 -

        Seeds from several lines of Arabidopsis were tested by a vertical plate growth
assay. A plate with standard Murashige and Skoog semisolid media containing 37.5
micromolar Pursuit (imazethapyr) was spotted with several seeds in 0.1% agarose.
The plate was held vertically, so that the roots would grow along the agar surface.
The seeds used were: 1) wild type ecotype Columbia 2; 2) the csrl-2 mutant
(homozygous for the AtAHASL S653N mutation in the genomic copy of the AHAS
large subunit gene); 3) Columbia 2 transformed with AP 1; 4) Columbia 2 transformed
with AP7; 5) Columbia 2 transformed with AP2. Note that numbers 2 and 3 are
roughly equivalent in terms of probable tolerance, as the AP1 plants are transformed
with a clone of the genomic XbaI fragment of csrl-2 (SEQ ID NO: 34). At this
concentration of imazethapyr, the wild type seedlings failed to germinate, the single
mutant plants (csrl-2 and API transformants) barely germinated.         AP7 and AP2
produced good tolerant growth, although the AP7 plants appear to have slightly less
root growth.    Note that all lines germinated and grew well on media without
imazethapyr. The results of the vertical plate growth assay are depicted in Figure 10.
        ZP   constructs  were    introduced      into  maize  immature   embryos    via
Agrobacterium-mediated transformation.            Transformed cells were selected on
selection media supplemented with 0.75 [M Pursuit* for 3-4 weeks.           Transgenic
plantlets were regenerated on plant regeneration media supplemented with 0.75 [M
Pursuit*.   Transgenic plantlets were rooted in the presence of 0.5 [M Pursuit*.
Transgenic plants were subjected to TaqMan analysis for the presence of the
transgene before being transplanted to potting mixture and grown to maturity in
greenhouse. The results of the maize transformation experiments are shown in Table
2. Maize plants transformed with the ZP constructs were sprayed with varying rates
of imazamox, in several field locations and in the greenhouse. The relative ratings of
the ZP constructs' whole plant test data are summarized in Table 2.
                                          - 80 -

Example 6
Expression of AtAHASL Mutant Genes in Soybean
        Vectors were prepared for expressing the AtAHASL genes in transformed
soybean plants. Vectors AUP2 and AUP3 were made by cloning a polymerase chain
reaction product of the parsley ubiquitin promoter, amplified to incorporate sites for
the Asp718 and NcoI restriction enzymes, digested and ligated into the same sites of
AP2 and AP3 by standard cloning techniques (see, Figures 11 and 12).           AUP2
encodes an AtAHASL protein with the A122T and S653N mutations, and AUP3
encodes an AtAHASL protein with the A122T and S653N mutations. Vector BAPI
was made by cloning the entire promoter, coding sequence and 3'-untranslated region
sequence of API into a standard dicot transformation backbone containing the BAR
selectable marker expression cassette, by standard blunt-ended cloning techniques.
        Constructs AP2, AUP2, and AUP3 were introduced into soybean's axillary
meristem cells at the primary node of seedling explants via Agrobacterium-mediated
transformation. After inoculation and co-cultivation with Agrobacteria, the explants
were transferred to shoot induction media without selection for one week.          The
explants were subsequently transferred to a shoot induction medium with 5 pM
imazapyr (Arsenal) for 3 weeks to select for transformed cells. Explants with healthy
callus/shoot pads at the primary node were then transferred to shoot elongation
medium containing 3 pM imazapyr until a shoot elongated or the explant died.
Transgenic plantlets were rooted, transplanted to potting mixture, subjected to
TaqMan analysis for the presence of the trangene, and then grown to maturity in
greenhouse.   Construct BAPI was used to produce transformed soybean plants in a
like manner, except that the selection agent was BASTA.
        The transformed soybean plants were tested for herbicide tolerance in both
greenhouse and field studies. For the field study, imazapyr was applied at a rate of
300 g ai/ha at V3 stage. For the greenhouse study, imazapyr was applied at about the
V2 stage. The results of these studies are summarized in Table 3.
                                         - 81 -

Table 3
                                                        Maximum             Field
                Transformation
Transformation tormt         Pasley                     Greenhouse          Tolerance
Vector, Native ect            rey   Mutations           Tolerance (grams(grams
Arabidopsis       biquitin promoter                     Imazapyr         per mazapyr
promoter                                                hectare)            per hectare)
                BAPI*               S653N               500                 NA
                                                        AP2 - 1000          AP2 - NA
AP2             AUP2                A122T & S653N       AUP2 - 1500         AUP2
 -      _       AUP3                P197S & S653N       NA                  300**
               * BAPI (figure 12) was transformed using the
                                                               BAR gene for selection,
        as imazapyr selection in soybeans with the S653N mutation alone has not been
        optimized.
               ** Some injury compared to AUP2
Example 7
Transformant Selection
        The polynucleotides generated by the invention may be used as selectable
markers for plant transformation.     The polynucleotides generated by the invention
may be used as selectable markers to identify and/or select transformed plants which
may comprise additional genes of interest.      Plants or plant cells transformed with
vectors containing the multiple mutant forms of the AHAS large subunit genes can be
selected from non-transformed plants or plant cells by plating on minimal media, such
as MS media, which incorporate AHAS inhibitors or AHAS inhibiting herbicides,
such as imidazolinones.     The transformed plants or tissues will be able to continue
growing in the presence of these inhibitors, while the untransformed plants or tissues
will die. In the case of transformed tissues, since the non-transformed tissues may
receive branched chain amino acids from the transformed tissues, the actively
growing tissues are removed from the slower growing or dying tissues and replated on
selective media.
                                         - 82 -

        Whole plants may also be selected by planting the seeds and waiting for
germination and seedling growth, followed by spraying the seedlings with AHAS
inhibitors or AHAS inhibiting herbicides, such as imidazolinones.    The transformed
plants will survive while the untransformed plants will be killed.
Example 8
Field Trials with Transformed Maize
        Field trials were conducted to assess whether or not maize plants transformed
with one of the vectors comprising AHASL double and triple mutants displayed any
gross   physiological or reproductive      affects with and without an imazamox
application.
Materials and Methods
Source of Test Material
        The genetically modified organism was produced by transforming corn inbred
J553. Fl hybrid seed from 8 vector constructs were produced using TR5753 as an
inbred male tester. The vector constructs are described in Table 4. Seed for the trial
were produced in an isolated crossing block on the island of Kauai, Hawaii. USA
during the 2006-2007 contraseason.      Subsamples of each Fl hybrid produced were
analyzed for the presence of the correct vector construct and absence of adventitious
presence of other AHASL contructs.
        Nontransformed commercial hybrids were purchased from Midwest USA corn
seed companies and analyzed to confirm the absence of any adventitious presence of
other AHASL contructs.
                                         -  83 -

Table 4
                                                                  L2 Mutations
     Construct        pZm UBI + I::c-ZmAHAS L2::t-ZmAHAS
                      (at Designation)
     1                P197S
     2                A122T, R199A
     3                A122T
     4                A122T, M1241
     5                M1241, S653N
     6                A122T,S653N
     7                A122T, R199S, S653N
     8                S653N
Trial Methodology
         Trial design was a Split Plot in a Randomized Complete Block Design, with
the main plot being an herbicide treatment, and the sub plot being an Fl hybrid entry.
The herbicide treatments included 1) untreated and 2) imazamox applied at 150
gai/ha. The Fl hybrid entries included 29 events from 8 vector constructs and 4 non
transformed commercial hybrids (33951R from Pioneer Hi-Bred International, Inc,
Johnston, IA, USA; and 8342GLS/IT, 85461T, and 85901T from Garst Seed Co., Inc.,
Slater, IA. USA). Plot size was 2 rows; row width 2.5 feet; row length 20 feet. Each
treatment combination had 4 replications.      The trial was planted at three locations.
These locations were: Ames, IA, USA; Estherville, IA, USA; and York, NE, USA.
All trials were planted during May 2007.
Location conditions
         The Ames, IA location was in a corn-after-corn rotation which may have had
some impact on uniformity of emergence and early growth as significant amounts of
corn residue were present at planting.      No major influences on the crop due to
                                          -84-

weather, disease or insects were noted. The Estherville, IA site received heavy rain
driven by 70 mph wind gusts and sustained winds of around 40 mph on July 16. Root
lodging was observed in essentially every plot. No major influences on the crop due
to disease or insects were noted. The York, NE site received above-normal rainfall in
May, July and August and no major insect or disease issues were noted.
Results and Discussion
        Data analyses combined across three locations resulted in one vector construct
with a significant yield decrease (p < 0.05) when comparing yield with or without the
imazamox herbicide application (Table 5).           One vector construct had a significant
yield increase when treated with the imazamox application.               Other agronomic
characteristics were also collected from the three trial locations, and no significant
differences were detected within a construct when treated or untreated with imazamox
for the traits plant height, ear height, stalk lodging and root lodging (data not shown).
        The objective of the trial was to identify if an herbicide application of
imazamox applied to vector constructs that have been optimized to provide improved
herbicide tolerance to imazamox would result in gross, or obvious, physiological or
reproductive affects, primarily yield. Only one vector construct (Construct 1, single
mutant, P197L) had a significant (p < 0.05) negative response for grain yield when
treated with imazamox. The remaining seven vector constructs exhibited no adverse
physiological or reproductive affects in the presence or absence of the herbicide
imazamox.       The results of these field trials demonstrate the excellent agronomic
potential of maize plants transformed with a vector comprising either an AHASL
double or triple mutant.
                                             - 85 -

Table 5
                       Yield (bu/A)
Description            Herbicide (H)           Non-herbicide (NH)
Construct    Event     Mean         0.05       Mean        a= 0.05     H/NH)%       v
                                                                                   value
1            4         160.68          B        175.58       BC       91.51        0.003
2            4         176.72          AB       177.05       ABC      99.81        0.94
3            4         180.59          A        179.02       AB       100.87       0.74
4            4         173.57          AB       163.79       C        105.97       0.11
5            4         173.87          AB       180.84       AB       96.14        0.10
6            4         188.02          A        178.65       AB       105.24       0.04
7            1         187.45          AB       189.03       AB       99.16        0.88
8            4         183.14          A        177.54       ABC      103.15       0.27
33951R                 168.03          AB       176.89       ABC      94.99        0.09
85901T                 181.92          AB       197.57       A        92.08        0.04
G85461T                174.94          AB       186.74       AB       93.68        0.40
G8342GLS/IT            180.14          AB       177.53       ABC      101.47       0.84
        All publications and patent applications mentioned in the specification are
indicative of the level of those skilled in the art to which this invention pertains. All
publications and patent applications are herein incorporated by reference to the same
extent as if each individual publication or patent application was specifically and
individually indicated to be incorporated by reference.
                                           - 86  -

         Although the foregoing invention has been described in some detail by way of
illustration and example for purposes of clarity of understanding, it will be obvious
that certain changes and modifications may be practiced within the scope of the
appended claims.
         Comprises/comprising and grammatical variations thereof when used in this
specification are to be taken to specify the presence of stated features, integers, steps
or components or groups thereof, but do not preclude the presence or addition of one
or more other features, integers, steps, components or groups thereof.
                                           - 87 -

CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:
1.       A recombinant or mutagenized polynucleotide encoding a plant acetohydroxyacid
synthase large subunit (AHASL) polypeptide that is an amino acid-substituted polypeptide
comprising the herbicide-tolerance mutation combination of a threonine substitution at a
position corresponding to position 122 of SEQ ID NO: 1 or position 90 of SEQ ID NO:2
and a serine substitution at a position corresponding to position 197 of SEQ ID NO: 1 or
position 165 of SEQ ID NO:2;
the plant being selected from Arabidopsis thaliana, maize, rye, oat, triticale, rice, barley,
sorghum, millet, sugar beet, sugarcane, soybean, peanut, cotton, rapeseed, canola, Brassica
species, manihot, melon, squash, pepper, tagetes, potato, sweet potato, eggplant, tomato,
 Vicia species, pea, alfalfa, coffee, cacao, tea, Salix species, oil palm, coconut, and perennial
grass; and
the sequence of the recombinant or mutagenized AHASL polynucleotide having been
produced using a recombinant or mutagenesis methodology;
wherein the herbicide-tolerance mutations together in the AHASL polypeptide provide to
a plant a level of AHAS-inhibiting herbicide tolerance toward an imidazolinone or
sulfonylurea herbicide, which level is greater than the additive level of the AHAS
inhibiting herbicide tolerances provided by each said herbicide-tolerance mutation
expressed separately in an AHASL polypeptide in the plant.
2.       An expression vector comprising the polynucleotide according to claim 1, said
vector being capable of expressing said polynucleotide in a host cell.
3.       A transgenic plant comprising the expression vector of claim 2.
4.       The transgenic plant of claim 3, wherein the expression of the polynucleotide in the
plant results in tolerance to an herbicide selected from imidazolinones and sulfonylureas.
5.       A purified AHASL protein encoded by the polynucleotide of claim 1.
                                               - 88 -

6.       A plant comprising:
         (a) a first polynucleotide encoding a first plant acetohydroxyacid synthase large
         subunit (AHASL) polypeptide having a first herbicide-tolerance mutation and a
         second polynucleotide encoding a second plant AHASL polypeptide having a
         second herbicide-tolerance mutation, or
         (b) a polynucleotide encoding a plant AHASL polypeptide having both said first
         and second herbicide-tolerance mutations;
the first herbicide-tolerance mutation being a threonine substitution for the amino acid at
the position corresponding to position 122 of SEQ ID NO:1 or position 90 of SEQ ID
NO:2, and the second herbicide-tolerance mutation being a serine substitution for the
amino acid at the position corresponding to position 197 of SEQ ID NO: 1 or position 165
of SEQ ID NO:2;
the plant AHASL polypeptide being selected from AHASL polypeptides of Arabidopsis
thaliana, maize, rye, oat, triticale, rice, barley, sorghum, millet, sugar beet, sugarcane,
soybean, peanut, cotton, rapeseed, canola, Brassica species, manihot, melon, squash,
pepper, tagetes, potato, sweet potato, eggplant, tomato, Vicia species, pea, alfalfa, coffee,
cacao, tea, Salix species, oil palm, coconut, and perennial grass; and
the sequence of the polynucleotide having been produced using a recombinant or
mutagenesis methodology;
wherein the herbicide-tolerance mutations together in the plant provide to it a level of
AHAS-inhibiting herbicide tolerance toward an imidazolinone or sulfonylurea herbicide,
which level is greater than the additive level of the AHAS-inhibiting herbicide tolerances
provided by each said herbicide-tolerance mutation expressed separately in an AHASL
polypeptide in the plant.
7.       A transgenic plant according to claim 3 or 4, or a plant according to claim 6,
wherein the plant is a monocot or a dicot.
8.       A seed of a transgenic plant according to claim 3 or 4, or seed of a plant according
to claim 6, wherein the seed comprises the polynucleotide(s).
                                             - 89 -

9.       A method for controlling weeds in a field, said method comprising both:
         (i) growing in a field a plant comprising the polynucleotide of claim 1, or the plant
         of any one of claims 3-4 and 6; and
         (ii) contacting said plant and weeds in the field with an effective amount of an
         AHAS-inhibiting herbicide to which the plant is tolerant and which would inhibit
         the growth of a corresponding wild-type plant,
thereby controlling the weeds.
 10.     A method for producing a transgenic plant comprising the steps of:
         (i) transforming a plant cell with the expression vector of claim 2; and
         (ii) regenerating from the plant cell a transgenic plant that expresses the AHASL
         mutant polypeptide.
 11.     A method for identifying or selecting a plant cell, plant tissue, plant or part thereof
comprising:
         (i) providing a plant cell, plant tissue, plant or part thereof, wherein said plant cell,
         plant tissue, plant or part thereof comprises the polynucleotide of claim 1;
         (ii) contacting the plant cell, plant tissue, plant or part thereof with at least one
         AHAS-inhibiting compound;
         (iii) determining whether the plant cell, plant tissue, plant or part thereof is affected
         by the inhibitor or inhibiting compound thereby identifying or selecting the plant
         cell, plant tissue, plant or part thereof.
 12.     A method for producing an herbicide-tolerant plant comprising crossing a first plant
that is tolerant to a herbicide to a second plant that is not tolerant to the herbicide, wherein
the first plant is a plant according to any one of claims 3, 4, and 6.
 13.      The method of claim 12 further comprising selecting for a progeny plant that is
tolerant to the herbicide.
 14.     A plant produced by the method of claim 12 or 13.
                                                -90-

15.     The seed of claim 8, wherein said seed is treated with an AHAS-inhibiting
herbicide.
 16.    A method for combating undesired vegetation comprising contacting, with an
AHAS inhibiting herbicide:
        a seed of a plant comprising the polynucleotide of claim 1,
        a seed of a plant according to any one of claims 3, 4, and 6, or
        the seed of claim 8,
before sowing and/or after pregermination.
 17.    A method according to any one of claims 8, 11, and 16, or the seed of claim 15,
wherein the AHAS-inhibiting compound or AHAS-inhibiting herbicide comprises one or
more of an imidazolinone and a sulfonylurea.
 18.    A method or seed according to claim 17, wherein the imidazolinone comprises one
or more of imazethapyr, imazapic, imazamox, and imazapyr.
 19.    A product produced from the plant according to any one of claims 3, 4, and 6 or
from the seed of any one of claims 8 and 15-18.
20.     The product of claim 19 wherein the product is seed oil or plant meal.
21.     The product of claim 20 wherein the plant meal is from a cereal plant.
22.     The product of claim 20 or 21 wherein said meal is used as a solid carrier for a
herbicide composition.
23.     A method for identifying a plant, plant part, plant tissue, plant cell, or plant seed
comprising the polynucleotide of claim 1 or the polynucleotide(s) of the plants of any one
of claims 3, 4, and 6, said method comprising performing PCR of hybridization testing of
the AHASL genes in said plant, plant part, plant tissue, plant cell, or plant seed.
                                            -91 -

24.     A method for identifying a plant according to any one of claims 3, 4, and 6, said
method comprising:
        (a) providing biological material from a plant,
        (b) performing PCR or hybridization testing of the AHASL genes in said biological
        material to determine if the biological material comprises the polynucleotide(s) of
       the plant of any one of claims 3, 4, and 6, and
        (c) identifying, based on the results of step (b), that the plant of step (a) is a plant
        according to any one of claims 3, 4, and 6.
25.     The method of claim 24, wherein said biological material is a plant seed.
26.     A recombinant or mutagenized polynucleotide according to claim 1, an expression
vector according to claim 2, a plant according to any one of claims 3, 4, 6 or 7, a purified
protein according to claim 5, a seed according to claim 8 or 15, a method according to any
one of claims 9-13, 16-18 or 23-25, or a product according to any one of claims 19-22,
substantially as hereinbefore described.
                            BASF PLANT SCIENCE GmbH
WATERMARK INTELLECTUAL PROPERTY PTY LTD
P32345AU04
                                            - 92 -

<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
<removed-apn> <removed-date>
                                                    341792Sequenc eLi s t i ng
<removed-date>
                                               SEQUENCE LI STI NG
              <110>   Mc El v er , J ohn
                      Si ngh, Bi j ay
              <120>   AHAS MUTANTS
              <130>   038867/ 341792
              <160>   34
              <150> US 60/ 910, 028
              <151> 2007- 04- 04
<removed-apn>
              <170>   Pat ent I n v er s i on 3. 4
              <210>   1
              <211>   670
              <212>   PRT
              <213>   Ar abi dops i s t hal i ana
              <220>
              <221>   MI SC_FEATURE
              <223>   Ar abi dops i s t hal i ana ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                      ( At AHASL)
              <400>   1
              Met Al a Al a Al a Thr Thr Thr Thr Thr Thr Ser Ser Ser I l e Ser Phe
              1                  5                   10                    15
              Ser Thr Ly s Pr o Ser Pr o Ser Ser Ser Ly s Ser Pr o Leu Pr o I l e Ser
                           20                    25                    30
              Ar g Phe Ser Leu Pr o Phe Ser Leu As n Pr o As n Ly s Ser Ser Ser Ser
                       35                   40                      45
              Ser Ar g Ar g Ar g Gl y I l e Ly s Ser Ser Ser Pr o Ser Ser I l e Ser Al a
                  50                        55                    60
              Val Leu As n Thr Thr Thr As n Val Thr Thr Thr Pr o Ser Pr o Thr Ly s
              65                   70                   75                    80
              Pr o Thr Ly s Pr o Gl u Thr Phe I l e Ser Ar g Phe Al a Pr o As p Gl n Pr o
                                 85                     90                      95
              Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Gl n Gl y Val
                             100                     105                     110
              Gl u Thr Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n
                       115                    120                    125
              Al a Leu Thr Ar g Ser Ser Ser I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u
                   130                  135                     140
              Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Ser Ser Gl y Ly s
              145                    150                      155                    160
                                                                Page 1

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Pr o Gl y I l e Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val
                                   165                     170                     175
              Ser Gl y Leu Al a As p Al a Leu Leu As p Ser Val Pr o Leu Val Al a I l e
                           180                    185                   190
              Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u
                       195                     200                     205
<removed-apn>
              Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu
                  210                     215                    220
              Val Met As p Val Gl u As p I l e Pr o Ar g I l e I l e Gl u Gl u Al a Phe Phe
              225                   230                        235                      240
              Leu Al a Thr Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p Val Pr o Ly s
                               245                      250                  255
              As p I l e Gl n Gl n Gl n Leu Al a I l e Pr o As n Tr p Gl u Gl n Al a Met Ar g
                              260                      265                      270
              Leu Pr o Gl y Ty r Met Ser Ar g Met Pr o Ly s Pr o Pr o Gl u As p Ser Hi s
                       275                    280                     285
              Leu Gl u Gl n I l e Val Ar g Leu I l e Ser Gl u Ser Ly s Ly s Pr o Val Leu
                  290                      295                    300
              Ty r Val Gl y Gl y Gl y Cy s Leu As n Ser Ser As p Gl u Leu Gl y Ar g Phe
              305                     310                   315                     320
              Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y
                               325                      330                  335
              Ser Ty r Pr o Cy s As p As p Gl u Leu Ser Leu Hi s Met Leu Gl y Met Hi s
                            340                     345                  350
              Gl y Thr Val Ty r Al a As n Ty r Al a Val Gl u Hi s Ser As p Leu Leu Leu
                       355                     360                    365
              Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a
                   370                   375                    380
              Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Ser Al a Gl u
              385                    390                       395                      400
              I l e Gl y Ly s As n Ly s Thr Pr o Hi s Val Ser Val Cy s Gl y As p Val Ly s
                                   405                    410                    415
              Leu Al a Leu Gl n Gl y Met As n Ly s Val Leu Gl u As n Ar g Al a Gl u Gl u
                           420                     425                    430
                                                            Page 2

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Leu Ly s Leu As p Phe Gl y Val Tr p Ar g As n Gl u Leu As n Val Gl n Ly s
                       435                   440                     445
              Gl n Ly s Phe Pr o Leu Ser Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o Pr o
                   450                   455                   460
              Gl n Ty r Al a I l e Ly s Val Leu As p Gl u Leu Thr As p Gl y Ly s Al a I l e
              465                       470                   475                     480
<removed-apn>
              I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r
                                 485                     490                     495
              As n Ty r Ly s Ly s Pr o Ar g Gl n Tr p Leu Ser Ser Gl y Gl y Leu Gl y Al a
                             500                      505                   510
              Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Ser Val Al a As n Pr o
                       515                    520                      525
              As p Al a I l e Val Val As p I l e As p Gl y As p Gl y Ser Phe I l e Met As n
                   530                     535                       540
              Val Gl n Gl u Leu Al a Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s Val
              545                    550                     555                    560
              Leu Leu Leu As n As n Gl n Hi s Leu Gl y Met Val Met Gl n Tr p Gl u As p
                               565                     570                   575
              Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Phe Leu Gl y As p Pr o Al a
                            580                      585                   590
              Gl n Gl u As p Gl u I l e Phe Pr o As n Met Leu Leu Phe Al a Al a Al a Cy s
                        595                      600                  605
              Gl y I l e Pr o Al a Al a Ar g Val Thr Ly s Ly s Al a As p Leu Ar g Gl u Al a
                   610                       615                    620
              I l e Gl n Thr Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e
              625                    630                     635                   640
              Cy s Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y Thr
                                  645                    650                     655
              Phe As n As p Val I l e Thr Gl u Gl y As p Gl y Ar g I l e Ly s Ty r
                            660                     665                       670
              <210>   2
              <211>   638
              <212>   PRT
              <213>   Zea may s
              <220>
                                                           Page 3

                                                    341792Sequenc eLi s t i ng
<removed-date>
              <221>   MI SC_FEATURE
              <223>   Zea may s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number t wo
                      ( ZmAHASL2)
              <400>   2
              Met Al a Thr Al a Al a Al a Al a Ser Thr Al a Leu Thr Gl y Al a Thr Thr
              1                 5                      10                     15
              Al a Al a Pr o Ly s Al a Ar g Ar g Ar g Al a Hi s Leu Leu Al a Thr Ar g Ar g
                             20                       25                     30
<removed-apn>
              Al a Leu Al a Al a Pr o I l e Ar g Cy s Ser Al a Al a Ser Pr o Al a Met Pr o
                       35                        40                     45
              Met Al a Pr o Pr o Al a Thr Pr o Leu Ar g Pr o Tr p Gl y Pr o Thr As p Pr o
                  50                      55                      60
              Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Ser Leu Gl u Ar g Cy s Gl y Val
              65                       70                     75                      80
              Ar g As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n
                                85                       90                      95
              Al a Leu Thr Ar g Ser Pr o Val I l e Al a As n Hi s Leu Phe Ar g Hi s Gl u
                           100                     105                    110
              Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Ty r Al a Ar g Ser Ser Gl y Ar g
                        115                     120                     125
              Val Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val
                  130                      135                    140
              Ser Al a Leu Al a As p Al a Leu Leu As p Ser Val Pr o Met Val Al a I l e
              145                    150                   155                   160
              Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u
                                165                      170                    175
              Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu
                             180                   185                     190
              Val Leu As p Val As p As p I l e Pr o Ar g Val Val Gl n Gl u Al a Phe Phe
                      195                      200                    205
              Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e Pr o Ly s
                  210                    215                    220
              As p I l e Gl n Gl n Gl n Met Al a Val Pr o Val Tr p As p Ly s Pr o Met Ser
              225                       230                   235                     240
              Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Al a Thr Gl u Leu
                                 245                      250                     255
                                                           Page 4

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Ser Ar g Ar g Pr o Val Leu
                            260                  265                     270
              Ty r Val Gl y Gl y Gl y Cy s Al a Al a Ser Gl y Gl u Gl u Leu Ar g Ar g Phe
                       275                      280                     285
              Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met Gl y Leu Gl y
                  290                     295                  300
<removed-apn>
              As n Phe Pr o Ser As p As p Pr o Leu Ser Leu Ar g Met Leu Gl y Met Hi s
              305                    310                   315                   320
              Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p Leu Leu Leu
                                325                     330                     335
              Al a Leu Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s I l e Gl u Al a
                            340                    345                    350
              Phe Al a Ser Ar g Al a Ly s I l e Val Hi s Val As p I l e As p Pr o Al a Gl u
                       355                      360                     365
              I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a As p Val Ly s
                    370                      375                     380
              Leu Al a Leu Gl n Gl y Met As n Al a Leu Leu Gl u Gl y Ser Thr Ser Ly s
              385                    390                   395                   400
              Ly s Ser Phe As p Phe Gl y Ser Tr p As n As p Gl u Leu As p Gl n Gl n Ly s
                                405                    410                     415
              Ar g Gl u Phe Pr o Leu Gl y Ty r Ly s Thr Ser As n Gl u Gl u I l e Gl n Pr o
                            420                     425                    430
              Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y Gl u Al a I l e
                        435                     440                    445
              I l e Gl y Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Ty r Ty r
                    450                    455                     460
              Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser Ser Al a Gl y Leu Gl y Al a
              465                     470                    475                    480
              Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Al a Ser Val Al a As n Pr o
                                485                     490                    495
              Gl y Val Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe Leu Met As n
                           500                     505                    510
              Val Gl n Gl u Leu Al a Met I l e Ar g I l e Gl u As n Leu Pr o Val Ly s Val
                       515                     520                      525
                                                           Page 5

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Phe Val Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u As p
                  530                    535                   540
              Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o Gl u
              545                     550                     555                     560
              As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Thr I l e Al a Ly s Gl y Phe
                                 565                      570                     575
<removed-apn>
              As n I l e Pr o Al a Val Ar g Val Thr Ly s Ly s As n Gl u Val Ar g Al a Al a
                              580                   585                     590
              I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o Ty r Leu Leu As p I l e I l e
                         595                   600                     605
              Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y Al a
                  610                      615                    620
              Phe Ly s As p Met I l e Leu As p Gl y As p Gl y Ar g Thr Val Ty r
              625                     630                     635
              <210>   3
              <211>   652
              <212>   PRT
              <213>   Br as s i c a napus
              <220>
              <221>   MI SC_FEATURE
              <223>   Br as s i c a napus A genome ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                      number one ( BnAHASL1A)
              <400>   3
              Met Al a Al a Al a Thr Ser Ser Ser Pr o I l e Ser Leu Thr Al a Ly s Pr o
              1                  5                    10                     15
              Ser Ser Ly s Ser Pr o Leu Pr o I l e Ser Ar g Phe Ser Leu Pr o Phe Ser
                           20                      25                   30
              Leu Thr Pr o Gl n Ly s Pr o Ser Ser Ar g Leu Hi s Ar g Pr o Leu Al a I l e
                      35                      40                     45
              Ser Al a Val Leu As n Ser Pr o Val As n Val Al a Pr o Gl u Ly s Thr As p
                  50                    55                     60
              Ly s I l e Ly s Thr Phe I l e Ser Ar g Ty r Al a Pr o As p Gl u Pr o Ar g Ly s
              65                      70                       75                       80
              Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Gl n Gl y Val Gl u Thr
                                   85                    90                      95
              Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu
                                                         Page 6

                                                   341792Sequenc eLi s t i ng
<removed-date>
                             100                     105                      110
              Thr Ar g Ser Ser Thr I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y
                       115                    120                    125
              Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Ser Ser Gl y Ly s Pr o Gl y
                   130                    135                     140
              I l e Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val Ser Gl y
              145                       150                     155                  160
<removed-apn>
              Leu Al a As p Al a Met Leu As p Ser Val Pr o Leu Val Al a I l e Thr Gl y
                                 165                  170                     175
              Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o
                            180                      185                    190
              I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu Val Met
                        195                   200                      205
              As p Val As p As p I l e Pr o Ar g I l e Val Gl n Gl u Al a Phe Phe Leu Al a
                   210                      215                      220
              Thr Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p Val Pr o Ly s As p I l e
              225                    230                   235                     240
              Gl n Gl n Gl n Leu Al a I l e Pr o As n Tr p As p Gl n Pr o Met Ar g Leu Pr o
                                 245                       250                     255
              Gl y Ty r Met Ser Ar g Leu Pr o Gl n Pr o Pr o Gl u Val Ser Gl n Leu Gl y
                            260                    265                    270
              Gl n I l e Val Ar g Leu I l e Ser Gl u Ser Ly s Ar g Pr o Val Leu Ty r Val
                         275                    280                     285
              Gl y Gl y Gl y Ser Leu As n Ser Ser Gl u Gl u Leu Gl y Ar g Phe Val Gl u
                   290                    295                   300
              Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Ser Ty r
              305                     310                  315                   320
              Pr o Cy s As n As p Gl u Leu Ser Leu Gl n Met Leu Gl y Met Hi s Gl y Thr
                                  325                   330                   335
              Val Ty r Al a As n Ty r Al a Val Gl u Hi s Ser As p Leu Leu Leu Al a Phe
                            340                     345                   350
              Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a
                       355                     360                   365
              Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Ser Al a Gl u I l e Gl y
                                                             Page 7

                                                  341792Sequenc eLi s t i ng
<removed-date>
                  370                      375                   380
              Ly s As n Ly s Thr Pr o Hi s Val Ser Val Cy s Gl y As p Val Ly s Leu Al a
              385                     390                   395                    400
              Leu Gl n Gl y Met As n Ly s Val Leu Gl u As n Ar g Al a Gl u Gl u Leu Ly s
                                405                    410                      415
              Leu As p Phe Gl y Val Tr p Ar g Ser Gl u Leu Ser Gl u Gl n Ly s Gl n Ly s
                           420                    425                    430
<removed-apn>
              Phe Pr o Leu Ser Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o Pr o Gl n Ty r
                       435                  440                      445
              Al a I l e Gl n Val Leu As p Gl u Leu Thr Gl n Gl y Ly s Al a I l e I l e Ser
                   450                     455                    460
              Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r
              465                    470                     475                     480
              Ar g Ly s Pr o Ar g Gl n Tr p Leu Ser Ser Ser Gl y Leu Gl y Al a Met Gl y
                                  485                   490                    495
              Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Ser Val Al a As n Pr o As p Al a
                           500                       505                    510
              I l e Val Val As p I l e As p Gl y As p Gl y Ser Phe I l e Met As n Val Gl n
                        515                      520                     525
              Gl u Leu Al a Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s I l e Leu Leu
                   530                     535                    540
              Leu As n As n Gl n Hi s Leu Gl y Met Val Met Gl n Tr p Gl u As p Ar g Phe
              545                     550                  555                      560
              Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As p Pr o Al a Ar g Gl u
                                  565                     570                     575
              As n Gl u I l e Phe Pr o As n Met Leu Gl n Phe Al a Gl y Al a Cy s Gl y I l e
                              580                   585                     590
              Pr o Al a Al a Ar g Val Thr Ly s Ly s Gl u Gl u Leu Ar g Gl u Al a I l e Gl n
                        595                    600                     605
              Thr Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Cy s Pr o
                  610                   615                    620
              Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y Thr Phe Ly s
              625                     630                     635                   640
              As p Val I l e Thr Gl u Gl y As p Gl y Ar g Thr Ly s Ty r
                                                           Page 8

                                                     341792Sequenc eLi s t i ng
<removed-date>
                                    645                    650
              <210>   4
              <211>   644
              <212>   PRT
              <213>   Or y z a s at i v a
              <220>
              <221>   MI SC_FEATURE
              <223>   Ri c e ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( Os AHASL)
<removed-apn>
              <400>   4
              Met Al a Thr Thr Al a Al a Al a Al a Al a Al a Al a Leu Ser Al a Al a Al a
              1                5                        10                     15
              Thr Al a Ly s Thr Gl y Ar g Ly s As n Hi s Gl n Ar g Hi s Hi s Val Leu Pr o
                            20                      25                       30
              Al a Ar g Gl y Ar g Val Gl y Al a Al a Al a Val Ar g Cy s Ser Al a Val Ser
                        35                      40                      45
              Pr o Val Thr Pr o Pr o Ser Pr o Al a Pr o Pr o Al a Thr Pr o Leu Ar g Pr o
                   50                    55                       60
              Tr p Gl y Pr o Al a Gl u Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a
              65                       70                       75                      80
              Leu Gl u Ar g Cy s Gl y Val Ser As p Val Phe Al a Ty r Pr o Gl y Gl y Al a
                                 85                    90                      95
              Ser Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser Pr o Val I l e Thr As n
                           100                      105                   110
              Hi s Leu Phe Ar g Hi s Gl u Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Ty r
                       115                     120                     125
              Al a Ar g Al a Ser Gl y Ar g Val Gl y Val Cy s Val Al a Thr Ser Gl y Pr o
                   130                     135                   140
              Gl y Al a Thr As n Leu Val Ser Al a Leu Al a As p Al a Leu Leu As p Ser
              145                    150                   155                    160
              Val Pr o Met Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y
                               165                      170                    175
              Thr As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e
                            180                    185                    190
              Thr Ly s Hi s As n Ty r Leu Val Leu As p Val Gl u As p I l e Pr o Ar g Val
                       195                    200                    205
              I l e Gl n Gl u Al a Phe Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val
                                                         Page 9

                                                   341792Sequenc eLi s t i ng
<removed-date>
                   210                      215                   220
              Leu Val As p I l e Pr o Ly s As p I l e Gl n Gl n Gl n Met Al a Val Pr o Val
              225                     230                       235                    240
              Tr p As p Thr Ser Met As n Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s
                                245                    250                      255
              Pr o Pr o Al a Thr Gl u Leu Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u
                             260                   265                   270
<removed-apn>
              Ser Ar g Ar g Pr o I l e Leu Ty r Val Gl y Gl y Gl y Cy s Ser Al a Ser Gl y
                       275                      280                     285
              As p Gl u Leu Ar g Tr p Phe Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr
                   290                    295                   300
              Thr Leu Met Gl y Leu Gl y As n Phe Pr o Ser As p As p Pr o Leu Ser Leu
              305                  310                    315                    320
              Ar g Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p
                                325                   330                      335
              Ly s Al a As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val
                             340                  345                    350
              Thr Gl y Ly s I l e Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e
                       355                      360                     365
              As p I l e As p Pr o Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser
                   370                       375                       380
              I l e Cy s Al a As p Val Ly s Leu Al a Leu Gl n Gl y Leu As n Al a Leu Leu
              385                      390                    395                    400
              Gl n Gl n Ser Thr Thr Ly s Thr Ser Ser As p Phe Ser Al a Tr p Hi s As n
                                405                  410                    415
              Gl u Leu As p Gl n Gl n Ly s Ar g Gl u Phe Pr o Leu Gl y Ty r Ly s Thr Phe
                            420                      425                    430
              Gl y Gl u Gl u I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu
                        435                       440                      445
              Thr Ly s Gl y Gl u Al a I l e I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met
                  450                       455                     460
              Tr p Al a Al a Gl n Ty r Ty r Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser
              465                      470                     475                     480
              Ser Al a Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y
                                                        Page 10

                                                    341792Sequenc eLi s t i ng
<removed-date>
                                  485                     490                          495
              Al a Ser Val Al a As n Pr o Gl y Val Thr Val Val As p I l e As p Gl y As p
                           500                     505                    510
              Gl y Ser Phe Leu Met As n I l e Gl n Gl u Leu Al a Leu I l e Ar g I l e Gl u
                       515                    520                    525
              As n Leu Pr o Val Ly s Val Met Val Leu As n As n Gl n Hi s Leu Gl y Met
                   530                   535                   540
<removed-apn>
              Val Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr
              545                    550                     555                      560
              Ty r Leu Gl y As n Pr o Gl u Cy s Gl u Ser Gl u I l e Ty r Pr o As p Phe Val
                                 565                     570                       575
              Thr I l e Al a Ly s Gl y Phe As n I l e Pr o Al a Val Ar g Val Thr Ly s Ly s
                             580                      585                    590
              Ser Gl u Val Ar g Al a Al a I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o
                       595                      600                    605
              Ty r Leu Leu As p I l e I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met
                   610                      615                     620
              I l e Pr o Ser Gl y Gl y Al a Phe Ly s As p Met I l e Leu As p Gl y As p Gl y
              625                      630                    635                      640
              Ar g Thr Val Ty r
              <210>   5
              <211>   655
              <212>   PRT
              <213>   Hel i ant hus annuus
              <220>
              <221>   MI SC_FEATURE
              <223>   Sunf l ower ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number
                      1( HaAHASL1)
              <400>   5
              Met Al a Al a Pr o Pr o As n Pr o Ser I l e Ser Phe Ly s Pr o Pr o Ser Pr o
              1                  5                        10                     15
              Al a Al a Al a Leu Pr o Pr o Ar g Ser Al a Phe Leu Pr o Ar g Phe Al a Leu
                             20                     25                     30
              Pr o I l e Thr Ser Thr Thr Gl n Ly s Ar g Hi s Ar g Leu Hi s I l e Ser As n
                         35                   40                      45
                                                             Page 11

                                              341792Sequenc eLi s t i ng
<removed-date>
              Val Leu Ser As p Ser Ly s Ser Thr Thr Thr Thr Thr Thr Thr Thr Gl n
                  50                    55                   60
              Ar g Pr o Leu Pr o Val Gl n Pr o Phe Val Ser Ar g Ty r Al a Pr o As p Gl n
              65                     70                    75                       80
              Pr o Ar g Ly s Gl y Al a As p Val Leu Val Gl u Al a Leu Gl u Ar g Gl u Gl y
                                  85                    90                      95
              Val Thr As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s
<removed-apn>
                           100                    105                    110
              Gl n Al a Leu Thr Ar g Ser Ser Thr I l e Ar g As n Val Leu Pr o Ar g Hi s
                        115                  120                     125
              Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Al a Ser Gl y
                   130                    135                      140
              Leu Pr o Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu
              145                    150                     155                     160
              Val Ser Gl y Leu Al a As p Al a Leu Leu As p Ser Val Pr o Met Val Al a
                               165                    170                   175
              I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n
                             180                     185                     190
              Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r
                       195                     200                    205
              Leu Val Leu As p Val Gl u As p I l e Pr o Ar g I l e Val Ar g Gl u Al a Phe
                  210                   215                        220
              Ty r Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu I l e As p Val Pr o
              225                   230                      235                    240
              Ly s As p I l e Gl n Gl n Gl n Leu Val Val Pr o Ly s Tr p As p Gl u Pr o Met
                                   245                   250                      255
              Ar g Leu Pr o Gl y Ty r Leu Ser Ar g Met Pr o Ly s Pr o Gl n Ty r As p Gl y
                            260                    265                     270
              Hi s Leu Gl u Gl n I l e Val Ar g Leu Val Gl y Gl u Al a Ly s Ar g Pr o Val
                       275                      280                    285
              Leu Ty r Val Gl y Gl y Gl y Cy s Leu As n Ser As p As p Gl u Leu Ar g Ar g
                  290                     295                    300
              Phe Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu
              305                  310                      315                  320
                                                          Page 12

                                                 341792Sequenc eLi s t i ng
<removed-date>
              Gl y Al a Ty r Pr o Al a Ser Ser As p Leu Ser Leu Hi s Met Leu Gl y Met
                                  325                   330                  335
              Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Ser As p Leu Leu
                            340                     345                    350
              Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u
                       355                   360                    365
              Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Pr o Al a
<removed-apn>
                   370                    375                       380
              Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Gl y As p I l e
              385                       390                     395                      400
              Ly s Val Al a Leu Gl n Gl y Leu As n Ly s I l e Leu Gl u Gl u Ly s As n Ser
                                405                     410                      415
              Val Thr As n Leu As p Phe Ser Thr Tr p Ar g Ly s Gl u Leu As p Gl u Gl n
                           420                  425                     430
              Ly s Met Ly s Phe Pr o Leu Ser Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o
                       435                   440                   445
              Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Gl y Gl y As n Al a
                   450                       455                   460
              I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe
              465                      470                     475                     480
              Ty r Ly s Ty r As n Ly s Pr o Ar g Gl n Tr p Leu Thr Ser Gl y Gl y Leu Gl y
                                  485                      490                   495
              Al a Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Al a Val Al a Ar g
                            500                    505                       510
              Pr o As p Al a Val Val Val As p I l e As p Gl y As p Gl y Ser Phe Met Met
                        515                   520                       525
              As n Val Gl n Gl u Leu Al a Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s
                   530                    535                     540
              I l e Leu Leu Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u
              545                    550                     555                   560
              As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o
                                 565                      570                    575
              Ser Ly s Gl u Ser Gl u I l e Phe Pr o As n Met Val Ly s Phe Al a Gl u Al a
                            580                     585                   590
                                                            Page 13

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Cy s As p I l e Pr o Al a Al a Ar g Val Thr Gl n Ly s Al a As p Leu Ar g Al a
                        595                       600                      605
              Al a I l e Gl n Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val
                   610                     615                     620
              I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Al a Gl y Gl y
              625                      630                    635                      640
              Gl y Phe Ser As p Val I l e Thr Gl u Gl y As p Gl y Ar g Thr Ly s Ty r
<removed-apn>
                                645                     650                     655
              <210>   6
              <211>   646
              <212>   PRT
              <213>   Hel i ant hus annuus
              <220>
              <221>   MI SC_FEATURE
              <223>   Sunf l ower ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number
                      2( HaAHASL2)
              <400>   6
              Met Al a Al a I l e Hi s Pr o Pr o Hi s Pr o Ser I l e Thr Al a Ly s Pr o Pr o
              1                   5                        10                      15
              Pr o Ser Ser Al a Al a Al a Val Al a Leu Pr o Pr o Hi s Phe Al a Phe Ser
                           20                      25                     30
              I l e Thr Ser Thr Ser Hi s Ly s Ar g Hi s Ar g Leu Hi s I l e Ser As n Val
                        35                    40                      45
              Leu Ser As p Ser Thr Thr Thr Thr Gl y Al a Thr Thr I l e Hi s Pr o Pr o
                  50                   55                    60
              Pr o Phe Val Ser Ar g Ty r Al a Pr o As p Gl n Pr o Ar g Ly s Gl y Al a As p
              65                    70                       75                       80
              Val Leu Val Gl u Al a Leu Gl u Ar g Gl u Gl y Val Thr As p Val Phe Al a
                               85                      90                    95
              Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser
                             100                    105                      110
              As n Thr I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe
                       115                     120                      125
              Al a Al a Gl u Gl y Ty r Al a Ar g Al a Ser Gl y Val Pr o Gl y Val Cy s I l e
                   130                      135                    140
              Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val Ser Gl y Leu Al a As p
              145                    150                    155                   160
                                                             Page 14

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Al a Leu Leu As p Ser Val Pr o Met Val Al a I l e Thr Gl y Gl n Val Pr o
                                165                  170                      175
              Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u
                            180                      185                    190
              Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu Val Leu As p Val Gl u
                      195                     200                    205
<removed-apn>
              As p I l e Pr o Ar g I l e Val Ar g Gl u Al a Phe Ty r Leu Al a Ser Ser Gl y
                   210                       215                     220
              Ar g Pr o Gl y Pr o Val Leu I l e As p Val Pr o Ly s As p I l e Gl n Gl n Gl n
              225                     230                     235                       240
              Leu Val Val Pr o Ly s Tr p As p Gl u Pr o Met Ar g Leu Pr o Gl y Ty r Leu
                               245                      250                    255
              Ser Ar g Met Pr o Ly s Pr o Gl n Ty r As p Gl y Hi s Leu Gl u Gl n I l e Val
                           260                      265                     270
              Ar g Leu Val Gl y Gl u Al a Ly s Ar g Pr o Val Leu Ty r Val Gl y Gl y Gl y
                       275                     280                    285
              Cy s Leu As n Ser As p As p Gl u Leu Ar g Ar g Phe Val Gl u Leu Thr Gl y
                   290                    295                    300
              I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Al a Ty r Pr o Al a Ser
              305                     310                  315                      320
              Ser As p Leu Ser Leu Hi s Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a
                               325                   330                   335
              As n Ty r Al a Val As p Ly s Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g
                             340                    345                  350
              Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a
                       355                    360                    365
              Ly s I l e Val Hi s I l e As p I l e As p Pr o Al a Gl u I l e Gl y Ly s As n Ly s
                   370                       375                       380
              Gl n Pr o Hi s Val Ser I l e Cy s Gl y As p I l e Ly s Val Al a Leu Gl n Gl y
              385                    390                        395                    400
              Leu As n Ly s I l e Leu Gl u Gl u Ly s As n Ser Leu As p Phe Ser As n Tr p
                                  405                     410                  415
              Ar g Ly s Gl u Leu As p Gl u Gl n Ly s Val Ly s Phe Pr o Leu Ser Phe Ly s
                             420                     425                   430
                                                             Page 15

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Thr Phe Gl y Gl u Al a I l e Pr o Pr o Gl n Ty r Al a I l e Hi s Val Leu As p
                      435                       440                       445
              Gl u Leu Thr Gl y Gl y As n Al a I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s
                   450                    455                      460
              Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r As n Ly s Pr o Ar g Gl n Tr p
              465                     470                     475                      480
<removed-apn>
              Leu Thr Ser Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a
                               485                    490                    495
              I l e Gl y Al a Al a Val Al a Ar g Pr o As p Al a Val Val Val As p I l e As p
                              500                     505                   510
              Gl y As p Gl y Ser Phe Met Met As n Val Gl n Gl u Leu Al a Thr I l e Ar g
                        515                  520                    525
              Val Gl u As n Leu Pr o Val Ly s I l e Leu Leu Leu As n As n Gl n Hi s Leu
                  530                    535                    540
              Gl y Met Val Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a
              545                   550                     555                      560
              Hi s Thr Ty r Leu Gl y As n Pr o Ser Ly s Gl u Ser Gl u I l e Phe Pr o As n
                                565                     570                     575
              Met Leu Ly s Phe Al a Gl u Al a Cy s As p I l e Pr o Al a Al a Ar g Val Thr
                           580                     585                       590
              Ar g Ly s Gl y As p Leu Ar g Al a Al a I l e Gl n Ly s Met Leu As p Thr Pr o
                        595                     600                      605
              Gl y Pr o Ty r Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu
                   610                    615                     620
              Pr o Met I l e Pr o Al a Gl y Gl y Gl y Phe Ser As p Val I l e Thr Gl u Gl y
              625                      630                    635                     640
              As p Gl y Ar g Met Ly s Ty r
                                 645
              <210>   7
              <211>   646
              <212>   PRT
              <213>   Hel i ant hus annuus
              <220>
              <221>   mi s c _f eat ur e
              <223>   Sunf l ower ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number
                      3( HaAHASL3)
                                                             Page 16

                                                  341792Sequenc eLi s t i ng
<removed-date>
              <400>   7
              Met Al a Val Pr o Leu Thr Phe I l e Ser Gl y Ly s Pr o Pr o Phe Ser Al a
              1                 5                     10                      15
              Thr Pr o Ser Gl n Leu Thr Thr As n Leu Ser Leu Pr o Leu Thr Leu Leu
                           20                    25                   30
              Pr o I l e I l e Pr o Ser Ly s Thr Hi s Val Ser Ly s Hi s Leu I l e I l e Thr
                         35                      40                     45
<removed-apn>
              As n Al a I l e Al a Ly s Hi s Ser Hi s Ser Hi s Ly s Al a Phe Val Val Ser
                   50                        55                     60
              Ar g Phe Gl y Pr o As p Gl u Pr o Ar g Ly s Gl y Ser As p Val Leu Val Gl u
              65                      70                       75                   80
              Al a Leu Gl u Ar g Gl u Gl y Val Thr As n Val Phe Al a Ty r Pr o Gl y Gl y
                                 85                     90                     95
              Al a Thr Leu Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser Thr I l e I l e Ar g
                           100                       105                  110
              As n I l e Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y
                         115                     120                    125
              Ty r Al a Ar g Al a Ser Gl y Leu Thr Gl y Val Cy s I l e Ser Thr Ser Gl y
                   130                     135                   140
              Pr o Gl y Al a Thr As n Leu Val Ser Gl y Leu Al a As p Al a Leu Leu As p
              145                     150                  155                    160
              Ser Val Pr o I l e Val Al a I l e Thr Gl y Gl n Val Pr o Ar g As n Met I l e
                                 165                     170                     175
              Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Ser Ar g Ser
                            180                    185                     190
              I l e Thr Ly s Hi s As n Ty r Leu Val Leu As n Val Gl n As p I l e Pr o Ar g
                        195                     200                   205
              I l e Val Hi s Gl u Al a Phe Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o
                    210                    215                  220
              Val Leu I l e As p I l e Pr o Ly s As p I l e Gl n Gl n Gl n Leu Val Val Pr o
              225                      230                       235                   240
              As n Tr p As p Gl u Gl n Gl n Gl n Pr o Met Ar g Leu As p Gl y Ty r I l e Ser
                                  245                     250                     255
              Ar g Leu Pr o Ly s Pr o Pr o As n Gl u Thr Hi s Leu Ar g Gl n I l e Val Ar g
                            260                      265                    270
                                                          Page 17

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Phe I l e Ly s Gl u Ser Ly s Ar g Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s
                        275                     280                   285
              Met As n Ser Ser As p Gl u Leu Gl y Ar g Phe Val Gl u Leu Thr Gl y I l e
                  290                    295                   300
              Pr o Val Al a As n Thr Leu Met Gl y Leu Gl y Thr Ty r Pr o Gl y Ser Hi s
              305                    310                   315                    320
<removed-apn>
              As p Leu Ser Leu Hi s Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n
                               325                   330                    335
              Ty r Al a I l e As p Ly s Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe
                              340                    345                   350
              As p As p Ar g Val Thr Gl y Ly s I l e Gl u Al a Phe Al a Ser Ar g Al a Ly s
                        355                    360                      365
              I l e Val Hi s I l e As p I l e As p Pr o Al a Gl u I l e Gl y Ly s As n Ly s Gl n
                    370                       375                       380
              Pr o Hi s Phe Ser I l e Cy s Gl y As p I l e Ly s Al a Al a Leu Gl n Gl y Leu
              385                     390                       395                     400
              As n Ly s I l e Leu Gl u Ar g Gl y Gl u As p Leu As p Phe As p Phe Ser Pr o
                                  405                      410                   415
              Tr p Ly s Gl u Gl u Val Met As n Gl n Ly s Al a Ser As n Pr o Leu Ser Ty r
                             420                    425                     430
              Ly s Thr Phe Gl y As p Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu
                       435                      440                      445
              As n Gl u Val Thr Gl y Gl y As n Al a I l e I l e Thr Thr Gl y Val Gl y Gl n
                   450                    455                       460
              Hi s Gl n Met Tr p Ser Al a Gl n Phe Ty r Ly s Ty r As n Ar g Pr o Ar g Gl n
              465                    470                     475                      480
              Tr p Leu Thr Ser Al a Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a
                               485                     490                   495
              Al a I l e Gl y Al a Al a Val Al a Ar g Pr o As p Al a Val Val Val As p I l e
                              500                     505                    510
              As p Gl y As p Gl y Ser Phe Met Met As n Val Gl n Gl u Leu Al a Thr I l e
                        515                   520                    525
              Ar g Val Gl u As n Leu Pr o Val Ly s Met Met Val Leu As n As n Gl n Hi s
                   530                    535                   540
                                                        Page 18

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Leu Gl y Met Val Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g
              545                  550                      555                     560
              Al a Hi s Thr Ty r Leu Gl y As n Pr o Thr As n Gl u Ser Gl y I l e Phe Pr o
                                 565                    570                      575
              As n Met Leu Ly s Phe Al a Gl u Al a Cy s As p I l e Pr o Al a Al a Ar g Val
                           580                     585                       590
<removed-apn>
              Thr Ly s Ly s Gl y As p Val Ar g Thr Al a I l e Gl n Ly s Met Leu As p Thr
                       595                     600                      605
              Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u Hi s Val
                   610                    615                     620
              Leu Pr o Met I l e Pr o Al a Gl y Gl y Gl y Phe As n As p I l e I l e Thr As p
              625                     630                     635                       640
              Gl y As p Gl y Ar g Thr Gl n
                                  645
              <210>   8
              <211>   638
              <212>   PRT
              <213>   Zea may s
              <220>
              <221>   MI SC_FEATURE
              <223>   Zea may s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number
                      1( ZmAHASL1)
              <400>   8
              Met Al a Thr Al a Al a Thr Al a Al a Al a Al a Leu Thr Gl y Al a Thr Thr
              1                 5                       10                     15
              Al a Thr Pr o Ly s Ser Ar g Ar g Ar g Al a Hi s Hi s Leu Al a Thr Ar g Ar g
                            20                      25                      30
              Al a Leu Al a Al a Pr o I l e Ar g Cy s Ser Al a Leu Ser Ar g Al a Thr Pr o
                       35                        40                    45
              Thr Al a Pr o Pr o Al a Thr Pr o Leu Ar g Pr o Tr p Gl y Pr o As n Gl u Pr o
                  50                      55                      60
              Ar g Ly s Gl y Ser As p I l e Leu Val Gl u Al a Leu Gl u Ar g Cy s Gl y Val
              65                      70                      75                      80
              Ar g As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n
                                85                       90                      95
              Al a Leu Thr Ar g Ser Pr o Val I l e Al a As n Hi s Leu Phe Ar g Hi s Gl u
                                                         Page 19

                                                   341792Sequenc eLi s t i ng
<removed-date>
                             100                     105                      110
              Gl n Gl y Gl u Al a Phe Al a Al a Ser Al a Ty r Al a Ar g Ser Ser Gl y Ar g
                        115                     120                     125
              Val Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val
                  130                      135                    140
              Ser Al a Leu Al a As p Al a Leu Leu As p Ser Val Pr o Met Val Al a I l e
              145                    150                   155                   160
<removed-apn>
              Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u
                                165                      170                    175
              Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu
                             180                   185                     190
              Val Leu As p Val As p As p I l e Pr o Ar g Val Val Gl n Gl u Al a Phe Phe
                      195                      200                    205
              Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e Pr o Ly s
                  210                    215                    220
              As p I l e Gl n Gl n Gl n Met Al a Val Pr o Al a Tr p As p Thr Pr o Met Ser
              225                       230                    235                    240
              Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Al a Thr Gl u Phe
                                 245                      250                     255
              Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Ser Ar g Ar g Pr o Val Leu
                            260                  265                     270
              Ty r Val Gl y Gl y Gl y Cy s Al a Al a Ser Gl y Gl u Gl u Leu Cy s Ar g Phe
                       275                      280                     285
              Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met Gl y Leu Gl y
                  290                     295                  300
              As n Phe Pr o Ser As p As p Pr o Leu Ser Leu Ar g Met Leu Gl y Met Hi s
              305                    310                   315                   320
              Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p Leu Leu Leu
                                325                     330                     335
              Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s I l e Gl u Al a
                            340                    345                    350
              Phe Al a Gl y Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Pr o Al a Gl u
                       355                       360                       365
              I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a As p Val Ly s
                                                            Page 20

                                                  341792Sequenc eLi s t i ng
<removed-date>
                  370                      375                   380
              Leu Al a Leu Gl n Gl y Met As n Thr Leu Leu Gl u Gl y Ser Thr Ser Ly s
              385                    390                  395                   400
              Ly s Ser Phe As p Phe Gl y Ser Tr p Hi s As p Gl u Leu As p Gl n Gl n Ly s
                                405                    410                     415
              Ar g Gl u Phe Pr o Leu Gl y Ty r Ly s I l e Phe As n Gl u Gl u I l e Gl n Pr o
                            420                     425                      430
<removed-apn>
              Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y Gl u Al a I l e
                        435                     440                    445
              I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Ty r Ty r
                    450                    455                     460
              Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser Ser Al a Gl y Leu Gl y Al a
              465                     470                    475                    480
              Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Al a Al a Val Al a As n Pr o
                                485                     490                     495
              Gl y Val Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe Leu Met As n
                           500                     505                    510
              I l e Gl n Gl u Leu Al a Met I l e Ar g I l e Gl u As n Leu Pr o Val Ly s Val
                         515                     520                      525
              Phe Val Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u As p
                  530                    535                   540
              Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Phe Leu Gl y As n Pr o Gl u
              545                     550                     555                    560
              As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Al a I l e Al a Ly s Gl y Phe
                                 565                      570                      575
              As n I l e Pr o Al a Val Ar g Val Thr Ly s Ly s Ser Gl u Val Hi s Al a Al a
                              580                   585                    590
              I l e Ly s Ly s Met Leu Gl u Al a Pr o Gl y Pr o Ty r Leu Leu As p I l e I l e
                         595                    600                     605
              Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y Al a
                  610                      615                    620
              Phe Ly s As p Met I l e Leu As p Gl y As p Gl y Ar g Thr Val Ty r
              625                     630                     635
              <210>     9
                                                           Page 21

                                                    341792Sequenc eLi s t i ng
<removed-date>
              <211>   665
              <212>   PRT
              <213>   Amar ant hus s p.
              <220>
              <221>   MI SC_FEATURE
              <223>   Amar ant hus ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( As AHASL)
              <400>   9
              Met Val Thr Leu As n Hi s I l e Ser Ser Phe Thr Ly s Pr o As n Ly s Thr
              1               5                       10                     15
<removed-apn>
              Ty r Leu Gl n Ser Ser I l e Ty r Al a I l e Pr o Phe Ser As n Ser Leu Ly s
                            20                      25                      30
              Pr o Thr Ser Ser Ser Ser I l e Leu Al a Al a Leu Phe Ly s Ser Hi s Hi s
                       35                    40                    45
              Leu Leu Leu Gl n Ser Pr o Ly s Pr o Ly s Pr o Pr o Ser Al a Thr I l e Thr
                  50                    55                       60
              Gl n Ser Pr o Ser Ser Leu Thr As p As p Ly s Pr o Ser Ser Phe Val Ser
              65                    70                     75                   80
              Ar g Phe Ser Pr o Gl u Gl u Pr o Ar g Ly s Gl y Cy s As p Val Leu Val Gl u
                                85                       90                     95
              Al a Leu Gl u Ar g Gl u Gl y Val Thr As p Val Phe Al a Ty r Pr o Gl y Gl y
                            100                    105                    110
              Al a Ser Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser As n I l e I l e Ar g
                       115                      120                   125
              As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl n Gl y
                   130                    135                     140
              Ty r Al a Ar g Al a Thr Gl y Ar g Val Gl y Val Cy s I l e Al a Thr Ser Gl y
              145                     150                    155                     160
              Pr o Gl y Al a Thr As n Leu Val Ser Gl y Phe Al a As p Al a Leu Leu As p
                                 165                   170                    175
              Ser Val Pr o Leu Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e
                           180                    185                     190
              Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser
                       195                     200                     205
              I l e Thr Ly s Hi s As n Ty r Leu Val Leu As p Val Gl u As p I l e Pr o Ar g
                    210                     215                  220
              I l e Val Ly s Gl u Al a Phe Phe Leu Al a As n Ser Gl y Ar g Pr o Gl y Pr o
                                                         Page 22

                                                    341792Sequenc eLi s t i ng
<removed-date>
              225                      230                    235                          240
              Val Leu I l e As p I l e Pr o Ly s As p I l e Gl n Gl n Gl n Leu Val Val Pr o
                                 245                        250                    255
              As n Tr p Gl u Gl n Pr o I l e Ly s Leu Gl y Gl y Ty r Leu Ser Ar g Leu Pr o
                             260                      265                    270
              Ly s Pr o Thr Phe Ser Al a As n Gl u Gl u Gl y Leu Leu As p Gl n I l e Val
                        275                   280                    285
<removed-apn>
              Ar g Leu Val Gl y Gl u Ser Ly s Ar g Pr o Val Leu Ty r Thr Gl y Gl y Gl y
                   290                   295                    300
              Cy s Leu As n Ser Ser Gl u Gl u Leu Ar g Ly s Phe Val Gl u Leu Thr Gl y
              305                   310                     315                  320
              I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Al a Phe Pr o Cy s Thr
                                  325                  330                    335
              As p As p Leu Ser Leu Gl n Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a
                            340                  345                    350
              As n Ty r Al a Val As p Ly s Al a As p Leu Leu Leu Al a Phe Gl y Val Ar g
                        355                     360                   365
              Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a
                  370                    375                     380
              Ly s I l e Val Hi s I l e As p I l e As p Ser Al a Gl u I l e Gl y Ly s As n Ly s
              385                       390                      395                       400
              Gl n Pr o Hi s Val Ser I l e Cy s Gl y Gl u I l e Ly s Val Al a Leu Gl n Gl y
                                 405                      410                     415
              Leu As n Ly s I l e Leu Gl u Ser Ar g Ly s Gl y Ly s Leu Ly s Leu As p Phe
                            420                     425                     430
              Ser As n Tr p Ar g Gl u Gl u Leu As n Gl u Gl n Ly s Ly s Ly s Phe Pr o Leu
                       435                     440                      445
              Ser Phe Ly s Ser Phe Gl y As p Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n
                  450                   455                       460
              Val Leu As p Gl u Leu Thr Leu Gl y As p Al a I l e Val Ser Thr Gl y Val
              465                   470                    475                    480
              Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r Ar g As n Pr o
                                  485                     490                     495
              Ar g Gl n Tr p Leu Thr Ser Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu
                                                        Page 23

                                                    341792Sequenc eLi s t i ng
<removed-date>
                            500                       505                      510
              Pr o Al a Cy s Ty r Gl y Al a Al a Val Al a Ar g Pr o As p Al a Val Val Val
                        515                      520                     525
              As p I l e As p Gl y As p Gl y Ser Phe I l e Met As n Val Gl n Gl u Leu Al a
                   530                       535                    540
              Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s I l e Met Leu Leu As n As n
              545                     550                    555                    560
<removed-apn>
              Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a
                                 565                   570                     575
              As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o Ser As n Ser Ser Gl u I l e
                             580                    585                    590
              Phe Pr o As p Met Leu Ly s Phe Al a Gl u Al a Cy s As p I l e Pr o Al a Al a
                       595                   600                      605
              Ar g Val Thr Ly s Val Ser As p Leu Ar g Al a Al a I l e Gl n Thr Met Leu
                   610                  615                     620
              As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u
              625                     630                   635                      640
              Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Al a Al a Phe Ly s As p Thr I l e
                                645                     650                     655
              Thr Gl u Gl y As p Gl y Ar g Ar g Al a Ty r
                            660                      665
              <210>   10
              <211>   655
              <212>   PRT
              <213>   Br as s i c a napus
              <220>
              <221>   MI SC_FEATURE
              <223>   Br as s i c a napus ac et ohy dr ox y ac i d s y nt has e C genome l ar ge s ubuni t
                      number 1 ( BnAHASL1C)
              <400>   10
              Met Al a Al a Al a Thr Ser Ser Ser Pr o I l e Ser Leu Thr Al a Ly s Pr o
              1                  5                    10                     15
              Ser Ser Ly s Ser Pr o Leu Pr o I l e Ser Ar g Phe Ser Leu Pr o Phe Ser
                           20                      25                   30
              Leu Thr Pr o Gl n Ly s As p Ser Ser Ar g Leu Hi s Ar g Pr o Leu Al a I l e
                      35                      40                     45
                                                             Page 24

                                               341792Sequenc eLi s t i ng
<removed-date>
              Ser Al a Val Leu As n Ser Pr o Val As n Val Al a Pr o Pr o Ser Pr o Gl u
                  50                    55                     60
              Ly s Thr As p Ly s As n Ly s Thr Phe Val Ser Ar g Ty r Al a Pr o As p Gl u
              65                      70                   75                       80
              Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Gl n Gl y
                                  85                      90                      95
              Val Gl u Thr Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s
<removed-apn>
                           100                    105                    110
              Gl n Al a Leu Thr Ar g Ser Ser Thr I l e Ar g As n Val Leu Pr o Ar g Hi s
                        115                  120                     125
              Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Ser Ser Gl y
                   130                    135                      140
              Ly s Pr o Gl y I l e Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu
              145                       150                     155                     160
              Val Ser Gl y Leu Al a As p Al a Met Leu As p Ser Val Pr o Leu Val Al a
                               165                    170                   175
              I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n
                             180                     185                     190
              Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r
                       195                     200                    205
              Leu Val Met As p Val As p As p I l e Pr o Ar g I l e Val Gl n Gl u Al a Phe
                  210                   215                        220
              Phe Leu Al a Thr Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p Val Pr o
              225                  230                      235                  240
              Ly s As p I l e Gl n Gl n Gl n Leu Al a I l e Pr o As n Tr p As p Gl n Pr o Met
                                   245                      250                      255
              Ar g Leu Pr o Gl y Ty r Met Ser Ar g Leu Pr o Gl n Pr o Pr o Gl u Val Ser
                            260                    265                     270
              Gl n Leu Gl y Gl n I l e Val Ar g Leu I l e Ser Gl u Ser Ly s Ar g Pr o Val
                       275                      280                    285
              Leu Ty r Val Gl y Gl y Gl y Ser Leu As n Ser Ser Gl u Gl u Leu Gl y Ar g
                  290                     295                  300
              Phe Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu
              305                  310                      315                  320
                                                            Page 25

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Gl y Ser Ty r Pr o Cy s As n As p Gl u Leu Ser Leu Gl n Met Leu Gl y Met
                                 325                     330                  335
              Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val Gl u Hi s Ser As p Leu Leu
                            340                     345                    350
              Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u
                       355                   360                    365
              Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Ser Al a
<removed-apn>
                   370                    375                       380
              Gl u I l e Gl y Ly s As n Ly s Thr Pr o Hi s Val Ser Val Cy s Gl y As p Val
              385                       390                    395                    400
              Ly s Leu Al a Leu Gl n Gl y Met As n Ly s Val Leu Gl u As n Ar g Al a Gl u
                                405                     410                    415
              Gl u Leu Ly s Leu As p Phe Gl y Val Tr p Ar g Ser Gl u Leu Ser Gl u Gl n
                            420                   425                    430
              Ly s Gl n Ly s Phe Pr o Leu Ser Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o
                        435                   440                   445
              Pr o Gl n Ty r Al a I l e Gl n I l e Leu As p Gl u Leu Thr Gl u Gl y Ly s Al a
                   450                       455                     460
              I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe
              465                      470                     475                     480
              Ty r Ly s Ty r Ar g Ly s Pr o Ar g Gl n Tr p Leu Ser Ser Ser Gl y Leu Gl y
                                  485                      490                  495
              Al a Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Ser Val Al a As n
                            500                    505                      510
              Pr o As p Al a I l e Val Val As p I l e As p Gl y As p Gl y Ser Phe I l e Met
                        515                     520                       525
              As n Val Gl n Gl u Leu Al a Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s
                   530                    535                     540
              I l e Leu Leu Leu As n As n Gl n Hi s Leu Gl y Met Val Met Gl n Tr p Gl u
              545                    550                     555                   560
              As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As p Pr o
                                 565                      570                    575
              Al a Ar g Gl u As n Gl u I l e Phe Pr o As n Met Leu Gl n Phe Al a Gl y Al a
                             580                      585                   590
                                                           Page 26

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Cy s Gl y I l e Pr o Al a Al a Ar g Val Thr Ly s Ly s Gl u Gl u Leu Ar g Gl u
                        595                       600                      605
              Al a I l e Gl n Thr Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val
                   610                    615                     620
              I l e Cy s Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y
              625                       630                    635                     640
              Thr Phe Ly s As p Val I l e Thr Gl u Gl y As p Gl y Ar g Thr Ly s Ty r
<removed-apn>
                                645                     650                     655
              <210>   11
              <211>   637
              <212>   PRT
              <213>   Br as s i c a napus
              <220>
              <221>   MI SC_FEATURE
              <223>   Br as s i c a napus ac et ohy dr ox y ac i d s y nt has e A genome l ar ge s ubuni t
                      number 2 ( BnAHASL2A)
              <400>   11
              Met Al a Ser Phe Ser Phe Phe Gl y Thr I l e Pr o Ser Ser Pr o Thr Ly s
              1                5                    10                      15
              Al a Ser Val Phe Ser Leu Pr o Val Ser Val Thr Thr Leu Pr o Ser Phe
                           20                   25                  30
              Pr o Ar g Ar g Ar g Al a Thr Ar g Val Ser Val Ser Al a As n Ser Ly s Ly s
                        35                      40                   45
              As p Gl n As p Ar g Thr Al a Ser Ar g Ar g Gl u As n Pr o Ser Thr Phe Ser
                   50                      55                      60
              Ser Ly s Ty r Al a Pr o As n Val Pr o Ar g Ser Gl y Al a As p I l e Leu Val
              65                      70                     75                       80
              Gl u Al a Leu Gl u Ar g Gl n Gl y Val As p Val Val Phe Al a Ty r Pr o Gl y
                                 85                      90                    95
              Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser As n Thr I l e
                            100                      105                   110
              Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y I l e Phe Al a Al a Gl u
                        115                    120                       125
              Gl y Ty r Al a Ar g Ser Ser Gl y Ly s Pr o Gl y I l e Cy s I l e Al a Thr Ser
                   130                    135                       140
              Gl y Pr o Gl y Al a Met As n Leu Val Ser Gl y Leu Al a As p Al a Leu Phe
              145                     150                   155                    160
                                                             Page 27

                                                  341792Sequenc eLi s t i ng
<removed-date>
              As p Ser Val Pr o Leu I l e Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met
                                165                      170                     175
              I l e Gl y Thr Met Al a Phe Gl n Gl u Thr Pr o Val Val Gl u Val Thr Ar g
                             180                    185                   190
              Thr I l e Thr Ly s Hi s As n Ty r Leu Val Met Gl u Val As p As p I l e Pr o
                        195                     200                  205
<removed-apn>
              Ar g I l e Val Ar g Gl u Al a Phe Phe Leu Al a Thr Ser Val Ar g Pr o Gl y
                   210                      215                  220
              Pr o Val Leu I l e As p Val Pr o Ly s As p Val Gl n Gl n Gl n Phe Al a I l e
              225                     230                    235                     240
              Pr o As n Tr p Gl u Gl n Pr o Met Ar g Leu Pr o Leu Ty r Met Ser Thr Met
                                  245                    250                   255
              Pr o Ly s Pr o Pr o Ly s Val Ser Hi s Leu Gl u Gl n I l e Leu Ar g Leu Val
                             260                    265                     270
              Ser Gl u Ser Ly s Ar g Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s Leu As n
                       275                    280                    285
              Ser Ser Gl u Gl u Leu Ar g Ar g Phe Val Gl u Leu Thr Gl y I l e Pr o Val
                  290                    295                   300
              Al a Ser Thr Phe Met Gl y Leu Gl y Ser Ty r Pr o Cy s As p As p Gl u Gl u
              305                  310                    315                      320
              Phe Ser Leu Gl n Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r
                               325                   330                    335
              Al a Val Gl u Ty r Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p
                            340                   345                   350
              As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e
                        355                   360                    365
              Val Hi s I l e As p I l e As p Ser Thr Gl u I l e Gl y Ly s As n Ly s Thr Pr o
                  370                        375                     380
              Hi s Val Ser Val Cy s Cy s As p Val Gl n Leu Al a Leu Gl n Gl y Met As n
              385                   390                    395                    400
              Gl u Val Leu Gl u As n Ar g Ar g As p Val Leu As p Phe Gl y Gl u Tr p Ar g
                                405                     410                    415
              Cy s Gl u Leu As n Gl u Gl n Ar g Leu Ly s Phe Pr o Leu Ar g Ty r Ly s Thr
                            420                     425                    430
                                                           Page 28

                                                     341792Sequenc eLi s t i ng
<removed-date>
              Phe Gl y Gl u Gl u I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Leu Leu As p Gl u
                       435                       440                       445
              Leu Thr As p Gl y Ly s Al a I l e I l e Thr Thr Gl y Val Gl y Gl n Hi s Gl n
                  450                     455                      460
              Met Tr p Al a Al a Gl n Phe Ty r Ar g Phe Ly s Ly s Pr o Ar g Gl n Tr p Leu
              465                     470                    475                      480
<removed-apn>
              Ser Ser Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Met
                                485                    490                    495
              Gl y Al a Al a I l e Al a As n Pr o Gl y Al a Val Val Val As p I l e As p Gl y
                             500                       505                   510
              As p Gl y Ser Phe I l e Met As n I l e Gl n Gl u Leu Al a Thr I l e Ar g Val
                        515                    520                      525
              Gl u As n Leu Pr o Val Ly s Val Leu Leu I l e As n As n Gl n Hi s Leu Gl y
                   530                    535                    540
              Met Val Leu Gl n Tr p Gl u As p Hi s Phe Ty r Al a Al a As n Ar g Al a As p
              545                   550                     555                      560
              Ser Phe Leu Gl y As p Pr o Al a As n Pr o Gl u Al a Val Phe Pr o As p Met
                               565                      570                    575
              Leu Leu Phe Al a Al a Ser Cy s Gl y I l e Pr o Al a Al a Ar g Val Thr Ar g
                          580                     585                       590
              Ar g Gl u As p Leu Ar g Gl u Al a I l e Gl n Thr Met Leu As p Thr Pr o Gl y
                        595                     600                    605
              Pr o Phe Leu Leu As p Val Val Cy s Pr o Hi s Gl n As p Hi s Val Leu Pr o
                   610                  615                     620
              Leu I l e Pr o Ser Gl y Gl y Thr Phe Ly s As p I l e I l e Val
              625                     630                    635
              <210>   12
              <211>   668
              <212>   PRT
              <213>   Camel i na mi c r oc ar pa
              <220>
              <221>   MI SC_FEATURE
              <223>   Camel i na mi c r oc ar pa ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                      number 1 ( CmAHASL1)
              <400>   12
              Met Al a Al a Al a Thr Thr Thr Ser Ser Ser Ser I l e Pr o Phe Ser Thr
              1                  5                   10                     15
                                                      Page 29

                                                 341792Sequenc eLi s t i ng
<removed-date>
              Ly s Hi s Ser Ser Ser Ly s Ser Pr o Leu Pr o I l e Ser Ar g Phe Thr Leu
                            20                    25                      30
              Pr o Phe Ser Leu As n Pr o As n Ly s Ser Ser Ser Ser Ser Ser Ar g Ar g
                       35                     40                   45
              Ar g Gl y I l e Ly s Ser Thr Al a Leu Ser I l e Ser Al a Val Leu As n Thr
                   50                      55                     60
<removed-apn>
              Thr Thr As n Val Ser Thr Thr Thr Pr o Gl n Ser Ly s Pr o Thr Ly s Pr o
              65                   70                    75                     80
              Gl u Ly s Ly s Ly s Phe Val Ser Ar g Phe Al a Pr o As p Gl n Pr o Ar g Ly s
                                  85                   90                       95
              Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Gl n Gl y Val Gl u Thr
                             100                     105                     110
              Al a Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu
                       115                      120                     125
              Thr Ar g Ser Ser Ser I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y
                  130                    135                    140
              Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Ser Thr Gl y Ly s Pr o Gl y
              145                    150                      155                    160
              I l e Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val Ser Gl y
                                    165                    170                   175
              Leu Al a As p Al a Leu Leu As p Ser Val Pr o Leu Val Al a I l e Thr Gl y
                            180                   185                   190
              Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o
                       195                      200                    205
              I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu Val Met
                    210                   215                     220
              As p Val Gl u As p I l e Pr o Ar g I l e Val Gl u Gl u Al a Phe Phe Leu Al a
              225                      230                      235                   240
              Thr Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p Val Pr o Ly s As p I l e
                                245                    250                    255
              Gl n Gl n Gl n Leu Al a I l e Pr o As n Tr p Gl u Gl n Ser Met Ar g Leu Pr o
                             260                      265                    270
              Gl y Ty r Met Ser Ar g Met Pr o Ly s Pr o Pr o Gl u As p Ser Hi s Leu Gl u
                        275                   280                      285
                                                         Page 30

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Gl n I l e Val Ar g Leu I l e Ser Gl u Ser Ly s Ly s Pr o Val Leu Ty r Val
                   290                      295                    300
              Gl y Gl y Gl y Cy s Leu As n Ser Ser Gl u Gl u Leu Gl y Ar g Phe Val Gl u
              305                     310                    315                   320
              Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Al a Ty r
                                 325                   330                   335
<removed-apn>
              Pr o Cy s As p As p Gl u Leu Ser Leu Hi s Met Leu Gl y Met Hi s Gl y Thr
                             340                   345                   350
              Val Ty r Al a As n Ty r Ser Val Gl u Hi s Ser As p Leu Leu Leu Al a Phe
                       355                    360                    365
              Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a
                   370                    375                    380
              Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Ser Al a Gl u I l e Gl y
              385                      390                       395                      400
              Ly s As n Ly s Thr Pr o Hi s Val Ser Val Cy s Gl y As p Val Ly s Leu Al a
                                 405                   410                     415
              Leu Gl n Gl y Met As n Ly s Val Leu Gl u As n Ar g Al a Gl u Gl u Leu Ly s
                            420                   425                      430
              Leu As p Phe Gl y Val Tr p Ar g Ser Gl u Leu As n Gl u Gl n Ly s Gl n Ly s
                       435                    440                    445
              Phe Pr o Leu Ser Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o Pr o Gl n Ty r
                  450                   455                    460
              Al a I l e Gl n Val Leu As p Gl u Leu Thr As p Gl y Ar g Al a I l e I l e Ser
              465                     470                    475                        480
              Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r
                                485                     490                     495
              Ly s Ly s Pr o Ar g Gl n Tr p Leu Ser Ser Al a Gl y Leu Gl y Al a Met Gl y
                             500                    505                    510
              Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Ser Val Al a As n Pr o As p Ser
                       515                      520                    525
              I l e Val Val As p I l e As p Gl y As p Gl y Ser Phe I l e Met As n Val Gl n
                    530                     535                    540
              Gl u Leu Al a Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s I l e Leu I l e
              545                     550                    555                     560
                                                          Page 31

                                                     341792Sequenc eLi s t i ng
<removed-date>
              Leu As n As n Gl n Hi s Leu Gl y Met Val Met Gl n Tr p Gl u As p Ar g Phe
                                 565                   570                     575
              Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o Al a Gl u Gl u
                             580                     585                     590
              As p Gl u I l e Phe Pr o As n Met Leu Gl n Phe Al a Ser Al a Cy s Gl y I l e
                        595                     600                   605
<removed-apn>
              Pr o Al a Al a Ar g Val Thr Ly s I l e Al a Gl u Leu Ar g Gl u Al a I l e Gl n
                   610                    615                      620
              Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Cy s Pr o
              625                   630                     635                     640
              Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y Thr Phe As n
                                  645                    650                    655
              As p Val I l e Thr Gl u Gl y As p Gl y Ar g Thr Ly s Ty r
                             660                     665
              <210>   13
              <211>   665
              <212>   PRT
              <213>   Camel i na mi c r oc ar pa
              <220>
              <221>   MI SC_FEATURE
              <223>   Camel i na mi c r oc ar pa ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                      number 2 ( CmAHASL2)
              <400>   13
              Met Al a Al a Al a Thr Thr Thr Ser Ser Ser Ser I l e Pr o Phe Ser Thr
              1                  5                   10                     15
              Ly s Pr o Ser Ser Ser Ly s Ser Pr o Leu Pr o I l e Ser Ar g Phe Thr Leu
                            20                    25                      30
              Pr o Phe Ser Leu As n Pr o As n Ly s Ser Ser Ser Ar g Ar g Ar g Gl y I l e
                       35                     40                    45
              Ly s Ser Thr Ser Leu Ser I l e Ser Al a Val Leu As n Thr Thr Thr As n
                   50                  55                     60
              Val Ser Thr Thr Thr Pr o Pr o Ser Ly s Pr o Thr Ly s Pr o Gl u Ly s Ly s
              65                  70                      75                      80
              Ly s Phe Val Ser Ar g Phe Al a Pr o As p Gl n Pr o Ar g Ly s Gl y Al a As p
                               85                      90                       95
              I l e Leu Val Gl u Al a Leu Gl u Ar g Gl n Gl y Val Gl u Thr Val Phe Al a
                                                          Page 32

                                                   341792Sequenc eLi s t i ng
<removed-date>
                             100                     105                      110
              Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser
                        115                    120                       125
              Ser Ser I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe
                  130                     135                     140
              Al a Al a Gl u Gl y Ty r Al a Ar g Ser Thr Gl y Ly s Pr o Gl y I l e Cy s I l e
              145                      150                    155                       160
<removed-apn>
              Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val Ser Gl y Leu Al a As p
                                165                     170                  175
              Al a Leu Leu As p Ser Val Pr o Leu Val Al a I l e Thr Gl y Gl n Val Pr o
                           180                   185                     190
              Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u
                        195                     200                    205
              Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu Val Met As p Val Gl u
                  210                    215                     220
              As p I l e Pr o Ar g I l e Val Gl u Gl u Al a Phe Phe Leu Al a Thr Ser Gl y
              225                        230                    235                  240
              Ar g Pr o Gl y Pr o Val Leu Val As p Val Pr o Ly s As p I l e Gl n Gl n Gl n
                                  245                  250                       255
              Leu Al a I l e Pr o As n Tr p Gl u Gl n Ser Met Ar g Leu Pr o Gl y Ty r Met
                             260                      265                   270
              Ser Ar g Met Pr o Ly s Pr o Pr o Gl u As p Ser Hi s Leu Gl u Gl n I l e Val
                       275                     280                    285
              Ar g Leu I l e Ser Gl u Ser Ly s Ly s Pr o Val Leu Ty r Val Gl y Gl y Gl y
                   290                    295                    300
              Cy s Leu As n Ser Ser Gl u Gl u Leu Gl y Ar g Phe Val Gl u Leu Thr Gl y
              305                   310                     315                  320
              I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Al a Ty r Pr o Cy s As p
                                  325                  330                     335
              As p Gl u Leu Ser Leu Hi s Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a
                            340                  345                    350
              As n Ty r Ser Val Gl u Hi s Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g
                        355                   360                   365
              Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a
                                                        Page 33

                                                    341792Sequenc eLi s t i ng
<removed-date>
                   370                      375                    380
              Ly s I l e Val Hi s I l e As p I l e As p Ser Al a Gl u I l e Gl y Ly s As n Ly s
              385                       390                      395                       400
              Thr Pr o Hi s Val Ser Val Cy s Gl y As p Val Ly s Leu Al a Leu Gl n Gl y
                                405                    410                   415
              Met As n Ly s Val Leu Gl u As n Ar g Gl y Gl u Gl u Leu Ly s Leu As p Phe
                            420                    425                     430
<removed-apn>
              Gl y Val Tr p Ar g Ser Gl u Leu As n Gl u Gl n Ly s Gl n Ly s Phe Pr o Leu
                       435                    440                      445
              Ser Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n
                  450                   455                       460
              Val Leu As p Gl u Leu Thr As p Gl y Ly s Al a I l e I l e Ser Thr Gl y Val
              465                   470                     475                      480
              Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r Ly s Ly s Pr o
                                  485                     490                     495
              Ar g Gl n Tr p Leu Ser Ser Al a Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu
                             500                   505                    510
              Pr o Al a Al a I l e Gl y Al a Ser Val Al a As n Pr o As p Al a Val Val Val
                        515                      520                     525
              As p I l e As p Gl y As p Gl y Ser Phe I l e Met As n Val Gl n Gl u Leu Al a
                   530                       535                    540
              Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s I l e Leu I l e Leu As n As n
              545                     550                    555                      560
              Gl n Hi s Leu Gl y Met Val Met Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a
                                 565                   570                     575
              As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o Al a Thr Gl u As p Gl u I l e
                             580                    585                     590
              Phe Pr o As n Met Leu Gl n Phe Al a Ser Al a Cy s Gl y I l e Pr o Ser Al a
                       595                   600                     605
              Ar g Val Thr Ly s Ly s Al a Gl u Leu Ar g Gl u Al a I l e Gl n Ly s Met Leu
                   610                    615                     620
              As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Cy s Pr o Hi s Gl n Gl u
              625                     630                   635                       640
              Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y Thr Phe As n As p Val I l e
                                                         Page 34

                                                     341792Sequenc eLi s t i ng
<removed-date>
                                  645                      650                           655
              Thr Gl u Gl y As p Gl y Ar g Thr Ly s Ty r
                            660                     665
              <210>   14
              <211>   567
              <212>   PRT
              <213>   Sol anum pt y c hant hum
<removed-apn>
              <220>
              <221>   MI SC_FEATURE
              <223>   Par t i al Sol anum pt y c hant hum ac et ohy dr ox y ac i d s y nt has e l ar ge
                      s ubuni t ( SpAHASL)
              <400>   14
              Pr o Ar g Ly s Gl y Cy s As p Val Leu Val Gl u Al a Leu Gl u Ar g Gl u Gl y
              1                   5                     10                      15
              Val Thr As p Val Phe Al a Ty r Pr o Gl y Gl y Thr Ser Met Gl u I l e Hi s
                           20                     25                    30
              Gl n Al a Leu Thr Ar g Ser As n I l e I l e Ar g As n Val Leu Pr o Ar g Hi s
                        35                    40                        45
              Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Al a Thr Gl y
                   50                     55                       60
              Phe Pr o Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu
              65                     70                      75                      80
              Val Ser Gl y Leu Al a As p Al a Leu Leu As p Ser I l e Pr o I l e Val Al a
                               85                     90                        95
              I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n
                             100                     105                     110
              Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r
                       115                     120                    125
              Leu Val Met As p Val Gl u As p I l e Pr o Ar g I l e Val Ar g Gl u Al a Phe
                  130                   135                        140
              Phe Leu Al a Ly s Ser Gl y Ar g Pr o Gl y Pr o Val Leu I l e As p Val Pr o
              145                   150                      155                    160
              Ly s As p I l e Gl n Gl n Gl n Leu Val I l e Pr o As n Tr p As p Gl n Pr o Met
                                   165                     170                      175
              Ar g Leu Pr o Gl y Ty r Met Ser Ar g Leu Pr o Ly s Leu Pr o As n Gl u Met
                            180                    185                    190
                                                              Page 35

                                                 341792Sequenc eLi s t i ng
<removed-date>
              Leu Leu Gl u Gl n I l e Val Ar g Leu I l e Ser Gl u Ser Ly s Ly s Pr o Val
                      195                      200                      205
              Leu Ty r Val Gl y Gl y Gl y Cy s Ser Gl n Ser Ser Gl u Gl u Leu Ar g Ar g
                  210                     215                   220
              Phe Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu
              225                  230                      235                  240
              Gl y Al a Phe Pr o Thr Gl y As p Gl u Leu Ser Leu Gl n Met Leu Gl y Met
<removed-apn>
                                 245                    250                  255
              Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ser Ser As p Leu Leu
                            260                     265                   270
              Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u
                       275                   280                    285
              Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Ser Al a
                   290                    295                       300
              Gl u I l e Gl y Ly s As n Ly s Leu Pr o Hi s Al a Ser I l e Cy s Al a As p I l e
              305                       310                     315                      320
              Ly s Leu Al a Leu Gl n Gl y Leu As n Ser I l e Leu Gl u Gl y Ly s Gl u Gl y
                                325                    330                      335
              Ly s Leu Ly s Leu As p Phe Ser Al a Tr p Ar g Gl n Gl u Leu As n Gl u Gl n
                            340                   345                     350
              Ly s Val Ly s Ty r Pr o Leu As n Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o
                       355                     360                   365
              Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr As n Gl y As n Al a
                   370                       375                   380
              I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe
              385                      390                     395                     400
              Ty r Ly s Ty r Ly s Ly s Pr o Ar g Gl n Tr p Leu Thr Ser Gl y Gl y Leu Gl y
                                  405                      410                   415
              Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Met Gl y Al a Al a Val Gl y Ar g
                            420                    425                     430
              Pr o Gl y Gl u I l e Val Val As p I l e As p Gl y As p Gl y Ser Phe Met Met
                        435                     440                       445
              As n Val Gl n Gl u Leu Al a Thr I l e Ly s Val Gl u As n Leu Pr o Val Ly s
                   450                    455                     460
                                                            Page 36

                                                 341792Sequenc eLi s t i ng
<removed-date>
              I l e Met Leu Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u
              465                    470                     475                   480
              As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As p Pr o
                                 485                      490                    495
              Al a As n Gl u Gl u Gl u I l e Phe Pr o As n Met Leu Ly s Phe Al a Gl u Al a
                             500                      505                   510
              Cy s Gl y Val Pr o Al a Al a Ar g Val Thr Hi s Ar g As p Gl u Leu Ar g Al a
<removed-apn>
                        515                     520                    525
              Al a I l e Gl n Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val
                   530                     535                     540
              I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y
              545                      550                    555                     560
              Al a Phe Ly s As p Val I l e Thr
                                 565
              <210>   15
              <211>   641
              <212>   PRT
              <213>   Sor ghum bi c ol or
              <220>
              <221>   MI SC_FEATURE
              <223>   Sor ghum bi c ol or ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( SbAHASL)
              <400>   15
              Met Al a Thr Thr Al a Al a Al a Al a Al a Al a Al a Leu Al a Gl y Al a Thr
              1                5                        10                      15
              Thr Al a Al a Pr o Ly s Al a Ar g Ar g Ar g Al a Hi s Leu Leu Al a Al a Ar g
                            20                       25                     30
              Ar g Al a Leu Al a Al a Pr o I l e Ar g Cy s Ser Al a Al a Pr o Pr o Al a Thr
                        35                       40                      45
              Leu Thr Val Thr Al a Pr o Pr o Al a Thr Pr o Leu Ar g Pr o Tr p Gl y Pr o
                  50                    55                     60
              Thr As p Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g
              65                      70                       75                     80
              Cy s Gl y Val Ar g As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u
                                 85                     90                      95
              I l e Hi s Gl n Al a Leu Thr Ar g Ser Pr o Val I l e Al a As n Hi s Leu Phe
                              100                   105                      110
                                                             Page 37

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Ar g Hi s Gl u Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Phe Al a Ar g Ser
                        115                      120                      125
              Ser Gl y Ar g Val Gl y Val Cy s Val Al a Thr Ser Gl y Pr o Gl y Al a Thr
                  130                    135                   140
              As n Leu Val Ser Al a Leu Al a As p Al a Leu Leu As p Ser Val Pr o Met
              145                   150                    155                   160
              Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a
<removed-apn>
                                 165                     170                     175
              Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s
                            180                     185                    190
              As n Ty r Leu Val Leu As p Val As p As p I l e Pr o Ar g Val Val Gl n Gl u
                        195                  200                       205
              Al a Phe Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p
                   210                  215                     220
              I l e Pr o Ly s As p I l e Gl n Gl n Gl n Met Al a Val Pr o Val Tr p As p Thr
              225                        230                     235                    240
              Pr o Met Ser Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Al a
                               245                       250                     255
              Thr Gl u Leu Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Ser Ar g Ar g
                           260                   265                    270
              Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s Al a Al a Ser Gl y Gl u Gl u Leu
                       275                    280                     285
              Ar g Ar g Phe Val Gl u Met Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met
                   290                   295                     300
              Gl y Leu Gl y As n Phe Pr o Gl y As p As p Pr o Leu Ser Leu Ar g Met Leu
              305                    310                      315                  320
              Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p
                                 325                    330                     335
              Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s
                          340                    345                    350
              I l e Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p
                         355                    360                      365
              Pr o Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a
                   370                       375                      380
                                                            Page 38

                                                341792Sequenc eLi s t i ng
<removed-date>
              As p Val Ly s Leu Al a Leu Gl n Gl y Met As n Al a Leu Leu Gl u Gl y Ser
              385                    390                    395                    400
              Thr Ser Ly s Ly s Ser Phe As p Phe Gl y Ser Tr p Gl n Al a Gl u Leu As p
                                405                   410                     415
              Gl n Gl n Ly s Ar g Gl u Phe Pr o Leu Gl y Ty r Ly s Thr Phe As p As p Gl u
                             420                    425                    430
              I l e Gl n Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y
<removed-apn>
                         435                       440                    445
              Gl u Al a I l e I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a
                   450                       455                     460
              Gl n Ty r Ty r Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser Ser Al a Gl y
              465                     470                      475                   480
              Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Al a Al a Val
                                485                    490                      495
              Al a As n Pr o Gl y I l e Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe
                             500                    505                       510
              Leu Met As n I l e Gl n Gl u Leu Al a Met I l e Ar g I l e Gl u As n Leu Pr o
                      515                      520                       525
              Val Ly s Val Phe Val Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n
                  530                  535                     540
              Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y
              545                     550                      555                    560
              As n Pr o Gl u As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Thr I l e Al a
                                  565                      570                   575
              Ly s Gl y Phe As n I l e Pr o Al a Val Ar g Val Thr Ly s Ly s Ser Gl u Val
                            580                      585                    590
              Hi s Al a Al a I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o Ty r Leu Leu
                        595                      600                    605
              As p I l e I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser
                   610                       615                    620
              Gl y Gl y Al a Phe Ly s As p Met I l e Leu As p Gl y As p Gl y Ar g Thr Val
              625                     630                     635                     640
              Ty r
                                                           Page 39

                                                    341792Sequenc eLi s t i ng
<removed-date>
              <210>   16
              <211>   657
              <212>   PRT
              <213>   Sol anum t uber os um
              <220>
              <221>   MI SC_FEATURE
              <223>   Pot at o ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number 1
                      ( St AHASL1)
              <400>   16
<removed-apn>
              Met Al a Al a Al a Ser Pr o Ser Pr o Cy s Phe Ser Ly s As n Leu Pr o Pr o
              1                  5                      10                    15
              Ser Ser Ser Ly s Ser Ser I l e Leu Leu Pr o Ly s Ser Thr Phe Thr Phe
                          20                     25                    30
              Hi s As n Hi s Pr o Ly s Ly s Thr Ser Pr o Leu Hi s Leu Thr Hi s Thr Gl n
                        35                      40                    45
              Hi s Hi s Ser Ar g Phe Thr Val Ser As n Val I l e Leu Ser Thr Thr Thr
                   50                    55                     60
              Hi s As n As p Val Ser Gl u Pr o Gl u I l e Phe Val Ser Ar g Phe Al a Pr o
              65                     70                       75                    80
              As p Gl u Pr o Ar g Ly s Gl y Cy s As p Val Leu Val Gl u Al a Leu Gl u Ar g
                                  85                      90                    95
              Gl u Gl y Val Ly s As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u
                            100                    105                      110
              I l e Hi s Gl n Al a Leu Thr Ar g Ser As n I l e I l e Ar g As n Val Leu Pr o
                         115                    120                       125
              Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Al a
                   130                      135                    140
              Thr Gl y Phe Pr o Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr
              145                    150                     155                     160
              As n Leu Val Ser Gl y Leu Al a As p Al a Leu Leu As p Ser I l e Pr o I l e
                               165                     170                    175
              Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a
                             180                    185                      190
              Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s
                       195                     200                   205
              As n Ty r Leu Val Met As p Val Gl u As p I l e Pr o Ar g Val Val Ar g Gl u
                   210                   215                      220
                                                             Page 40

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Al a Phe Phe Leu Al a Ly s Ser Gl y Ar g Pr o Gl y Pr o Val Leu I l e As p
              225                   230                     235                     240
              Val Pr o Ly s As p I l e Gl n Gl n Pr o Leu Val I l e Pr o As n Tr p As p Gl n
                                 245                      250                      255
              Pr o Met Ar g Leu Pr o Gl y Ty r Met Ser Ar g Leu Pr o Ly s Leu Pr o As n
                            260                    265                    270
<removed-apn>
              Gl u Met Leu Leu Gl u Gl n I l e Val Ar g Leu I l e Ser Gl u Ser Ly s Ly s
                       275                     280                    285
              Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s Thr Gl n Ser Ser Gl u Gl u Leu
                   290                   295                     300
              Ar g Ar g Phe Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met
              305                    310                     315                  320
              Gl y Leu Gl y Al a Phe Pr o Val Gl y As p Gl u Leu Ser Leu Gl n Met Leu
                                 325                    330                   335
              Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ser Ser As p
                            340                    345                     350
              Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s
                      355                   360                     365
              Leu Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p
                  370                    375                      380
              Ser Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a
              385                      390                      395                     400
              As p I l e Ly s Leu Al a Leu Gl n Gl y Leu As n Ser I l e Leu Gl u Gl y Ly s
                                  405                    410                     415
              Gl u Gl y Ly s Leu Ly s Leu As p Phe Ser Al a Tr p Ar g Gl n Gl u Leu Thr
                             420                   425                     430
              Gl u Gl n Ly s Val Ly s Ty r Pr o Leu As n Ty r Ly s Thr Phe Gl y Gl u Al a
                        435                     440                    445
              I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr As n Gl y
                    450                      455                     460
              As n Al a I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a
              465                       470                    475                     480
              Gl n Ty r Ty r Ly s Ty r Ly s Ly s Pr o Ar g Gl n Tr p Leu Thr Ser Gl y Gl y
                                  485                      490                   495
                                                           Page 41

                                                    341792Sequenc eLi s t i ng
<removed-date>
              Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Al a Val
                            500                   505                       510
              Gl y Ar g Pr o Gl y Gl u I l e Val Val As p I l e As p Gl y As p Gl y Ser Phe
                        515                      520                      525
              I l e Met As n Val Gl n Gl u Leu Al a Thr I l e Ly s Val Gl u As n Leu Pr o
                    530                    535                     540
<removed-apn>
              Val Ly s I l e Met Leu Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n
              545                    550                     555                  560
              Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y
                                  565                     570                     575
              As p Pr o Al a As n Gl u Gl u Gl u I l e Phe Pr o As n Met Leu Ly s Phe Al a
                             580                       585                   590
              Gl u Al a Cy s Gl y Val Pr o Al a Al a Ar g Val Ser Hi s Ar g As p As p Leu
                        595                     600                    605
              Ar g Al a Al a I l e Gl n Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu
                   610                       615                   620
              As p Val I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser
              625                     630                     635                     640
              Gl y Gl y Al a Phe Ly s As p Val I l e Thr Gl u Gl y As p Gl y Ar g Ar g Ser
                                 645                     650                      655
              Ty r
              <210>   17
              <211>   659
              <212>   PRT
              <213>   Sol anum t uber os um
              <220>
              <221>   MI SC_FEATURE
              <223>   Pot at o ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t number 2
                      ( St AHASL2)
              <220>
              <221>   mi s c _f eat ur e
              <222>   ( 406) . . ( 406)
              <223>   Xaa c an be any nat ur al l y oc c ur r i ng ami no ac i d
              <400>   17
              Met Al a Al a Al a Al a Ser Pr o Ser Pr o Cy s Phe Ser Ly s Thr Leu Pr o
              1                  5                      10                    15
              Pr o Ser Ser Ser Ly s Ser Ser Thr I l e Leu Pr o Ar g Ser Thr Phe Pr o
                                                       Page 42

                                                   341792Sequenc eLi s t i ng
<removed-date>
                             20                      25                       30
              Phe Hi s As n Hi s Pr o Gl n Ly s Al a Ser Pr o Leu Hi s Leu Thr Hi s Thr
                       35                       40                     45
              Hi s Hi s Hi s Ar g Ar g Gl y Phe Al a Val Ser As n Val Val I l e Ser Thr
                   50                       55                    60
              Thr Thr Hi s As n As p Val Ser Gl u Pr o Gl u Thr Phe Val Ser Ar g Phe
              65                     70                     75                   80
<removed-apn>
              Al a Pr o As p Gl u Pr o Ar g Ly s Gl y Cy s As p Val Leu Val Gl u Al a Leu
                                  85                       90                    95
              Gl u Ar g Gl u Gl y Val Thr As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser
                             100                   105                     110
              Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser As n I l e I l e Ar g As n Val
                       115                      120                     125
              Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a
                  130                      135                    140
              Ar g Al a Thr Gl y Phe Pr o Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y
              145                    150                      155                    160
              Al a Thr As n Leu Val Ser Gl y Leu Al a As p Al a Leu Leu As p Ser I l e
                                165                   170                    175
              Pr o I l e Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr
                             180                      185                    190
              As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr
                        195                    200                    205
              Ly s Hi s As n Ty r Leu Val Met As p Val Gl u As p I l e Pr o Ar g Val Val
                   210                    215                    220
              Ar g Gl u Al a Phe Phe Leu Al a Ly s Ser Gl y Ar g Pr o Gl y Pr o Val Leu
              225                    230                    235                     240
              I l e As p Val Pr o Ly s As p I l e Gl n Gl n Gl n Leu Val I l e Pr o As n Tr p
                                  245                       250                     255
              As p Gl n Pr o Met Ar g Leu Pr o Gl y Ty r Met Ser Ar g Leu Pr o Ly s Leu
                             260                    265                   270
              Pr o As n Gl u Met Leu Leu Gl u Gl n I l e I l e Ar g Leu I l e Ser Gl u Ser
                        275                   280                       285
              Ly s Ly s Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s Leu Gl n Ser Ser Gl u
                                                         Page 43

                                                   341792Sequenc eLi s t i ng
<removed-date>
                   290                      295                   300
              Gl u Leu Ar g Ar g Phe Val Gl u Leu Thr Gl y I l e Ser Val Al a Ser Thr
              305                    310                   315                    320
              Leu Met Gl y Leu Gl y Al a Phe Pr o Thr Gl y As p Gl u Leu Ser Leu Gl n
                               325                    330                    335
              Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Gl y
                           340                   345                      350
<removed-apn>
              Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr
                       355                  360                    365
              Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p
                   370                    375                     380
              I l e As p Ser Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e
              385                      390                       395                    400
              Cy s Al a As p I l e Ly s Xaa Al a Leu Gl n Gl y Leu As n Ser I l e Leu Gl u
                                   405                    410                     415
              Gl y Ly s Gl u Gl y Ly s Leu Ly s Leu As p Phe Ser Al a Tr p Ar g Gl n Gl u
                             420                    425                    430
              Leu Thr Gl u Gl n Ly s Val Ly s Ty r Pr o Leu Ser Phe Ly s Thr Phe Gl y
                      435                     440                   445
              Gl u Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr
                   450                       455                      460
              As n Gl y As n Al a I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p
              465                       470                    475                     480
              Al a Al a Gl n Ty r Ty r Ly s Ty r Ly s Ly s Pr o Ar g Gl n Tr p Leu Thr Ser
                                  485                      490                     495
              Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a
                            500                    505                     510
              Al a Val Gl y Ar g Pr o Gl y Gl u I l e Val Val As p I l e As p Gl y As p Gl y
                       515                      520                      525
              Ser Phe I l e Met As n Val Gl n Gl u Leu Al a Thr I l e Ly s Val Gl u As n
                  530                    535                    540
              Leu Pr o Val Ly s I l e Met Leu Leu As n As n Gl n Hi s Leu Gl y Met Val
              545                     550                   555                    560
              Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r
                                                          Page 44

                                                    341792Sequenc eLi s t i ng
<removed-date>
                                  565                     570                         575
              Leu Gl y As p Pr o Al a As n Gl u Gl u Gl u I l e Phe Pr o As n Met Leu Ly s
                            580                      585                      590
              Phe Al a Gl u Al a Cy s Gl y Val Pr o Al a Al a Ar g Val Ser Hi s Ar g As p
                       595                     600                     605
              As p Leu Ar g Al a Al a I l e Gl n Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r
                   610                      615                    620
<removed-apn>
              Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e
              625                    630                     635                   640
              Pr o Ser Gl y Gl y Al a Phe Ly s As p Val I l e Thr Gl u Gl y As p Gl y Ar g
                                 645                    650                      655
              Ar g Ser Ty r
              <210>   18
              <211>   651
              <212>   PRT
              <213>   Gl y c i ne max
              <220>
              <221>   MI SC_FEATURE
              <223>   Soy bean ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( GmAHASL)
              <400>   18
              Met Al a Al a Thr Al a Ser Ar g Thr Thr Ar g Phe Ser Ser Ser Ser Ser
              1                 5                     10                   15
              Hi s Pr o Thr Phe Pr o Ly s Ar g I l e Thr Ar g Ser Thr Leu Pr o Leu Ser
                            20                       25                   30
              Hi s Gl n Thr Leu Thr Ly s Pr o As n Hi s Al a Leu Ly s I l e Ly s Cy s Ser
                        35                    40                      45
              I l e Ser Ly s Pr o Pr o Thr Al a Al a Pr o Phe Thr Ly s Gl u Al a Pr o Thr
                    50                     55                     60
              Thr Gl u Pr o Phe Val Ser Ar g Phe Al a Ser Gl y Gl u Pr o Ar g Ly s Gl y
              65                    70                    75                       80
              Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Gl n Gl y Val Thr Thr Val
                                  85                     90                     95
              Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu Thr
                            100                     105                      110
              Ar g Ser Al a Al a I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y
                                                          Page 45

                                                    341792Sequenc eLi s t i ng
<removed-date>
                        115                       120                      125
              Val Phe Al a Al a Gl u Gl y Ty r Al a Ar g Ser Ser Gl y Leu Pr o Gl y Val
                  130                     135                    140
              Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val Ser Gl y Leu
              145                     150                     155                   160
              Al a As p Al a Leu Met As p Ser Val Pr o Val Val Al a I l e Thr Gl y Gl n
                                 165                   170                    175
<removed-apn>
              Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o I l e
                            180                     185                     190
              Val Gl u Val Ser Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu I l e Leu As p
                       195                    200                     205
              Val As p As p I l e Pr o Ar g Val Val Al a Gl u Al a Phe Phe Val Al a Thr
                  210                       215                    220
              Ser Gl y Ar g Pr o Gl y Pr o Val Leu I l e As p I l e Pr o Ly s As p Val Gl n
              225                     230                     235                      240
              Gl n Gl n Leu Al a Val Pr o As n Tr p As p Gl u Pr o Val As n Leu Pr o Gl y
                                 245                     250                    255
              Ty r Leu Al a Ar g Leu Pr o Ar g Pr o Pr o Al a Gl u Al a Gl n Leu Gl u Hi s
                            260                     265                      270
              I l e Val Ar g Leu I l e Met Gl u Al a Gl n Ly s Pr o Val Leu Ty r Val Gl y
                        275                     280                     285
              Gl y Gl y Ser Leu As n Ser Ser Al a Gl u Leu Ar g Ar g Phe Val Gl u Leu
                   290                   295                    300
              Thr Gl y I l e Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Thr Phe Pr o
              305                     310                  315                   320
              I l e Gl y As p Gl u Ty r Ser Leu Gl n Met Leu Gl y Met Hi s Gl y Thr Val
                                   325                   330                    335
              Ty r Al a As n Ty r Al a Val As p As n Ser As p Leu Leu Leu Al a Phe Gl y
                             340                     345                  350
              Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a Ser
                       355                    360                    365
              Ar g Al a Ly s I l e Val Hi s I l e As p I l e As p Ser Al a Gl u I l e Gl y Ly s
                   370                      375                       380
              As n Ly s Gl n Al a Hi s Val Ser Val Cy s Al a As p Leu Ly s Leu Al a Leu
                                                         Page 46

                                                  341792Sequenc eLi s t i ng
<removed-date>
              385                     390                   395                         400
              Ly s Gl y I l e As n Met I l e Leu Gl u Gl u Ly s Gl y Val Gl u Gl y Ly s Phe
                                   405                     410                     415
              As p Leu Gl y Gl y Tr p Ar g Gl u Gl u I l e As n Val Gl n Ly s Hi s Ly s Phe
                            420                      425                      430
              Pr o Leu Gl y Ty r Ly s Thr Phe Gl n As p Al a I l e Ser Pr o Gl n Hi s Al a
                       435                    440                      445
<removed-apn>
              I l e Gl u Val Leu As p Gl u Leu Thr As n Gl y As p Al a I l e Val Ser Thr
                    450                    455                    460
              Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r Ly s
              465                     470                     475                     480
              Ar g Pr o Ar g Gl n Tr p Leu Thr Ser Gl y Gl y Leu Gl y Al a Met Gl y Phe
                                  485                   490                    495
              Gl y Leu Pr o Al a Al a I l e Gl y Al a Al a Val Al a As n Pr o Gl y Al a Val
                            500                       505                     510
              Val Val As p I l e As p Gl y As p Gl y Ser Phe I l e Met As n Val Gl n Gl u
                      515                       520                    525
              Leu Al a Thr I l e Ar g Val Gl u As n Leu Pr o Val Ly s I l e Leu Leu Leu
                  530                     535                    540
              As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u As p Ar g Phe Ty r
              545                     550                   555                     560
              Ly s Ser As n Ar g Al a Hi s Thr Ty r Leu Gl y As p Pr o Ser Ser Gl u Ser
                                 565                    570                    575
              Gl u I l e Phe Pr o As n Met Leu Ly s Phe Al a As p Al a Cy s Gl y I l e Pr o
                             580                    585                     590
              Al a Al a Ar g Val Thr Ly s Ly s Gl u Gl u Leu Ar g Al a Al a I l e Gl n Ar g
                        595                    600                     605
              Met Leu As p Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Val Pr o Hi s
                  610                    615                    620
              Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser As n Gl y Ser Phe Ly s As p
              625                    630                     635                    640
              Val I l e Thr Gl u Gl y As p Gl y Ar g Thr Ar g Ty r
                                 645                     650
              <210>   19
                                                           Page 47

                                                    341792Sequenc eLi s t i ng
<removed-date>
              <211>   648
              <212>   PRT
              <213>   Xant hi um s p.
              <220>
              <221>   MI SC_FEATURE
              <223>   Coc k l ebur ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( Xs AHASL)
              <400>   19
              Met Al a Al a I l e Pr o Hi s Thr As n Pr o Ser I l e Thr Thr Ly s Pr o Pr o
              1                   5                       10                     15
<removed-apn>
              Ser Ser Pr o Pr o Ar g Pr o Thr Phe Leu Al a Ar g Phe Thr Phe Pr o I l e
                           20                     25                    30
              Thr Ser Thr Ser Hi s Ly s Ar g Hi s Ar g Leu Hi s I l e Ser As n Val Leu
                      35                     40                       45
              Ser As p Ser Ly s Pr o Thr I l e Thr Hi s Ser Pr o Leu Pr o Thr Gl u Ser
                  50                     55                      60
              Phe I l e Ser Ar g Ty r Al a Pr o As p Gl n Pr o Ar g Ly s Gl y Al a As p Val
              65                      70                       75                       80
              Leu Val Gl u Al a Leu Gl u Ar g Gl u Gl y Val Thr As p Val Phe Al a Ty r
                                85                      90                   95
              Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser Thr
                             100                     105                    110
              Thr I l e Ar g As n Val Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a
                        115                    120                      125
              Al a Gl u Gl y Ty r Al a Ar g Al a Ser Gl y Leu Pr o Gl y Val Cy s I l e Al a
                   130                      135                    140
              Thr Ser Gl y Pr o Gl y Al a Thr As n Leu Val Ser Gl y Leu Al a As p Al a
              145                    150                   155                    160
              Leu Leu As p Ser Val Pr o Met Val Al a I l e Thr Gl y Gl n Val Pr o Ar g
                               165                   170                     175
              Ar g Met I l e Gl y Thr As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val
                             180                    185                      190
              Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r Leu Val Leu As p Val Gl u As p
                       195                     200                   205
              I l e Pr o Ar g I l e Val Ar g Gl u Al a Phe Ty r Leu Al a Ser Ser Gl y Ar g
                    210                      215                    220
              Pr o Gl y Pr o Val Leu I l e As p Val Pr o Ly s As p I l e Gl n Gl n Gl n Leu
                                                          Page 48

                                                    341792Sequenc eLi s t i ng
<removed-date>
              225                      230                    235                          240
              Val Val Pr o Ly s Tr p As p Gl u Pr o I l e Ar g Leu Pr o Gl y Ty r Leu Ser
                                245                       250                     255
              Ar g Leu Pr o Ly s Thr Gl u As n As n Gl y Gl n Leu Gl u Hi s I l e Val Ar g
                            260                     265                     270
              Leu Val Ser Gl u Al a Ly s Ar g Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s
                      275                     280                   285
<removed-apn>
              Leu As n Ser Gl y As p Gl u Leu Ar g Ar g Phe Val Gl u Leu Thr Gl y I l e
                  290                     295                   300
              Pr o Val Al a Ser Thr Leu Met Gl y Leu Gl y Al a Ty r Pr o Al a Ser Ser
              305                   310                   315                     320
              As p Leu Ser Leu Hi s Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n
                               325                   330                    335
              Ty r Al a Val As p Ly s Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe
                            340                    345                   350
              As p As p Ar g Val Thr Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a Ly s
                        355                    360                    365
              I l e Val Hi s I l e As p I l e As p Ser Al a Gl u I l e Gl y Ly s As n Ly s Gl n
                    370                       375                      380
              Pr o Hi s Val Ser I l e Cy s Gl y As p I l e Ly s Val Al a Leu Gl n Gl y Leu
              385                     390                       395                    400
              As n Ly s I l e Leu Gl u Val Ly s As n Ser Val Thr As n Leu As p Phe Ser
                                  405                    410                   415
              As n Tr p Ar g Ly s Gl u Leu As p Gl u Gl n Ly s Val Ly s Ty r Pr o Leu Ser
                             420                     425                     430
              Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val
                       435                    440                       445
              Leu As p Gl u Leu Thr Gl y Gl y As n Al a I l e I l e Ser Thr Gl y Val Gl y
                  450                    455                        460
              Gl n Hi s Gl n Met Tr p Al a Al a Gl n Phe Ty r Ly s Ty r As n Ly s Pr o Ar g
              465                     470                     475                      480
              Gl n Tr p Leu Thr Ser Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o
                                485                    490                    495
              Al a Al a I l e Gl y Al a Al a Val Al a Ar g Pr o As p Al a Val Val Val As p
                                                            Page 49

                                                    341792Sequenc eLi s t i ng
<removed-date>
                             500                      505                      510
              I l e As p Gl y As p Gl y Ser Phe I l e Met Ser Val Gl n Gl u Leu Al a Thr
                         515                    520                    525
              I l e Ar g Val Gl u As n Leu Pr o Val Ly s I l e Leu Leu Leu As n As n Gl n
                    530                    535                     540
              Hi s Leu Gl y Met Val Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n
              545                   550                     555                     560
<removed-apn>
              Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o Ser Ly s Gl u Ser Gl u I l e Phe
                                 565                     570                    575
              Pr o As n Met Leu Ly s Phe Al a Gl u Al a Cy s As p I l e Pr o Al a Al a Ar g
                            580                    585                       590
              Val Thr Ar g Ly s Al a As p Leu Ar g Al a Al a I l e Gl n Ly s Met Leu As p
                      595                     600                       605
              Thr Pr o Gl y Pr o Ty r Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u Hi s
                  610                     615                    620
              Val Leu Pr o Met I l e Pr o Al a Gl y Gl y Gl y Phe Met As p Val I l e Thr
              625                    630                      635                    640
              Gl u Gl y As p Gl y Ar g Met Ly s Ty r
                                  645
              <210>   20
              <211>   640
              <212>   PRT
              <213>   Lol i um mul t i f l or um
              <220>
              <221>   MI SC_FEATURE
              <223>   Ry egr as s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( LmAHASL)
              <400>   20
              Met Al a Thr Al a Thr Ser Thr Al a Val Al a Phe Ser Gl y Al a Thr Al a
              1                 5                    10                     15
              Thr Leu Pr o Ly s Pr o Ar g Thr Leu Pr o Ar g Hi s Leu Leu Pr o Ser Ser
                           20                     25                     30
              Ar g Ar g Al a Leu Al a Al a Pr o I l e Ar g Cy s Ser Al a Val Ser Pr o Ser
                        35                      40                       45
              Pr o Ser Pr o Al a Pr o Pr o Al a Thr Al a Leu Ar g Pr o Tr p Gl y Pr o Ser
                   50                      55                     60
              Gl u Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Cy s
                                                            Page 50

                                                  341792Sequenc eLi s t i ng
<removed-date>
              65                      70                    75                         80
              Gl y I l e Ser As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e
                                  85                     90                     95
              Hi s Gl n Al a Leu Thr Ser Ser Pr o Leu I l e Thr As n Hi s Leu Phe Ar g
                             100                  105                     110
              Hi s Gl u Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Ty r Al a Ar g Al a Ser
                        115                     120                     125
<removed-apn>
              Gl y Ar g Val Gl y Val Cy s Val Al a Thr Ser Gl y Pr o Gl y Al a Thr As n
                   130                    135                   140
              Leu Val Ser Al a Leu Al a As p Al a Leu Leu As p Ser I l e Pr o Met Val
              145                  150                    155                     160
              Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe
                                  165                     170                     175
              Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n
                            180                     185                    190
              Ty r Leu Val Leu As p Val Gl u As p I l e Pr o Ar g Val I l e Gl n Gl u Al a
                       195                   200                      205
              Phe Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e
                  210                  215                      220
              Pr o Ly s As p I l e Gl n Gl n Gl n Met Al a Val Pr o Val Tr p As p Al a Pr o
              225                       230                    235                     240
              Met Ser Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Al a Thr
                               245                       250                     255
              Gl u Leu Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Gl u Ar g Ar g Pr o
                           260                    265                    270
              I l e Leu Ty r Val Gl y Gl y Gl y Cy s Ser Al a Ser Gl y Gl u As p Val Ar g
                        275                     280                    285
              Ar g Phe Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met Gl y
                   290                  295                     300
              Leu Gl y As n Phe Pr o Ser As p As p Pr o Leu Ser Leu Ar g Met Leu Gl y
              305                    310                    315                  320
              Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p Leu
                                325                     330                     335
              Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s I l e
                                                       Page 51

                                                   341792Sequenc eLi s t i ng
<removed-date>
                             340                     345                      350
              Gl u Al a Phe Al a Ser Ar g Ser Ly s I l e Val Hi s I l e As p I l e As p Pr o
                        355                   360                       365
              Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a As p
                   370                       375                     380
              Val Ly s Leu Al a Leu Gl n Gl y Leu As n Al a Val Leu Thr Gl y Ser Ly s
              385                   390                     395                  400
<removed-apn>
              Cy s As p Ly s Ser Phe As p Phe Al a Ser Tr p Hi s As p Gl u Leu Gl u Gl n
                                 405                   410                     415
              Gl n Ly s Ar g Gl u Phe Pr o Leu Gl y Ty r Ly s Thr Phe Gl y Gl u Al a I l e
                             420                    425                    430
              Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y Gl u
                        435                       440                   445
              Al a I l e I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n
                   450                       455                     460
              Ty r Ty r Thr Ty r Ly s Ar g Pr o Ar g Gl n Val Leu Ser Ser Al a Gl y Leu
              465                     470                     475                   480
              Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Thr Al a Val Al a
                                 485                    490                     495
              As n Pr o Gl y Val Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe Leu
                             500                  505                       510
              Met As n I l e Gl n Gl u Leu Al a Leu I l e Ar g I l e Gl u As n Leu Pr o Val
                       515                      520                       525
              Ly s Val Met I l e Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p
                   530                    535                     540
              Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n
              545                     550                      555                    560
              Pr o Gl u As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Thr I l e Al a Ly s
                                  565                      570                    575
              Gl y Phe As n Val Pr o Al a Val Ar g Val Thr Ly s Ar g Ser Gl u Val Ar g
                            580                    585                   590
              Al a Al a I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o Ty r Leu Leu As p
                        595                     600                     605
              I l e I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y
                                                            Page 52

                                                        341792Sequenc eLi s t i ng
<removed-date>
                   610                            615                  620
              Gl y Al a Phe Ly s As p I l e I l e Met Gl u Gl y As p Gl y Ar g I l e Ser Ty r
              625                     630                       635                      640
              <210>      21
              <211>      607
              <212>      PRT
              <213>      Tr i t i c um aes t i v um
<removed-apn>
              <220>
              <221>      MI SC_FEATURE
              <223>      Wheat A genome ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                         ( TaAHASL1A) , par t i al
              <400>      21
              Leu Pr o Al a Ar g Val Val Ar g Cy s Cy s Al a Al a Ser Pr o Al a Al a Thr
              1                  5                      10                      15
              Ser Al a Al a Pr o Pr o Al a Thr Al a Leu Ar g Pr o Tr p Gl y Pr o Ser Gl u
                            20                      25                      30
              Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Cy s Gl y
                        35                        40                    45
              I l e Val As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s
                    50                    55                       60
              Gl n Al a Leu Thr Ar g Ser Pr o Val I l e Thr As n Hi s Leu Phe Ar g Hi s
              65                     70                     75                     80
              Gl u Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Ty r Al a Ar g Al a Ser Gl y
                                  85                     90                       95
              Ar g Val Gl y Val Cy s Val Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu
                            100                   105                     110
              Val Ser Al a Leu Al a As p Al a Leu Leu As p Ser I l e Pr o Met Val Al a
                      115                     120                    125
              I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n
                    130                    135                      140
              Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r
              145                     150                   155                      160
              Leu Val Leu As p Val Gl u As p I l e Pr o Ar g Val I l e Gl n Gl u Al a Phe
                               165                      170                      175
              Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e Pr o
                           180                    185                   190
                                                                Page 53

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Ly s As p I l e Gl n Gl n Gl n Met Al a Val Pr o I l e Tr p As p Thr Pr o Met
                        195                      200                      205
              Ser Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Ser Thr Gl u
                  210                      215                     220
              Ser Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Ser Ar g Ar g Pr o I l e
              225                   230                   235                     240
              Leu Ty r Val Gl y Gl y Gl y Cy s Al a Al a Ser Gl y Gl u Gl u Leu Ar g Ar g
<removed-apn>
                                245                      250                    255
              Phe Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met Gl y Leu
                           260                     265                 270
              Gl y As n Phe Pr o Ser As p As p Pr o Leu Ser Leu Ar g Met Leu Gl y Met
                        275                    280                   285
              Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p Leu Leu
                   290                    295                     300
              Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s I l e Gl u
              305                   310                     315                     320
              Al a Phe Al a Ser Ar g Ser Ly s I l e Val Hi s I l e As p I l e As p Pr o Al a
                                325                     330                        335
              Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a As p Val
                              340                      345                     350
              Ly s Leu Al a Leu Gl n Gl y Leu As n Al a Leu Leu As n Gl y Ser Ly s Al a
                       355                    360                    365
              Gl n Gl n Gl y Leu As p Phe Gl y Pr o Tr p Hi s Ly s Gl u Leu As p Gl n Gl n
                   370                    375                      380
              Ly s Ar g Gl u Phe Pr o Leu Gl y Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o
              385                     390                   395                      400
              Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y Gl u Al a
                                  405                     410                    415
              I l e I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Ty r
                               420                    425                     430
              Ty r Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser Ser Ser Gl y Leu Gl y
                       435                      440                   445
              Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Al a Al a Val Al a As n
                   450                   455                      460
                                                           Page 54

                                                341792Sequenc eLi s t i ng
<removed-date>
              Pr o Gl y Val Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe Leu Met
              465                   470                      475                   480
              As n I l e Gl n Gl u Leu Al a Leu I l e Ar g I l e Gl u As n Leu Pr o Val Ly s
                                   485                     490                      495
              Val Met I l e Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u
                            500                     505                  510
              As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o
<removed-apn>
                        515                     520                     525
              Gl u As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Thr I l e Al a Ly s Gl y
                   530                      535                    540
              Phe As n Val Pr o Al a Val Ar g Val Thr Ly s Ly s Ser Gl u Val Thr Al a
              545                    550                   555                   560
              Al a I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o Ty r Leu Leu As p I l e
                                   565                   570                    575
              I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y
                             580                     585                     590
              Al a Phe Ly s As p Met I l e Met Gl u Gl y As p Gl y Ar g Thr Ser Ty r
                       595                     600                      605
              <210>   22
              <211>   607
              <212>   PRT
              <213>   Tr i t i c um aes t i v um
              <220>
              <221>   MI SC_FEATURE
              <223>   Wheat B genome ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                      ( TaAHASL1B) , par t i al
              <400>   22
              Leu Pr o Al a Ar g I l e Val Ar g Cy s Cy s Al a Al a Ser Pr o Al a Al a Thr
              1                  5                        10                      15
              Ser Al a Al a Pr o Pr o Al a Thr Al a Leu Ar g Pr o Tr p Gl y Pr o Ser Gl u
                            20                      25                      30
              Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Cy s Gl y
                        35                        40                    45
              I l e Val As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s
                    50                    55                       60
              Gl n Al a Leu Thr Ar g Ser Pr o Val I l e Thr As n Hi s Leu Phe Ar g Hi s
              65                     70                     75                     80
                                                            Page 55

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Gl u Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Ty r Al a Ar g Al a Ser Gl y
                                  85                     90                       95
              Ar g Val Gl y Val Cy s Val Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu
                            100                   105                     110
              Val Ser Al a Leu Al a As p Al a Leu Leu As p Ser I l e Pr o Met Val Al a
                      115                     120                    125
<removed-apn>
              I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n
                    130                    135                      140
              Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r
              145                     150                   155                      160
              Leu Val Leu As p Val Gl u As p I l e Pr o Ar g Val I l e Gl n Gl u Al a Phe
                               165                      170                      175
              Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e Pr o
                           180                    185                   190
              Ly s As p I l e Gl n Gl n Gl n Met Al a Val Pr o Val Tr p As p Thr Pr o Met
                        195                      200                    205
              Ser Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Ser Thr Gl u
                  210                      215                     220
              Ser Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Ser Ar g Ar g Pr o I l e
              225                   230                   235                     240
              Leu Ty r Val Gl y Gl y Gl y Cy s Al a Al a Ser Gl y Gl u Gl u Leu Ar g Ar g
                                245                      250                    255
              Phe Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met Gl y Leu
                           260                     265                 270
              Gl y As n Phe Pr o Ser As p As p Pr o Leu Ser Leu Ar g Met Leu Gl y Met
                        275                    280                   285
              Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p Leu Leu
                   290                    295                     300
              Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s I l e Gl u
              305                   310                     315                     320
              Al a Phe Al a Ser Ar g Ser Ly s I l e Val Hi s I l e As p I l e As p Pr o Al a
                                325                     330                        335
              Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a As p Val
                              340                      345                     350
                                                           Page 56

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Ly s Leu Al a Leu Gl n Gl y Leu As n Al a Leu Leu As n Gl y Ser Ly s Al a
                       355                    360                    365
              Gl n Gl n Gl y Leu As p Phe Gl y Pr o Tr p Hi s Ly s Gl u Leu As p Gl n Gl n
                   370                    375                      380
              Ly s Ar g Gl u Phe Pr o Leu Gl y Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o
              385                     390                   395                      400
<removed-apn>
              Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y Gl u Al a
                                  405                     410                    415
              I l e I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Ty r
                               420                    425                     430
              Ty r Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser Ser Ser Gl y Leu Gl y
                       435                      440                   445
              Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Al a Al a Val Al a As n
                   450                   455                      460
              Pr o Gl y Val Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe Leu Met
              465                   470                      475                   480
              As n I l e Gl n Gl u Leu Al a Leu I l e Ar g I l e Gl u As n Leu Pr o Val Ly s
                                   485                     490                      495
              Val Met I l e Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u
                            500                     505                  510
              As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o
                        515                     520                     525
              Gl u As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Thr I l e Al a Ly s Gl y
                   530                      535                    540
              Phe As n Val Pr o Al a Val Ar g Val Thr Ly s Ly s Ser Gl u Val Thr Al a
              545                    550                   555                   560
              Al a I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o Ty r Leu Leu As p I l e
                                   565                   570                    575
              I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y
                             580                     585                     590
              Al a Phe Ly s As p Met I l e Met Gl u Gl y As p Gl y Ar g Thr Ser Ty r
                       595                     600                      605
              <210>   23
              <211>   607
              <212>   PRT
                                                           Page 57

                                                   341792Sequenc eLi s t i ng
<removed-date>
              <213>   Tr i t i c um aes t i v um
              <220>
              <221>   MI SC_FEATURE
              <223>   Wheat D genome ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t
                      ( TaAHASL1D) , par t i al
              <400>   23
              Leu Pr o Al a Ar g I l e Val Ar g Cy s Cy s Al a Al a Ser Pr o Al a Al a Thr
              1                  5                        10                      15
<removed-apn>
              Ser Al a Al a Pr o Pr o Al a Thr Al a Leu Ar g Pr o Tr p Gl y Pr o Ser Gl u
                            20                      25                      30
              Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu Gl u Ar g Cy s Gl y
                        35                        40                    45
              I l e Val As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser Met Gl u I l e Hi s
                    50                    55                       60
              Gl n Al a Leu Thr Ar g Ser Pr o Val I l e Thr As n Hi s Leu Phe Ar g Hi s
              65                     70                     75                     80
              Gl u Gl n Gl y Gl u Al a Phe Al a Al a Ser Gl y Ty r Al a Ar g Al a Ser Gl y
                                  85                     90                       95
              Ar g Val Gl y Val Cy s Val Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu
                            100                   105                     110
              Val Ser Al a Leu Al a As p Al a Leu Leu As p Ser I l e Pr o Met Val Al a
                      115                     120                    125
              I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr As p Al a Phe Gl n
                    130                    135                      140
              Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr Ly s Hi s As n Ty r
              145                     150                   155                      160
              Leu Val Leu As p Val Gl u As p I l e Pr o Ar g Val I l e Gl n Gl u Al a Phe
                               165                      170                      175
              Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e Pr o
                           180                    185                   190
              Ly s As p I l e Gl n Gl n Gl n Met Al a Val Pr o Val Tr p As p Thr Pr o Met
                        195                      200                    205
              Ser Leu Pr o Gl y Ty r I l e Al a Ar g Leu Pr o Ly s Pr o Pr o Ser Thr Gl u
                  210                      215                     220
              Ser Leu Gl u Gl n Val Leu Ar g Leu Val Gl y Gl u Ser Ar g Ar g Pr o I l e
              225                   230                   235                     240
                                                      Page 58

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Leu Ty r Val Gl y Gl y Gl y Cy s Al a Al a Ser Gl y Gl u Gl u Leu Ar g Ar g
                                245                      250                    255
              Phe Val Gl u Leu Thr Gl y I l e Pr o Val Thr Thr Thr Leu Met Gl y Leu
                           260                     265                 270
              Gl y As n Phe Pr o Ser As p As p Pr o Leu Ser Leu Ar g Met Leu Gl y Met
                        275                    280                   285
<removed-apn>
              Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s Al a As p Leu Leu
                   290                    295                     300
              Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr Gl y Ly s I l e Gl u
              305                   310                     315                     320
              Al a Phe Al a Ser Ar g Ser Ly s I l e Val Hi s I l e As p I l e As p Pr o Al a
                                325                     330                        335
              Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser I l e Cy s Al a As p Val
                              340                      345                     350
              Ly s Leu Al a Leu Gl n Gl y Leu As n As p Leu Leu As n Gl y Ser Ly s Al a
                       355                    360                    365
              Gl n Gl n Gl y Leu As p Phe Gl y Pr o Tr p Hi s Ly s Gl u Leu As p Gl n Gl n
                   370                    375                      380
              Ly s Ar g Gl u Phe Pr o Leu Gl y Phe Ly s Thr Phe Gl y Gl u Al a I l e Pr o
              385                     390                   395                      400
              Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr Ly s Gl y Gl u Al a
                                  405                     410                    415
              I l e I l e Al a Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n Ty r
                               420                    425                     430
              Ty r Thr Ty r Ly s Ar g Pr o Ar g Gl n Tr p Leu Ser Ser Ser Gl y Leu Gl y
                       435                      440                   445
              Al a Met Gl y Phe Gl y Leu Pr o Al a Al a Al a Gl y Al a Al a Val Al a As n
                   450                   455                      460
              Pr o Gl y Val Thr Val Val As p I l e As p Gl y As p Gl y Ser Phe Leu Met
              465                   470                      475                   480
              As n I l e Gl n Gl u Leu Al a Leu I l e Ar g I l e Gl u As n Leu Pr o Val Ly s
                                   485                     490                      495
              Val Met I l e Leu As n As n Gl n Hi s Leu Gl y Met Val Val Gl n Tr p Gl u
                            500                     505                  510
                                                         Page 59

                                                    341792Sequenc eLi s t i ng
<removed-date>
              As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r Leu Gl y As n Pr o
                        515                     520                     525
              Gl u As n Gl u Ser Gl u I l e Ty r Pr o As p Phe Val Thr I l e Al a Ly s Gl y
                   530                      535                    540
              Phe As n Val Pr o Al a Val Ar g Val Thr Ly s Ly s Ser Gl u Val Thr Al a
              545                    550                   555                   560
<removed-apn>
              Al a I l e Ly s Ly s Met Leu Gl u Thr Pr o Gl y Pr o Ty r Leu Leu As p I l e
                                   565                   570                    575
              I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e Pr o Ser Gl y Gl y
                             580                     585                     590
              Al a Phe Ly s As p Met I l e Met Gl u Gl y As p Gl y Ar g Thr Ser Ty r
                       595                     600                      605
              <210>   24
              <211>   659
              <212>   PRT
              <213>   Gos s y pi um hi r s ut um
              <220>
              <221>   MI SC_FEATURE
              <223>   Cot t on ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( GHAHASA5)
              <400>   24
              Met Al a Al a Al a Thr Al a As n Ser Al a Leu Pr o Ly s Leu Ser Thr Leu
              1                  5                      10                    15
              Thr Ser Ser Phe Ly s Ser Ser I l e Pr o I l e Ser Ly s Ser Ser Leu Pr o
                          20                     25                      30
              Phe Ser Thr Thr Pr o Gl n Ly s Pr o Thr Pr o Ty r Ar g Ser Phe As p Val
                      35                     40                      45
              Ser Cy s Ser Leu Ser Hi s Al a Ser Ser As n Pr o Ar g Ser Al a Al a Thr
                  50                    55                     60
              Ser Val Thr Pr o Ly s As n Al a Pr o Pr o Hi s As p Phe I l e Ser Ar g Ty r
              65                    70                       75                      80
              Al a As p As p Gl u Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu
                                  85                       90                      95
              Val Ar g Gl u Gl y Val Ly s As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser
                            100                    105                     110
              Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser Ly s I l e I l e Ar g As n Val
                       115                      120                     125
                                                          Page 60

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a
                  130                      135                    140
              Ar g Ser Ser Gl y I l e Pr o Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y
              145                     150                      155                    160
              Al a Thr As n Leu Val Ser Gl y Leu Al a As p Al a Met Leu As p Ser I l e
                                165                   170                    175
<removed-apn>
              Pr o Leu Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr
                           180                      185                    190
              As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr
                        195                    200                    205
              Ly s Hi s As n Ty r Leu Val Leu As p Val As p As p I l e Pr o Ar g I l e Val
                   210                    215                    220
              Ser Gl u Al a Phe Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu
              225                   230                   235                     240
              I l e As p Val Pr o Ly s As p I l e Gl n Gl n Gl n Leu Al a Val Pr o Ly s Tr p
                                  245                       250                    255
              As n Hi s Ser Leu Ar g Leu Pr o Gl y Ty r Leu Ser Ar g Leu Pr o Ly s Al a
                            260                    265                   270
              Pr o Gl y Gl u Al a Hi s Leu Gl u Gl n I l e Val Ar g Leu Val Ser Gl u Ser
                        275                     280                     285
              Ly s Ly s Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s Leu As n Ser Ser Gl u
                   290                    295                     300
              Gl u Leu Ly s Ar g Phe Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr
              305                    310                   315                     320
              Leu Met Gl y Leu Gl y Al a Phe Pr o I l e Ser As p As p Leu Ser Leu Gl n
                               325                      330                   335
              Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s
                           340                   345                      350
              Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr
                       355                  360                    365
              Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p
                   370                    375                     380
              I l e As p Ser Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Val Ser Val
              385                      390                       395                    400
                                                             Page 61

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Cy s Ser As p Val Ly s Leu Al a Leu Gl n Gl y I l e As n Ly s I l e Leu Gl u
                                405                    410                        415
              Thr Ly s Val Al a Ly s Leu As n Leu As p Ty r Ser Gl u Tr p Ar g Gl n Gl u
                           420                    425                     430
              Leu As n Gl u Gl n Ly s Leu Ly s Phe Pr o Leu Ser Ty r Ly s Thr Phe Gl y
                       435                     440                   445
<removed-apn>
              Gl u Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr
                   450                       455                      460
              Gl y Gl y As n Al a I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p
              465                       470                    475                     480
              Al a Al a Gl n Phe Ty r Ly s Ty r Ly s Ly s Pr o Ar g Gl n Tr p Leu Thr Ser
                                 485                      490                     495
              Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a
                            500                    505                     510
              Al a Val Al a As n Pr o Gl u Al a Val Val Val As p I l e As p Gl y As p Gl y
                       515                      520                    525
              Ser Phe I l e Met As n Val Gl n Gl u Leu Al a Thr I l e Ar g Val Gl u As n
                  530                    535                    540
              Leu Pr o Val Ly s I l e Leu Leu Leu As n As n Gl n Hi s Leu Gl y Met Val
              545                     550                   555                    560
              Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r
                                 565                     570                      575
              Leu Gl y As p Pr o Ser As n Gl u Ser Gl u I l e Phe Pr o As n Met Leu Ly s
                            580                    585                      590
              Phe Al a Gl u Al a Cy s Gl y I l e Pr o Al a Al a Ar g Val Thr Ly s Ly s Gl u
                       595                       600                     605
              As p Leu Ly s Al a Al a Met Gl n Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r
                   610                    615                    620
              Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e
              625                    630                     635                   640
              Pr o Ser Gl y Gl y Al a Phe Ly s As p Val I l e Thr Gl u Gl y As p Gl y Ar g
                                 645                    650                      655
              Thr Gl n Ty r
                                                           Page 62

                                                    341792Sequenc eLi s t i ng
<removed-date>
              <210>   25
              <211>   659
              <212>   PRT
              <213>   Gos s y pi um hi r s ut um
              <220>
              <221>   MI SC_FEATURE
              <223>   Cot t on ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( GHAHASA19)
              <400>   25
<removed-apn>
              Met Al a Al a Al a Thr Ser As n Ser Al a Leu Pr o Ly s Leu Ser Thr Leu
              1                  5                     10                    15
              Thr Ser Ser Phe Ly s Ser Ser I l e Pr o I l e Ser Ly s Ser Ser Leu Pr o
                          20                     25                      30
              Phe Ser Thr Thr Pr o Gl n Ly s Pr o Thr Pr o Ty r Ar g Ser Phe As p Val
                      35                     40                      45
              Ser Cy s Ser Leu Ser Hi s Al a Ser Ser As n Pr o Ar g As n Pr o Al a Al a
                  50                    55                     60
              Ser Val Thr Gl n Ly s Thr Al a Pr o Pr o Hi s Ty r Phe I l e Ser Ar g Ty r
              65                    70                      75                      80
              Al a As p As p Gl u Pr o Ar g Ly s Gl y Al a As p I l e Leu Val Gl u Al a Leu
                                  85                       90                      95
              Gl u Ar g Gl u Gl y Val Ly s As p Val Phe Al a Ty r Pr o Gl y Gl y Al a Ser
                             100                    105                     110
              Met Gl u I l e Hi s Gl n Al a Leu Thr Ar g Ser Ly s I l e I l e Ar g As n Val
                       115                      120                     125
              Leu Pr o Ar g Hi s Gl u Gl n Gl y Gl y Val Phe Al a Al a Gl u Gl y Ty r Al a
                  130                      135                    140
              Ar g Ser Ser Gl y I l e Ser Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y
              145                     150                     155                    160
              Ar g Thr As n Leu Val Ser Gl y Leu Al a As p Al a Met Leu As p Ser I l e
                                165                   170                    175
              Pr o Leu Val Al a I l e Thr Gl y Gl n Val Pr o Ar g Ar g Met I l e Gl y Thr
                           180                      185                    190
              As p Al a Phe Gl n Gl u Thr Pr o I l e Val Gl u Val Thr Ar g Ser I l e Thr
                        195                    200                    205
              Ly s Hi s As n Ty r Leu Val Leu As p Val As p As p I l e Pr o Ar g I l e Val
                   210                    215                    220
                                                        Page 63

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Ser Gl u Al a Phe Phe Leu Al a Ser Ser Gl y Ar g Pr o Gl y Pr o Val Leu
              225                   230                   235                     240
              I l e As p Val Pr o Ly s As p I l e Gl n Gl n Gl n Leu Al a Val Pr o Ly s Tr p
                                  245                       250                    255
              As n Hi s Ser Leu Ar g Leu Pr o Gl y Ty r Leu Ser Ar g Leu Pr o Ly s Al a
                            260                    265                   270
<removed-apn>
              Pr o Al a Gl u Al a Hi s Leu Gl u Gl n I l e Val Ar g Leu Val Ser Gl u Ser
                        275                     280                     285
              Ly s Ly s Pr o Val Leu Ty r Val Gl y Gl y Gl y Cy s Leu As n Ser Ser Gl u
                   290                    295                     300
              Gl u Leu Ly s Ar g Phe Val Gl u Leu Thr Gl y I l e Pr o Val Al a Ser Thr
              305                    310                   315                     320
              Leu Met Gl y Leu Gl y Al a Phe Pr o I l e Ser As p Gl u Leu Ser Leu Gl n
                               325                      330                   335
              Met Leu Gl y Met Hi s Gl y Thr Val Ty r Al a As n Ty r Al a Val As p Ly s
                           340                   345                      350
              Ser As p Leu Leu Leu Al a Phe Gl y Val Ar g Phe As p As p Ar g Val Thr
                       355                  360                    365
              Gl y Ly s Leu Gl u Al a Phe Al a Ser Ar g Al a Ly s I l e Val Hi s I l e As p
                   370                    375                     380
              I l e As p Ser Al a Gl u I l e Gl y Ly s As n Ly s Gl n Pr o Hi s Met Ser Val
              385                      390                       395                    400
              Cy s Ser As p Val Ly s Leu Al a Leu Gl n Gl y I l e As n Ly s I l e Leu Gl u
                                405                    410                        415
              Thr Thr Gl y Al a Ly s Leu As n Leu As p Ty r Ser Gl u Tr p Ar g Gl n Gl u
                           420                    425                     430
              Leu As n Gl u Gl n Ly s Leu Ly s Phe Pr o Leu Ser Ty r Ly s Thr Phe Gl y
                       435                     440                   445
              Gl u Al a I l e Pr o Pr o Gl n Ty r Al a I l e Gl n Val Leu As p Gl u Leu Thr
                   450                       455                      460
              Gl y Gl y As n Al a I l e I l e Ser Thr Gl y Val Gl y Gl n Hi s Gl n Met Tr p
              465                       470                    475                     480
              Al a Al a Gl n Phe Ty r Ly s Ty r Ly s Ly s Pr o Ar g Gl n Tr p Leu Thr Ser
                                 485                      490                     495
                                                           Page 64

                                                     341792Sequenc eLi s t i ng
<removed-date>
              Gl y Gl y Leu Gl y Al a Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a
                            500                    505                     510
              Al a Val Al a As n Pr o Gl u Al a Val Val Val As p I l e As p Gl y As p Gl y
                       515                      520                    525
              Ser Phe I l e Met As n Val Gl n Gl u Leu Al a Thr I l e Ar g Val Gl u As n
                  530                    535                    540
<removed-apn>
              Leu Pr o Val Ly s I l e Leu Leu Leu As n As n Gl n Hi s Leu Gl y Met Val
              545                     550                   555                    560
              Val Gl n Tr p Gl u As p Ar g Phe Ty r Ly s Al a As n Ar g Al a Hi s Thr Ty r
                                 565                     570                      575
              Leu Gl y As p Pr o Ser As n Gl u Ser Gl u I l e Phe Pr o As n Met Leu Ly s
                            580                    585                      590
              Phe Al a Gl u Al a Cy s Gl y I l e Pr o Al a Al a Ar g Val Thr Ly s Ly s Gl u
                       595                       600                     605
              As p Leu Ly s Al a Al a I l e Gl n Ly s Met Leu As p Thr Pr o Gl y Pr o Ty r
                   610                      615                    620
              Leu Leu As p Val I l e Val Pr o Hi s Gl n Gl u Hi s Val Leu Pr o Met I l e
              625                    630                     635                   640
              Pr o Ser Gl y Gl y Al a Phe Ly s As p Val I l e Thr Gl u Gl y As p Gl y Ar g
                                 645                    650                      655
              Thr Gl n Ty r
              <210>   26
              <211>   562
              <212>   PRT
              <213>   Es c her i c hi a c ol i
              <220>
              <221>   MI SC_FEATURE
              <223>   E. c ol i ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t I ( I l v B)
              <400>   26
              Met Al a Ser Ser Gl y Thr Thr Ser Thr Ar g Ly s Ar g Phe Thr Gl y Al a
              1                5                    10                     15
              Gl u Phe I l e Val Hi s Phe Leu Gl u Gl n Gl n Gl y I l e Ly s I l e Val Thr
                             20                    25                        30
              Gl y I l e Pr o Gl y Gl y Ser I l e Leu Pr o Val Ty r As p Al a Leu Ser Gl n
                         35                       40                     45
                                                            Page 65

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Ser Thr Gl n I l e Ar g Hi s I l e Leu Al a Ar g Hi s Gl u Gl n Gl y Al a Gl y
                  50                       55                       60
              Phe I l e Al a Gl n Gl y Met Al a Ar g Thr As p Gl y Ly s Pr o Al a Val Cy s
              65                       70                     75                      80
              Met Al a Cy s Ser Gl y Pr o Gl y Al a Thr As n Leu Val Thr Al a I l e Al a
                                85                      90                    95
<removed-apn>
              As p Al a Ar g Leu As p Ser I l e Pr o Leu I l e Cy s I l e Thr Gl y Gl n Val
                             100                     105                      110
              Pr o Al a Ser Met I l e Gl y Thr As p Al a Phe Gl n Gl u Val As p Thr Ty r
                        115                    120                     125
              Gl y I l e Ser I l e Pr o I l e Thr Ly s Hi s As n Ty r Leu Val Ar g Hi s I l e
                   130                        135                     140
              Gl u Gl u Leu Pr o Gl n Val Met Ser As p Al a Phe Ar g I l e Al a Gl n Ser
              145                     150                   155                      160
              Gl y Ar g Pr o Gl y Pr o Val Tr p I l e As p I l e Pr o Ly s As p Val Gl n Thr
                                  165                      170                      175
              Al a Val Phe Gl u I l e Gl u Thr Gl n Pr o Al a Met Al a Gl u Ly s Al a Al a
                           180                      185                     190
              Al a Pr o Al a Phe Ser Gl u Gl u Ser I l e Ar g As p Al a Al a Al a Met I l e
                        195                    200                      205
              As n Al a Al a Ly s Ar g Pr o Val Leu Ty r Leu Gl y Gl y Gl y Val I l e As n
                   210                      215                   220
              Al a Pr o Al a Ar g Val Ar g Gl u Leu Al a Gl u Ly s Al a Gl n Leu Pr o Thr
              225                     230                     235                     240
              Thr Met Thr Leu Met Al a Leu Gl y Met Leu Pr o Ly s Al a Hi s Pr o Leu
                              245                   250                     255
              Ser Leu Gl y Met Leu Gl y Met Hi s Gl y Val Ar g Ser Thr As n Ty r I l e
                           260                   265                   270
              Leu Gl n Gl u Al a As p Leu Leu I l e Val Leu Gl y Al a Ar g Phe As p As p
                       275                    280                     285
              Ar g Al a I l e Gl y Ly s Thr Gl u Gl n Phe Cy s Pr o As n Al a Ly s I l e I l e
                   290                      295                     300
              Hi s Val As p I l e As p Ar g Al a Gl u Leu Gl y Ly s I l e Ly s Gl n Pr o Hi s
              305                      310                     315                       320
                                                           Page 66

                                                   341792Sequenc eLi s t i ng
<removed-date>
              Val Al a I l e Gl n Al a As p Val As p As p Val Leu Al a Gl n Leu I l e Pr o
                                  325                     330                   335
              Leu Val Gl u Al a Gl n Pr o Ar g Al a Gl u Tr p Hi s Gl n Leu Val Al a As p
                           340                      345                     350
              Leu Gl n Ar g Gl u Phe Pr o Cy s Pr o I l e Pr o Ly s Al a Cy s As p Pr o Leu
                       355                     360                       365
<removed-apn>
              Ser Hi s Ty r Gl y Leu I l e As n Al a Val Al a Al a Cy s Val As p As p As n
                  370                      375                     380
              Al a I l e I l e Thr Thr As p Val Gl y Gl n Hi s Gl n Met Tr p Thr Al a Gl n
              385                      390                     395                    400
              Al a Ty r Pr o Leu As n Ar g Pr o Ar g Gl n Tr p Leu Thr Ser Gl y Gl y Leu
                                 405                      410                   415
              Gl y Thr Met Gl y Phe Gl y Leu Pr o Al a Al a I l e Gl y Al a Al a Leu Al a
                           420                    425                       430
              As n Pr o As p Ar g Ly s Val Leu Cy s Phe Ser Gl y As p Gl y Ser Leu Met
                        435                    440                    445
              Met As n I l e Gl n Gl u Met Al a Thr Al a Ser Gl u As n Gl n Leu As p Val
                  450                      455                    460
              Ly s I l e I l e Leu Met As n As n Gl u Al a Leu Gl y Leu Val Hi s Gl n Gl n
              465                      470                     475                    480
              Gl n Ser Leu Phe Ty r Gl u Gl n Gl y Val Phe Al a Al a Thr Ty r Pr o Gl y
                               485                     490                    495
              Ly s I l e As n Phe Met Gl n I l e Al a Al a Gl y Phe Gl y Leu Gl u Thr Cy s
                              500                     505                    510
              As p Leu As n As n Gl u Al a As p Pr o Gl n Al a Ser Leu Gl n Gl u I l e I l e
                       515                      520                    525
              As n Ar g Pr o Gl y Pr o Al a Leu I l e Hi s Val Ar g I l e As p Al a Gl u Gl u
                   530                      535                     540
              Ly s Val Ty r Pr o Met Val Pr o Pr o Gl y Al a Al a As n Thr Gl u Met Val
              545                    550                     555                    560
              Gl y Gl u
              <210>       27
              <211>       548
                                                           Page 67

                                                      341792Sequenc eLi s t i ng
<removed-date>
              <212>   PRT
              <213>   Es c her i c hi a c ol i
              <220>
              <221>   MI SC_FEATURE
              <223>   E. c ol i ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t I I ( I l v G)
              <400>   27
              Met As n Gl y Al a Gl n Tr p Val Val Hi s Al a Leu Ar g Al a Gl n Gl y Val
              1                  5                      10                      15
<removed-apn>
              As n Thr Val Phe Gl y Ty r Pr o Gl y Gl y Al a I l e Met Pr o Val Ty r As p
                           20                      25                       30
              Al a Leu Ty r As p Gl y Gl y Val Gl u Hi s Leu Leu Cy s Ar g Hi s Gl u Gl n
                       35                      40                     45
              Gl y Al a Al a Met Al a Al a I l e Gl y Ty r Al a Ar g Al a Thr Gl y Ly s Thr
                   50                      55                        60
              Gl y Val Cy s I l e Al a Thr Ser Gl y Pr o Gl y Al a Thr As n Leu I l e Thr
              65                       70                     75                      80
              Gl y Leu Al a As p Al a Leu Leu As p Ser I l e Pr o Val Val Al a I l e Thr
                                 85                    90                      95
              Gl y Gl n Val Ser Al a Pr o Phe I l e Gl y Thr As p Al a Phe Gl n Gl u Val
                            100                     105                    110
              As p Val Leu Gl y Leu Ser Leu Al a Cy s Thr Ly s Hi s Ser Phe Leu Val
                       115                  120                     125
              Gl n Ser Leu Gl u Gl u Leu Pr o Ar g I l e Met Al a Gl u Al a Phe As p Val
                   130                   135                      140
              Al a Cy s Ser Gl y Ar g Pr o Gl y Pr o Val Leu Val As p I l e Pr o Ly s As p
              145                     150                    155                      160
              I l e Gl n Leu Al a Ser Gl y As p Leu Gl u Pr o Tr p Phe Thr Thr Val Gl u
                                  165                    170                   175
              As n Gl u Val Thr Phe Pr o Hi s Al a Gl u Val Gl u Gl n Al a Ar g Gl n Met
                            180                    185                     190
              Leu Al a Ly s Al a Gl n Ly s Pr o Met Leu Ty r Val Gl y Gl y Gl y Val Gl y
                       195                      200                   205
              Met Al a Gl n Al a Val Pr o Al a Leu Ar g Gl u Phe Leu Al a Al a Thr Ly s
                  210                     215                    220
              Met Pr o Al a Thr Cy s Thr Leu Ly s Gl y Leu Gl y Al a Val Gl u Al a As p
              225                    230                   235                     240
                                                        Page 68

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Ty r Pr o Ty r Ty r Leu Gl y Met Leu Gl y Met Hi s Gl y Thr Ly s Al a Al a
                                  245                   250                    255
              As n Phe Al a Val Gl n Gl u Cy s As p Leu Leu I l e Al a Val Gl y Al a Ar g
                            260                     265                    270
              Phe As p As p Ar g Val Thr Gl y Ly s Leu As n Thr Phe Al a Pr o Hi s Al a
                       275                    280                   285
<removed-apn>
              Ser Val I l e Hi s Met As p I l e As p Pr o Al a Gl u Met As n Ly s Leu Ar g
                  290                     295                       300
              Gl n Al a Hi s Val Al a Leu Gl n Gl y As p Leu As n Al a Leu Leu Pr o Al a
              305                     310                    315                    320
              Leu Gl n Gl n Pr o Leu As n Gl n Ty r As p Tr p Gl n Gl n Hi s Cy s Al a Gl n
                                 325                     330                      335
              Leu Ar g As p Gl u Hi s Ser Tr p Ar g Ty r As p Hi s Pr o Gl y As p Al a I l e
                            340                     345                      350
              Ty r Al a Pr o Leu Leu Leu Ly s Gl n Leu Ser As p Ar g Ly s Pr o Al a As p
                        355                   360                    365
              Cy s Val Val Thr Thr As p Val Gl y Gl n Hi s Gl n Met Tr p Al a Al a Gl n
                   370                  375                     380
              Hi s I l e Al a Hi s Thr Ar g Pr o Gl u As n Phe I l e Thr Ser Ser Gl y Leu
              385                      390                     395                    400
              Gl y Thr Met Gl y Phe Gl y Leu Pr o Al a Al a Val Gl y Al a Gl n Val Al a
                                405                    410                     415
              Ar g Pr o As n As p Thr Val Val Cy s I l e Ser Gl y As p Gl y Ser Phe Met
                             420                   425                      430
              Met As n Val Gl n Gl u Leu Gl y Thr Val Ly s Ar g Ly s Gl n Leu Pr o Leu
                       435                    440                    445
              Ly s I l e Val Leu Leu As p As n Gl n Ar g Leu Gl y Met Val Ar g Gl n Tr p
                   450                    455                     460
              Gl n Gl n Leu Phe Phe Gl n Gl u Ar g Ty r Ser Gl u Thr Thr Leu Thr As p
              465                   470                     475                  480
              As n Pr o As p Phe Leu Met Leu Al a Ser Al a Phe Gl y I l e Hi s Gl y Gl n
                                 485                  490                      495
              Hi s I l e Thr Ar g Ly s As p Gl n Val Gl u Al a Al a Leu As p Thr Met Leu
                             500                     505                     510
                                                           Page 69

                                                      341792Sequenc eLi s t i ng
<removed-date>
              As n Ser As p Gl y Pr o Ty r Leu Leu Hi s Val Ser I l e As p Gl u Leu Gl u
                       515                     520                    525
              As n Val Tr p Pr o Leu Val Pr o Pr o Gl y Al a Ser As n Ser Gl u Met Leu
                   530                   535                     540
              Gl u Ly s Leu Ser
              545
<removed-apn>
              <210>   28
              <211>   574
              <212>   PRT
              <213>   Es c her i c hi a c ol i
              <220>
              <221>   MI SC_FEATURE
              <223>   E. c ol i ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t I I I ( I l v I )
              <400>   28
              Met Gl u Met Leu Ser Gl y Al a Gl u Met Val Val Ar g Ser Leu I l e As p
              1                5                      10                   15
              Gl n Gl y Val Ly s Gl n Val Phe Gl y Ty r Pr o Gl y Gl y Al a Val Leu As p
                            20                     25                       30
              I l e Ty r As p Al a Leu Hi s Thr Val Gl y Gl y I l e As p Hi s Val Leu Val
                         35                     40                       45
              Ar g Hi s Gl u Gl n Al a Al a Val Hi s Met Al a As p Gl y Leu Al a Ar g Al a
                   50                       55                     60
              Thr Gl y Gl u Val Gl y Val Val Leu Val Thr Ser Gl y Pr o Gl y Al a Thr
              65                     70                  75                      80
              As n Al a I l e Thr Gl y I l e Al a Thr Al a Ty r Met As p Ser I l e Pr o Leu
                                  85                       90                      95
              Val Val Leu Ser Gl y Gl n Val Al a Thr Ser Leu I l e Gl y Ty r As p Al a
                          100                    105                    110
              Phe Gl n Gl u Cy s As p Met Val Gl y I l e Ser Ar g Pr o Val Val Ly s Hi s
                       115                    120                      125
              Ser Phe Leu Val Ly s Gl n Thr Gl u As p I l e Pr o Gl n Val Leu Ly s Ly s
                  130                   135                      140
              Al a Phe Tr p Leu Al a Al a Ser Gl y Ar g Pr o Gl y Pr o Val Val Val As p
              145                    150                     155                   160
              Leu Pr o Ly s As p I l e Leu As n Pr o Al a As n Ly s Leu Pr o Ty r Val Tr p
                                 165                      170                     175
                                                           Page 70

                                                  341792Sequenc eLi s t i ng
<removed-date>
              Pr o Gl u Ser Val Ser Met Ar g Ser Ty r As n Pr o Thr Thr Thr Gl y Hi s
                            180                  185                    190
              Ly s Gl y Gl n I l e Ly s Ar g Al a Leu Gl n Thr Leu Val Al a Al a Ly s Ly s
                        195                       200                  205
              Pr o Val Val Ty r Val Gl y Gl y Gl y Al a I l e Thr Al a Gl y Cy s Hi s Gl n
                   210                   215                      220
<removed-apn>
              Gl n Leu Ly s Gl u Thr Val Gl u Al a Leu As n Leu Pr o Val Val Cy s Ser
              225                    230                    235                   240
              Leu Met Gl y Leu Gl y Al a Phe Pr o Al a Thr Hi s Ar g Gl n Al a Leu Gl y
                               245                     250                     255
              Met Leu Gl y Met Hi s Gl y Thr Ty r Gl u Al a As n Met Thr Met Hi s As n
                           260                    265                    270
              Al a As p Val I l e Phe Al a Val Gl y Val Ar g Phe As p As p Ar g Thr Thr
                        275                    280                    285
              As n As n Leu Al a Ly s Ty r Cy s Pr o As n Al a Thr Val Leu Hi s I l e As p
                   290                     295                     300
              I l e As p Pr o Thr Ser I l e Ser Ly s Thr Val Thr Al a As p I l e Pr o I l e
              305                     310                    315                      320
              Val Gl y As p Al a Ar g Gl n Val Leu Gl u Gl n Met Leu Gl u Leu Leu Ser
                                 325                    330                   335
              Gl n Gl u Ser Al a Hi s Gl n Pr o Leu As p Gl u I l e Ar g As p Tr p Tr p Gl n
                            340                     345                       350
              Gl n I l e Gl u Gl n Tr p Ar g Al a Ar g Gl n Cy s Leu Ly s Ty r As p Thr Hi s
                         355                      360                     365
              Ser Gl u Ly s I l e Ly s Pr o Gl n Al a Val I l e Gl u Thr Leu Tr p Ar g Leu
                  370                       375                      380
              Thr Ly s Gl y As p Al a Ty r Val Thr Ser As p Val Gl y Gl n Hi s Gl n Met
              385                     390                   395                     400
              Phe Al a Al a Leu Ty r Ty r Pr o Phe As p Ly s Pr o Ar g Ar g Tr p I l e As n
                                405                     410                      415
              Ser Gl y Gl y Leu Gl y Thr Met Gl y Phe Gl y Leu Pr o Al a Al a Leu Gl y
                            420                   425                    430
              Val Ly s Met Al a Leu Pr o Gl u Gl u Thr Val Val Cy s Val Thr Gl y As p
                       435                    440                   445
                                                        Page 71

                                                            341792Sequenc eLi s t i ng
<removed-date>
              Gl y Ser I l e Gl n Met As n I l e Gl n Gl u Leu Ser Thr Al a Leu Gl n Ty r
                   450                     455                     460
              Gl u Leu Pr o Val Leu Val Val As n Leu As n As n Ar g Ty r Leu Gl y Met
              465                   470                   475                     480
              Val Ly s Gl n Tr p Gl n As p Met I l e Ty r Ser Gl y Ar g Hi s Ser Gl n Ser
                                 485                      490                    495
<removed-apn>
              Ty r Met Gl n Ser Leu Pr o As p Phe Val Ar g Leu Al a Gl u Al a Ty r Gl y
                            500                   505                    510
              Hi s Val Gl y I l e Gl n I l e Ser Hi s Pr o Hi s Gl u Leu Gl u Ser Ly s Leu
                       515                       520                     525
              Ser Gl u Al a Leu Gl u Gl n Val Ar g As n As n Ar g Leu Val Phe Val As p
                  530                     535                     540
              Val Thr Val As p Gl y Ser Gl u Hi s Val Ty r Pr o Met Gl n I l e Ar g Gl y
              545                   550                    555                      560
              Gl y Gl y Met As p Gl u Met Tr p Leu Ser Ly s Thr Gl u Ar g Thr
                                 565                   570
              <210>     29
              <211>     1917
              <212>     DNA
              <213>     Zea may s
              <220>
              <221>     mi s c _f eat ur e
              <223>     Mai z e ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t 2 ( ZmAHASL2) c odi ng
                        s equenc e, S621N al l el e.
              <400> 29
              at ggc c ac c g c c gc c gc c gc gt c t ac c gc g c t c ac t ggc g c c ac t ac c gc t gc gc c c aag      60
              gc gaggc gc c gggc gc ac c t c c t ggc c ac c c gc c gc gc c c t c gc c gc gc c c at c aggt gc          120
              t c agc ggc gt c ac c c gc c at gc c gat ggc t c c c c c ggc c a c c c c gc t c c g gc c gt ggggc       180
              c c c ac c gat c c c c gc aaggg c gc c gac at c c t c gt c gagt c c c t c gagc g c t gc ggc gt c        240
              c gc gac gt c t t c gc c t ac c c c ggc ggc gc g t c c at ggaga t c c ac c aggc ac t c ac c c gc        300
              t c c c c c gt c a t c gc c aac c a c c t c t t c c gc c ac gagc aag gggaggc c t t t gc ggc c t c c     360
              ggc t ac gc gc gc t c c t c ggg c c gc gt c ggc gt c t gc at c g c c ac c t c c gg c c c c ggc gc c     420
              ac c aac c t t g t c t c c gc gc t c gc c gac gc g c t gc t c gat t c c gt c c c c at ggt c gc c at c   480
              ac gggac agg t gc c gc gac g c at gat t ggc ac c gac gc c t t c c aggagac gc c c at c gt c              540
              gaggt c ac c c gc t c c at c ac c aagc ac aac t ac c t ggt c c t c gac gt c ga c gac at c c c c         600
              c gc gt c gt gc aggaggc t t t c t t c c t c gc c t c c t c t ggt c gac c ggggc c ggt gc t t gt c        660
                                                                       Page 72

                                                        341792Sequenc eLi s t i ng
<removed-date>
              gac at c c c c a aggac at c c a gc agc agat g gc ggt gc c t g t c t gggac aa gc c c at gagt                     720
              c t gc c t gggt ac at t gc gc g c c t t c c c aag c c c c c t gc ga c t gagt t gc t t gagc aggt g               780
              c t gc gt c t t g t t ggt gaat c c c ggc gc c c t gt t c t t t at g t t ggc ggt gg c t gc gc agc a              840
              t c t ggt gagg agt t gc gac g c t t t gt ggag c t gac t ggaa t c c c ggt c ac aac t ac t c t t                  900
              at gggc c t c g gc aac t t c c c c agc gac gac c c ac t gt c t c t gc gc at gc t aggt at gc at                  960
              ggc ac ggt gt at gc aaat t a t gc agt ggat aaggc c gat c t gt t gc t t gc ac t t ggt gt g                      1020
              c ggt t t gat g at c gt gt gac agggaagat t gaggc t t t t g c aagc agggc t aagat t gt g                         1080
<removed-apn>
              c ac gt t gat a t t gat c c ggc t gagat t ggc aagaac aagc agc c ac at gt gt c c at c t gt                      1140
              gc agat gt t a agc t t gc t t t gc agggc at g aat gc t c t t c t t gaaggaag c ac at c aaag                     1200
              aagagc t t t g ac t t t ggc t c at ggaac gat gagt t ggat c agc agaagag ggaat t c c c c                         1260
              c t t gggt at a aaac at c t aa t gaggagat c c agc c ac aat at gc t at t c a ggt t c t t gat                    1320
              gagc t gac ga aaggc gaggc c at c at c ggc ac aggt gt t g ggc agc ac c a gat gt gggc g                          1380
              gc ac agt ac t ac ac t t ac aa gc ggc c aagg c agt ggt t gt c t t c agc t gg t c t t ggggc t                   1440
              at gggat t t g gt t t gc c ggc t gc t gc t ggt gc t t c t gt gg c c aac c c agg t gt t ac t gt t               1500
              gt t gac at c g at ggagat gg t agc t t t c t c at gaac gt t c aggagc t agc t at gat c c ga                     1560
              at t gagaac c t c c c ggt gaa ggt c t t t gt g c t aaac aac c agc ac c t ggg gat ggt ggt g                     1620
              c agt gggagg ac aggt t c t a t aaggc c aac agagc gc ac a c at ac t t ggg aaac c c agag                         1680
              aat gaaagt g agat at at c c agat t t c gt g ac gat c gc c a aagggt t c aa c at t c c agc g                     1740
              gt c c gt gt ga c aaagaagaa c gaagt c c gc gc agc gat aa agaagat gc t c gagac t c c a                          1800
              gggc c gt ac c t c t t ggat at aat c gt c c c a c ac c aggagc at gt gt t gc c t at gat c c c t                 1860
              aat ggt gggg c t t t c aagga t at gat c c t g gat ggt gat g gc aggac t gt gt ac t ga                           1917
              <210>      30
              <211>      2013
              <212>      DNA
              <213>      Ar abi dops i s t hal i ana
              <220>
              <221>      mi s c _f eat ur e
              <223>      Ar abi dops i s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( At AHASL)
                         c odi ng s equenc e, S653N mut ant al l el e.
              <400> 30
              at ggc ggc gg c aac aac aac aac aac aac a t c t t c t t c ga t c t c c t t c t c c ac c aaac c a                 60
              t c t c c t t c c t c c t c c aaat c ac c at t ac c a at c t c c agat t c t c c c t c c c at t c t c c c t a    120
              aac c c c aac a aat c at c c t c c t c c t c c c gc c gc c gc ggt a t c aaat c c ag c t c t c c c t c c         180
              t c c at c t c c g c c gt gc t c aa c ac aac c ac c aat gt c ac aa c c ac t c c c t c t c c aac c aaa           240
              c c t ac c aaac c c gaaac at t c at c t c c c ga t t c gc t c c ag at c aac c c c g c aaaggc gc t               300
              gat at c c t c g t c gaagc t t t agaac gt c aa ggc gt agaaa c c gt at t c gc t t ac c c t gga                   360
              ggt gc at c aa t ggagat t c a c c aagc c t t a ac c c gc t c t t c c t c aat c c g t aac gt c c t t             420
                                                                   Page 73

                                                         341792Sequenc eLi s t i ng
<removed-date>
              c c t c gt c ac g aac aaggagg t gt at t c gc a gc agaaggat ac gc t c gat c c t c aggt aaa          480
              c c aggt at c t gt at agc c ac t t c aggt c c c ggagc t ac aa at c t c gt t ag c ggat t agc c      540
              gat gc gt t gt t agat agt gt t c c t c t t gt a gc aat c ac ag gac aagt c c c t c gt c gt at g     600
              at t ggt ac ag at gc gt t t c a agagac t c c g at t gt t gagg t aac gc gt t c gat t ac gaag        660
              c at aac t at c t t gt gat gga t gt t gaagat at c c c t agga t t at t gagga agc t t t c t t t      720
              t t agc t ac t t c t ggt agac c t ggac c t gt t t t ggt t gat g t t c c t aaaga t at t c aac aa    780
<removed-apn>
              c agc t t gc ga t t c c t aat t g ggaac aggc t at gagat t ac c t ggt t at at gt c t aggat g        840
              c c t aaac c t c c ggaagat t c t c at t t ggag c agat t gt t a ggt t gat t t c t gagt c t aag      900
              aagc c t gt gt t gt at gt t gg t ggt ggt t gt t t gaat t c t a gc gat gaat t gggt aggt t t         960
              gt t gagc t t a c ggggat c c c t gt t gc gagt ac gt t gat gg ggc t gggat c t t at c c t t gt      1020
              gat gat gagt t gt c gt t ac a t at gc t t gga at gc at ggga c t gt gt at gc aaat t ac gc t        1080
              gt ggagc at a gt gat t t gt t gt t ggc gt t t ggggt aaggt t t gat gat c g t gt c ac gggt          1140
              aagc t t gagg c t t t t gc t ag t agggc t aag at t gt t c at a t t gat at t ga c t c ggc t gag    1200
              at t gggaaga at aagac t c c t c at gt gt c t gt gt gt ggt g at gt t aagc t ggc t t t gc aa        1260
              gggat gaat a aggt t c t t ga gaac c gagc g gaggagc t t a agc t t gat t t t ggagt t t gg           1320
              aggaat gagt t gaac gt ac a gaaac agaag t t t c c gt t ga gc t t t aagac gt t t ggggaa             1380
              gc t at t c c t c c ac agt at gc gat t aaggt c c t t gat gagt t gac t gat gg aaaagc c at a        1440
              at aagt ac t g gt gt c gggc a ac at c aaat g t gggc ggc gc agt t c t ac aa t t ac aagaaa          1500
              c c aaggc agt ggc t at c at c aggaggc c t t ggagc t at gg gat t t ggac t t c c t gc t gc g        1560
              at t ggagc gt c t gt t gc t aa c c c t gat gc g at agt t gt gg at at t gac gg agat ggaagc         1620
              t t t at aat ga at gt gc aaga gc t agc c ac t at t c gt gt ag agaat c t t c c agt gaaggt a        1680
              c t t t t at t aa ac aac c agc a t c t t ggc at g gt t at gc aat gggaagat c g gt t c t ac aaa     1740
              gc t aac c gag c t c ac ac at t t c t c ggggat c c ggc t c agg aggac gagat at t c c c gaac        1800
              at gt t gc t gt t t gc agc agc t t gc gggat t c c agc ggc ga gggt gac aaa gaaagc agat             1860
              c t c c gagaag c t at t c agac aat gc t ggat ac ac c aggac c t t ac c t gt t ggat gt gat t        1920
              t gt c c gc ac c aagaac at gt gt t gc c gat g at c c c gaat g gt ggc ac t t t c aac gat gt c      1980
              at aac ggaag gagat ggc c g gat t aaat ac t ga                                                     2013
              <210>     31
              <211>     2013
              <212>     DNA
              <213>     Ar abi dops i s t hal i ana
              <220>
              <221>     mi s c _f eat ur e
              <223>     Ar abi dops i s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( At AHASL)
                        c odi ng s equenc e, wi l d t y pe al l el e.
              <400>     31
                                                                   Page 74

                                                    341792Sequenc eLi s t i ng
<removed-date>
              at ggc ggc gg c aac aac aac aac aac aac a t c t t c t t c ga t c t c c t t c t c c ac c aaac c a                 60
              t c t c c t t c c t c c t c c aaat c ac c at t ac c a at c t c c agat t c t c c c t c c c at t c t c c c t a    120
              aac c c c aac a aat c at c c t c c t c c t c c c gc c gc c gc ggt a t c aaat c c ag c t c t c c c t c c         180
              t c c at c t c c g c c gt gc t c aa c ac aac c ac c aat gt c ac aa c c ac t c c c t c t c c aac c aaa           240
              c c t ac c aaac c c gaaac at t c at c t c c c ga t t c gc t c c ag at c aac c c c g c aaaggc gc t               300
              gat at c c t c g t c gaagc t t t agaac gt c aa ggc gt agaaa c c gt at t c gc t t ac c c t gga                   360
              ggt gc at c aa t ggagat t c a c c aagc c t t a ac c c gc t c t t c c t c aat c c g t aac gt c c t t             420
<removed-apn>
              c c t c gt c ac g aac aaggagg t gt at t c gc a gc agaaggat ac gc t c gat c c t c aggt aaa                       480
              c c aggt at c t gt at agc c ac t t c aggt c c c ggagc t ac aa at c t c gt t ag c ggat t agc c                   540
              gat gc gt t gt t agat agt gt t c c t c t t gt a gc aat c ac ag gac aagt c c c t c gt c gt at g                  600
              at t ggt ac ag at gc gt t t c a agagac t c c g at t gt t gagg t aac gc gt t c gat t ac gaag                     660
              c at aac t at c t t gt gat gga t gt t gaagat at c c c t agga t t at t gagga agc t t t c t t t                   720
              t t agc t ac t t c t ggt agac c t ggac c t gt t t t ggt t gat g t t c c t aaaga t at t c aac aa                 780
              c agc t t gc ga t t c c t aat t g ggaac aggc t at gagat t ac c t ggt t at at gt c t aggat g                     840
              c c t aaac c t c c ggaagat t c t c at t t ggag c agat t gt t a ggt t gat t t c t gagt c t aag                   900
              aagc c t gt gt t gt at gt t gg t ggt ggt t gt t t gaat t c t a gc gat gaat t gggt aggt t t                      960
              gt t gagc t t a c ggggat c c c t gt t gc gagt ac gt t gat gg ggc t gggat c t t at c c t t gt                   1020
              gat gat gagt t gt c gt t ac a t at gc t t gga at gc at ggga c t gt gt at gc aaat t ac gc t                     1080
              gt ggagc at a gt gat t t gt t gt t ggc gt t t ggggt aaggt t t gat gat c g t gt c ac gggt                       1140
              aagc t t gagg c t t t t gc t ag t agggc t aag at t gt t c at a t t gat at t ga c t c ggc t gag                 1200
              at t gggaaga at aagac t c c t c at gt gt c t gt gt gt ggt g at gt t aagc t ggc t t t gc aa                     1260
              gggat gaat a aggt t c t t ga gaac c gagc g gaggagc t t a agc t t gat t t t ggagt t t gg                        1320
              aggaat gagt t gaac gt ac a gaaac agaag t t t c c gt t ga gc t t t aagac gt t t ggggaa                          1380
              gc t at t c c t c c ac agt at gc gat t aaggt c c t t gat gagt t gac t gat gg aaaagc c at a                     1440
              at aagt ac t g gt gt c gggc a ac at c aaat g t gggc ggc gc agt t c t ac aa t t ac aagaaa                       1500
              c c aaggc agt ggc t at c at c aggaggc c t t ggagc t at gg gat t t ggac t t c c t gc t gc g                     1560
              at t ggagc gt c t gt t gc t aa c c c t gat gc g at agt t gt gg at at t gac gg agat ggaagc                      1620
              t t t at aat ga at gt gc aaga gc t agc c ac t at t c gt gt ag agaat c t t c c agt gaaggt a                     1680
              c t t t t at t aa ac aac c agc a t c t t ggc at g gt t at gc aat gggaagat c g gt t c t ac aaa                  1740
              gc t aac c gag c t c ac ac at t t c t c ggggat c c ggc t c agg aggac gagat at t c c c gaac                     1800
              at gt t gc t gt t t gc agc agc t t gc gggat t c c agc ggc ga gggt gac aaa gaaagc agat                          1860
              c t c c gagaag c t at t c agac aat gc t ggat ac ac c aggac c t t ac c t gt t ggat gt gat t                     1920
              t gt c c gc ac c aagaac at gt gt t gc c gat g at c c c gagt g gt ggc ac t t t c aac gat gt c                   1980
              at aac ggaag gagat ggc c g gat t aaat ac t ga                                                                  2013
                                                                          Page 75

                                                            341792Sequenc eLi s t i ng
<removed-date>
              <210>     32
              <211>     1917
              <212>     DNA
              <213>     Zea may s
              <220>
              <221>     mi s c _f eat ur e
              <223>     Mai z e ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t 2 ( ZmAHASL2) c odi ng
                        s equenc e, wi l d t y pe al l el e.
              <400> 32
<removed-apn>
              at ggc c ac c g c c gc c gc c gc gt c t ac c gc g c t c ac t ggc g c c ac t ac c gc t gc gc c c aag       60
              gc gaggc gc c gggc gc ac c t c c t ggc c ac c c gc c gc gc c c t c gc c gc gc c c at c aggt gc           120
              t c agc ggc gt c ac c c gc c at gc c gat ggc t c c c c c ggc c a c c c c gc t c c g gc c gt ggggc        180
              c c c ac c gat c c c c gc aaggg c gc c gac at c c t c gt c gagt c c c t c gagc g c t gc ggc gt c         240
              c gc gac gt c t t c gc c t ac c c c ggc ggc gc g t c c at ggaga t c c ac c aggc ac t c ac c c gc         300
              t c c c c c gt c a t c gc c aac c a c c t c t t c c gc c ac gagc aag gggaggc c t t t gc ggc c t c c      360
              ggc t ac gc gc gc t c c t c ggg c c gc gt c ggc gt c t gc at c g c c ac c t c c gg c c c c ggc gc c      420
              ac c aac c t t g t c t c c gc gc t c gc c gac gc g c t gc t c gat t c c gt c c c c at ggt c gc c at c    480
              ac gggac agg t gc c gc gac g c at gat t ggc ac c gac gc c t t c c aggagac gc c c at c gt c               540
              gaggt c ac c c gc t c c at c ac c aagc ac aac t ac c t ggt c c t c gac gt c ga c gac at c c c c          600
              c gc gt c gt gc aggaggc t t t c t t c c t c gc c t c c t c t ggt c gac c ggggc c ggt gc t t gt c         660
              gac at c c c c a aggac at c c a gc agc agat g gc ggt gc c t g t c t gggac aa gc c c at gagt              720
              c t gc c t gggt ac at t gc gc g c c t t c c c aag c c c c c t gc ga c t gagt t gc t t gagc aggt g        780
              c t gc gt c t t g t t ggt gaat c c c ggc gc c c t gt t c t t t at g t t ggc ggt gg c t gc gc agc a       840
              t c t ggt gagg agt t gc gac g c t t t gt ggag c t gac t ggaa t c c c ggt c ac aac t ac t c t t           900
              at gggc c t c g gc aac t t c c c c agc gac gac c c ac t gt c t c t gc gc at gc t aggt at gc at           960
              ggc ac ggt gt at gc aaat t a t gc agt ggat aaggc c gat c t gt t gc t t gc ac t t ggt gt g               1020
              c ggt t t gat g at c gt gt gac agggaagat t gaggc t t t t g c aagc agggc t aagat t gt g                  1080
              c ac gt t gat a t t gat c c ggc t gagat t ggc aagaac aagc agc c ac at gt gt c c at c t gt               1140
              gc agat gt t a agc t t gc t t t gc agggc at g aat gc t c t t c t t gaaggaag c ac at c aaag              1200
              aagagc t t t g ac t t t ggc t c at ggaac gat gagt t ggat c agc agaagag ggaat t c c c c                  1260
              c t t gggt at a aaac at c t aa t gaggagat c c agc c ac aat at gc t at t c a ggt t c t t gat             1320
              gagc t gac ga aaggc gaggc c at c at c ggc ac aggt gt t g ggc agc ac c a gat gt gggc g                   1380
              gc ac agt ac t ac ac t t ac aa gc ggc c aagg c agt ggt t gt c t t c agc t gg t c t t ggggc t            1440
              at gggat t t g gt t t gc c ggc t gc t gc t ggt gc t t c t gt gg c c aac c c agg t gt t ac t gt t        1500
              gt t gac at c g at ggagat gg t agc t t t c t c at gaac gt t c aggagc t agc t at gat c c ga              1560
              at t gagaac c t c c c ggt gaa ggt c t t t gt g c t aaac aac c agc ac c t ggg gat ggt ggt g              1620
              c agt gggagg ac aggt t c t a t aaggc c aac agagc gc ac a c at ac t t ggg aaac c c agag                  1680
                                                             Page 76

                                                               341792Sequenc eLi s t i ng
<removed-date>
              aat gaaagt g agat at at c c agat t t c gt g ac gat c gc c a aagggt t c aa c at t c c agc g                     1740
              gt c c gt gt ga c aaagaagaa c gaagt c c gc gc agc gat aa agaagat gc t c gagac t c c a                          1800
              gggc c gt ac c t c t t ggat at aat c gt c c c a c ac c aggagc at gt gt t gc c t at gat c c c t                 1860
              agt ggt gggg c t t t c aagga t at gat c c t g gat ggt gat g gc aggac t gt gt ac t ga                           1917
              <210>      33
              <211>      3234
              <212>      DNA
<removed-apn>
              <213>      Ar abi dops i s t hal i ana
              <220>
              <221>      mi s c _f eat ur e
              <223>      Ar abi dops i s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( At AHASL)
                         genomi c f r agment , S653N al l el e.
              <400> 33
              at ggc ggc gg c aac aac aac aac aac aac a t c t t c t t c ga t c t c c t t c t c c ac c aaac c a                 60
              t c t c c t t c c t c c t c c aaat c ac c at t ac c a at c t c c agat t c t c c c t c c c at t c t c c c t a    120
              aac c c c aac a aat c at c c t c c t c c t c c c gc c gc c gc ggt a t c aaat c c ag c t c t c c c t c c         180
              t c c at c t c c g c c gt gc t c aa c ac aac c ac c aat gt c ac aa c c ac t c c c t c t c c aac c aaa           240
              c c t ac c aaac c c gaaac at t c at c t c c c ga t t c gc t c c ag at c aac c c c g c aaaggc gc t               300
              gat at c c t c g t c gaagc t t t agaac gt c aa ggc gt agaaa c c gt at t c gc t t ac c c t gga                   360
              ggt gc at c aa t ggagat t c a c c aagc c t t a ac c c gc t c t t c c t c aat c c g t aac gt c c t t             420
              c c t c gt c ac g aac aaggagg t gt at t c gc a gc agaaggat ac gc t c gat c c t c aggt aaa                       480
              c c aggt at c t gt at agc c ac t t c aggt c c c ggagc t ac aa at c t c gt t ag c ggat t agc c                   540
              gat gc gt t gt t agat agt gt t c c t c t t gt a gc aat c ac ag gac aagt c c c t c gt c gt at g                  600
              at t ggt ac ag at gc gt t t c a agagac t c c g at t gt t gagg t aac gc gt t c gat t ac gaag                     660
              c at aac t at c t t gt gat gga t gt t gaagat at c c c t agga t t at t gagga agc t t t c t t t                   720
              t t agc t ac t t c t ggt agac c t ggac c t gt t t t ggt t gat g t t c c t aaaga t at t c aac aa                 780
              c agc t t gc ga t t c c t aat t g ggaac aggc t at gagat t ac c t ggt t at at gt c t aggat g                     840
              c c t aaac c t c c ggaagat t c t c at t t ggag c agat t gt t a ggt t gat t t c t gagt c t aag                   900
              aagc c t gt gt t gt at gt t gg t ggt ggt t gt t t gaat t c t a gc gat gaat t gggt aggt t t                      960
              gt t gagc t t a c ggggat c c c t gt t gc gagt ac gt t gat gg ggc t gggat c t t at c c t t gt                   1020
              gat gat gagt t gt c gt t ac a t at gc t t gga at gc at ggga c t gt gt at gc aaat t ac gc t                     1080
              gt ggagc at a gt gat t t gt t gt t ggc gt t t ggggt aaggt t t gat gat c g t gt c ac gggt                       1140
              aagc t t gagg c t t t t gc t ag t agggc t aag at t gt t c at a t t gat at t ga c t c ggc t gag                 1200
              at t gggaaga at aagac t c c t c at gt gt c t gt gt gt ggt g at gt t aagc t ggc t t t gc aa                     1260
              gggat gaat a aggt t c t t ga gaac c gagc g gaggagc t t a agc t t gat t t t ggagt t t gg                        1320
              aggaat gagt t gaac gt ac a gaaac agaag t t t c c gt t ga gc t t t aagac gt t t ggggaa                          1380
                                                                          Page 77

                                                         341792Sequenc eLi s t i ng
<removed-date>
              gc t at t c c t c c ac agt at gc gat t aaggt c c t t gat gagt t gac t gat gg aaaagc c at a             1440
              at aagt ac t g gt gt c gggc a ac at c aaat g t gggc ggc gc agt t c t ac aa t t ac aagaaa               1500
              c c aaggc agt ggc t at c at c aggaggc c t t ggagc t at gg gat t t ggac t t c c t gc t gc g             1560
              at t ggagc gt c t gt t gc t aa c c c t gat gc g at agt t gt gg at at t gac gg agat ggaagc              1620
              t t t at aat ga at gt gc aaga gc t agc c ac t at t c gt gt ag agaat c t t c c agt gaaggt a             1680
              c t t t t at t aa ac aac c agc a t c t t ggc at g gt t at gc aat gggaagat c g gt t c t ac aaa          1740
              gc t aac c gag c t c ac ac at t t c t c ggggat c c ggc t c agg aggac gagat at t c c c gaac             1800
<removed-apn>
              at gt t gc t gt t t gc agc agc t t gc gggat t c c agc ggc ga gggt gac aaa gaaagc agat                  1860
              c t c c gagaag c t at t c agac aat gc t ggat ac ac c aggac c t t ac c t gt t ggat gt gat t             1920
              t gt c c gc ac c aagaac at gt gt t gc c gat g at c c c gaat g gt ggc ac t t t c aac gat gt c           1980
              at aac ggaag gagat ggc c g gat t aaat ac t gagagat ga aac c ggt gat t at c agaac c                     2040
              t t t t at ggt c t t t gt at gc a t at ggt aaaa aaac t t agt t t gc aat t t c c t gt t t gt t t t      2100
              ggt aat t t ga gt t t c t t t t a gt t gt t gat c t gc c t gc t t t t t ggt t t ac g t c agac t ac t   2160
              ac t gc t gt t g t t gt t t ggt t t c c t t t c t t t c at t t t at aa at aaat aat c c ggt t c ggt t   2220
              t ac t c c t t gt gac t ggc t c a gt t t ggt t at t gc gaaat gc gaat ggt aaa t t gagt aat t            2280
              gaaat t c gt t at t agggt t c t aagc t gt t t t aac agt c ac t gggt t aat a t c t c t c gaat           2340
              c t t gc at gga aaat gc t c t t ac c at t ggt t t t t aat t gaa at gt gc t c at at gggc c gt g         2400
              gt t t c c aaat t aaat aaaac t ac gat gt c a t c gagaagt a aaat c aac t g t gt c c ac at t             2460
              at c agt t t t g t gt at ac gat gaaat agggt aat t c aaaat c t agc t t gat at gc c t t t t g            2520
              gt t c at t t t a ac c t t c t gt a aac at t t t t t c agat t t t ga ac aagt aaat c c aaaaaaaa         2580
              aaaaaaaaaa t c t c aac t c a ac ac t aaat t at t t t aat gt at aaaagat g c t t aaaac at                2640
              t t ggc t t aaa agaaagaagc t aaaaac at a gagaac t c t t gt aaat t gaa gt at gaaaat                     2700
              at ac t gaat t gggt at t at a t gaat t t t t c t gat t t agga t t c ac at gat c c aaaaagga             2760
              aat c c agaag c ac t aat c ag ac at t ggaag t aggaat at t t c aaaaagt t t t t t t t t t t t            2820
              aagt aagt ga c aaaagc t t t t aaaaaat ag aaaagaaac t agt at t aaag t t gt aaat t t                     2880
              aat aaac aaa agaaat t t t t t at at t t t t t c at t t c t t t t t c c agc at ga ggt t at gat g        2940
              gc aggat gt g gat t t c at t t t t t t c c t t t t gat agc c t t t t aat t gat c t at t at aat t g     3000
              ac gaaaaaat at t agt t aat t at agat at a t t t t aggt ag t at t agc aat t t ac ac t t c c             3060
              aaaagac t at gt aagt t gt a aat at gat gc gt t gat c t c t t c at c at t c a at ggt t agt c            3120
              aaaaaaat aa aagc t t aac t agt aaac t aa agt agt c aaa aat t gt ac t t t agt t t aaaa                  3180
              t at t ac at ga at aat c c aaa ac gac at t t a t gt gaaac aa aaac aat at c t aga                       3234
              <210>     34
              <211>     5717
              <212>     DNA
              <213>     Ar abi dops i s t hal i ana
                                                                      Page 78

                                                            341792Sequenc eLi s t i ng
<removed-date>
              <220>
              <221>      mi s c _f eat ur e
              <223>      Ar abi dops i s ac et ohy dr ox y ac i d s y nt has e l ar ge s ubuni t ( At AHASL)
                         genomi c f r agment , S653N al l el e.
              <400> 34
              t c t agat t at gt at t t c c aa c t t t c at t aa c aat at aat c gc at at aaat gaaaaat c gt               60
              t t c c aggat a at at t t t gat gaaat c t c at at t at t gt t c gt ac t c ggat t gat gt t gaa             120
              ggc t t gaagc gc t t c aaat t at agac c aga t t at t t aagt t t t t c t t t t g t t t ac t c c at         180
<removed-apn>
              at c aat t t ga t c c at t at ac t ac c t aagaa aat t t aggt a ac at agaat t at t t at t gt t             240
              at agt aaaaa aaaggaaaac c ac aaaaat a at c t ac t t t t ac gt at at ac t at t t t c at g                  300
              ac at aagt aa t t aagt t gt a c aac t t t t t t t t aat gaaaa gagagagt aa at t t at c at g                360
              t t c at gt gt a gt t ac c t c gt gaat aac c ga c ggt t at at a gac gc c t aac at gaat t gt t             420
              c agt t gaaga c agt t c aaaa c at gt gt t t c ac t c t aaaat c c t c aac aaa aaaaaagt gt                  480
              t aaaat t t gt aaac c t c t t t c aagc aaaaa aagaaaaagt gt t agaat c c c aagat t c t t                    540
              t c at aat c c g gaat c t t ggc t gaaaac gt a t aaaagagat t gac gt agt a ac aaggagt c                     600
              t t ggt at gc t t c c at gc t t t t t at c c t t t t t t gt c at gga ac c at gat t t ggt t ac c at t      660
              t at t at gt aa c c gaaat t t t c at t gt aat a at gaat at t t aaat t t t t ag c aaaaaaaaa                720
              c aaaaaaaaa c aaggagt c t t gt c t t c gt t c t c aaat t t c agagc t c t t g c ac t t t t c aa            780
              gagt t t t ac t t t gat gagt g agac at t t gt c t t t t t agt g t t t at t t t c t aaac t t aaaa          840
              t agt agc at c aac at c ac t c aat t at aat t c t t aagat gt t gt agaaaaa t at t t t at ag                900
              at ggaaagt a at c gat at t a agac aaat aa gaaac c aaac c ggac t t t gt gt t c agac c g                    960
              aat c aaat c t gaat t ggaga aat t at ggt g gaggc gaaag t c aac ggaac t aaagt at aa                       1020
              aac c aaat gt c aaaaat aaa ac c c aat t t t c at c c t t aaa c gaac c t gc t gaaac c c t aa              1080
              t t t c gat t ac c aat t c c gat c t aaaaagaa gt c at ggaag c c at t gat t c c gc aat c gat              1140
              c c t c t c agag at t t c gc t aa gagc agt gt t c gt c t c gt c c agc gc t gt c a c aaac c c gat         1200
              c gc aagggt a ac gc c t t t t c t c aaaaaaat c t c at t t c c g at t t t t gat c t gt agat t ag          1260
              ggt t t t c t ga aat t t t gat a t c at t t gt aa t t gaat t ggt t at c agaat t c ac gaaagt a            1320
              gc t gt gc gt a c ggc gat t gg at t t gt ggt g at gggat t c g t t ggat t c t t c gt gaagc t c            1380
              gt t t t c at c c c aat c aac aa c at c at c gt t ggat c t t c t t agt gt agt ac t t t c t t t ac g      1440
              aggt aat t ga t c t c gc at t a t at at c t ac a t t t t ggt t at gt t ac t t gac at at agt c at         1500
              t gat t c aat a gt t c t gt t aa t t c c t t t aaa gat c at t t t g ac t agac c ac at t c t t ggt t      1560
              c at t c c t c aa t aat t t gt aa t c at at t ggt ggat at agaa gt agat t ggt t at agat c ag              1620
              at agt ggaag ac t t t aggat gaat t t c agc t agt t t t t t t t t t t ggc t t a t t gt c t c aaa          1680
              agat t agt gc t t t gc t gt c t c c at t gc t t c t gc t at c gac ac gc t t c t gt c t c c t t gt at     1740
              c t t t at t at a t c t at t c gt c c c at gagt t t t gt t t gt t c t gt at t c gt t c gc t c t ggt gt   1800
              c at ggat gga gt c t c t gt t c c at gt t t c t g t aat gc at gt t gggt t gt t t c at gc aagaa           1860
                                                                     Page 79

                                                              341792Sequenc eLi s t i ng
<removed-date>
              at gc t gagat aaac ac t c at t t gt gaaagt t t c t aaac t c t gaat c gc gc t ac aggc aat                      1920
              gc t c c gagga gt aggaggag aagaac gaac c aaac gac at t at c agc c c t t t gaggaagc                            1980
              t c t t agt t t t gt t at t gt t t t t gt agc c aa at t c t c c at t c t t at t c c at t t t c ac t t at      2040
              c t c t t gt t c c t t at agac c t t at aagt t t t t t at t c at gt at ac aaat t a t at t gt c at c           2100
              aagaagt at c t t t aaaat c t aaat c t c aaa t c ac c aggac t at gt t t t t g t c c aat t c gt                 2160
              ggaac c aac t t gc agc t t gt at c c at t c t c t t aac c aat a aaaaaagaaa gaaagat c aa                       2220
<removed-apn>
              t t t gat aaat t t c t c agc c a c aaat t c t ac at t t aggt t t t agc at at c g aaggc t c aat                2280
              c ac aaat ac a at agat agac t agagat t c c agc gt c ac gt gagt t t t at c t at aaat aaa                       2340
              ggac c aaaaa t c aaat c c c g agggc at t t t c gt aat c c aa c at aaaac c c t t aaac t t c a                  2400
              agt c t c at t t t t aaac aaat c at gt t c ac a agt c t c t t c t t c t t c t c t gt t t c t c t at c t       2460
              c t t gc t c at c t t t c t c c t ga ac c at ggc gg c ggc aac aac aac aac aac a ac at c t t c t t             2520
              c gat c t c c t t c t c c ac c aaa c c at c t c c t t c c t c c t c c aa at c ac c at t a c c aat c t c c a   2580
              gat t c t c c c t c c c at t c t c c c t aaac c c c a ac aaat c at c c t c c t c c t c c c gc c gc c gc g     2640
              gt at c aaat c c agc t c t c c c t c c t c c at c t c c gc c gt gc t c aac ac aac c ac c aat gt c a           2700
              c aac c ac t c c c t c t c c aac c aaac c t ac c a aac c c gaaac at t c at c t c c c gat t c gc t c           2760
              c agat c aac c c c gc aaaggc gc t gat at c c t c gt c gaagc t t t agaac gt c aaggc gt ag                      2820
              aaac c gt at t c gc t t ac c c t ggaggt gc at c aat ggagat t c ac c aagc c t t aac c c gc t                   2880
              c t t c c t c aat c c gt aac gt c c t t c c t c gt c ac gaac aagg aggt gt at t c gc agc agaag                 2940
              gat ac gc t c g at c c t c aggt aaac c aggt a t c t gt at agc c ac t t c aggt c c c ggagc t a                 3000
              c aaat c t c gt t agc ggat t a gc c gat gc gt t gt t agat ag t gt t c c t c t t gt agc aat c a                3060
              c aggac aagt c c c t c gt c gt at gat t ggt a c agat gc gt t t c aagagac t c c gat t gt t g                   3120
              aggt aac gc g t t c gat t ac g aagc at aac t at c t t gt gat ggat gt t gaa gat at c c c t a                   3180
              ggat t at t ga ggaagc t t t c t t t t t agc t a c t t c t ggt ag ac c t ggac c t gt t t t ggt t g             3240
              at gt t c c t aa agat at t c aa c aac agc t t g c gat t c c t aa t t gggaac ag gc t at gagat                  3300
              t ac c t ggt t a t at gt c t agg at gc c t aaac c t c c ggaaga t t c t c at t t g gagc agat t g               3360
              t t aggt t gat t t c t gagt c t aagaagc c t g t gt t gt at gt t ggt ggt ggt t gt t t gaat t                   3420
              c t agc gat ga at t gggt agg t t t gt t gagc t t ac ggggat c c c t gt t gc g agt ac gt t ga                   3480
              t ggggc t ggg at c t t at c c t t gt gat gat g agt t gt c gt t ac at at gc t t ggaat gc at g                  3540
              ggac t gt gt a t gc aaat t ac gc t gt ggagc at agt gat t t gt t gt t ggc g t t t ggggt aa                     3600
              ggt t t gat ga t c gt gt c ac g ggt aagc t t g aggc t t t t gc t agt agggc t aagat t gt t c                   3660
              at at t gat at t gac t c ggc t gagat t ggga agaat aagac t c c t c at gt g t c t gt gt gt g                    3720
              gt gat gt t aa gc t ggc t t t g c aagggat ga at aaggt t c t t gagaac c ga gc ggaggagc                         3780
              t t aagc t t ga t t t t ggagt t t ggaggaat g agt t gaac gt ac agaaac ag aagt t t c c gt                       3840
              t gagc t t t aa gac gt t t ggg gaagc t at t c c t c c ac agt a t gc gat t aag gt c c t t gat g                3900
                                                                   Page 80

                                                             341792Sequenc eLi s t i ng
<removed-date>
              agt t gac t ga t ggaaaagc c at aat aagt a c t ggt gt c gg gc aac at c aa at gt gggc gg                      3960
              c gc agt t c t a c aat t ac aag aaac c aaggc agt ggc t at c at c aggaggc c t t ggagc t a                    4020
              t gggat t t gg ac t t c c t gc t gc gat t ggag c gt c t gt t gc t aac c c t gat gc gat agt t g              4080
              t ggat at t ga c ggagat gga agc t t t at aa t gaat gt gc a agagc t agc c ac t at t c gt g                   4140
              t agagaat c t t c c agt gaag gt ac t t t t at t aaac aac c a gc at c t t ggc at ggt t at gc                 4200
              aat gggaaga t c ggt t c t ac aaagc t aac c gagc t c ac ac at t t c t c ggg gat c c ggc t c                  4260
<removed-apn>
              aggaggac ga gat at t c c c g aac at gt t gc t gt t t gc agc agc t t gc ggg at t c c agc gg                  4320
              c gagggt gac aaagaaagc a gat c t c c gag aagc t at t c a gac aat gc t g gat ac ac c ag                      4380
              gac c t t ac c t gt t ggat gt g at t t gt c c gc ac c aagaac a t gt gt t gc c g at gat c c c ga             4440
              at ggt ggc ac t t t c aac gat gt c at aac gg aaggagat gg c c ggat t aaa t ac t gagaga                       4500
              t gaaac c ggt gat t at c aga ac c t t t t at g gt c t t t gt at gc at at ggt a aaaaaac t t a                4560
              gt t t gc aat t t c c t gt t t gt t t t ggt aat t t gagt t t c t t t t agt t gt t g at c t gc c t gc        4620
              t t t t t ggt t t ac gt c agac t ac t ac t gc t g t t gt t gt t t g gt t t c c t t t c t t t c at t t t a   4680
              t aaat aaat a at c c ggt t c g gt t t ac t c c t t gt gac t ggc t c agt t t ggt t at t gc gaaa              4740
              t gc gaat ggt aaat t gagt a at t gaaat t c gt t at t aggg t t c t aagc t g t t t t aac agt                  4800
              c ac t gggt t a at at c t c t c g aat c t t gc at ggaaaat gc t c t t ac c at t g gt t t t t aat t           4860
              gaaat gt gc t c at at gggc c gt ggt t t c c a aat t aaat aa aac t ac gat g t c at c gagaa                   4920
              gt aaaat c aa c t gt gt c c ac at t at c agt t t t gt gt at ac gat gaaat ag ggt aat t c aa                  4980
              aat c t agc t t gat at gc c t t t t ggt t c at t t t aac c t t c t gt aaac at t t t t t c agat t t          5040
              t gaac aagt a aat c c aaaaa aaaaaaaaaa aaat c t c aac t c aac ac t aa at t at t t t aa                      5100
              t gt at aaaag at gc t t aaaa c at t t ggc t t aaaagaaaga agc t aaaaac at agagaac t                          5160
              c t t gt aaat t gaagt at gaa aat at ac t ga at t gggt at t at at gaat t t t t c t gat t t a                 5220
              ggat t c ac at gat c c aaaaa ggaaat c c ag aagc ac t aat c agac at t gg aagt aggaat                         5280
              at t t c aaaaa gt t t t t t t t t t t t aagt aag t gac aaaagc t t t t aaaaaa t agaaaagaa                    5340
              ac t agt at t a aagt t gt aaa t t t aat aaac aaaagaaat t t t t t at at t t t t t c at t t c t               5400
              t t t t c c agc a t gaggt t at g at ggc aggat gt ggat t t c a t t t t t t t c c t t t t gat agc c           5460
              t t t t aat t ga t c t at t at aa t t gac gaaaa aat at t agt t aat t at agat at at t t t agg                5520
              t agt at t agc aat t t ac ac t t c c aaaagac t at gt aagt t gt aaat at ga t gc gt t gat c                   5580
              t c t t c at c at t c aat ggt t a gt c aaaaaaa t aaaagc t t a ac t agt aaac t aaagt agt c                   5640
              aaaaat t gt a c t t t agt t t a aaat at t ac a t gaat aat c c aaaac gac at t t at gt gaaa                   5700
              c aaaaac aat at c t aga                                                                                     5717
              1
              100
                                                                         Page 81

              341792Sequenc eLi s t i ng
<removed-date>
<removed-apn>
                      Page 82

